


=> d que stat l40

L1 1 SEA FILE=HCAPLUS ABB=ON PLU=ON US2004-771756/APPS
 L3 TRANSFER PLU=ON L1 1- RN : 58 TERMS
 L4 58 SEA FILE=REGISTRY ABB=ON PLU=ON L3
 L6 STR



VAR G1=14/15/16/17

VAR G2=14/15/16/17

VAR G3=14/15/16/17

NODE ATTRIBUTES:

NSPEC IS R AT 14

NSPEC IS R AT 15

NSPEC IS R AT 16

NSPEC IS R AT 17

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE

L8 573 SEA FILE=REGISTRY SSS FUL L6

L37 47 SEA FILE=REGISTRY ABB=ON PLU=ON L8 AND L4

L38 24 SEA FILE=REGISTRY ABB=ON PLU=ON L37 AND BR/ELS

L39 15 SEA FILE=REGISTRY ABB=ON PLU=ON L38 AND ?QUINAZOL?/CNS

L40 1 SEA FILE=REGISTRY ABB=ON PLU=ON L39 AND C18H15BRN2/MF

=> d ide l40

YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:y

L40 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN

RN 745836-70-8 REGISTRY

ED Entered STN: 16 Sep 2004


CN Pyrrolo[2,1-b]quinazoline, 3-[(2-bromophenyl)methylene]-1,2,3,9-tetrahydro- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C18 H15 Br N2

SR CA

LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file stnguide

FILE 'STNGUIDE' ENTERED AT 11:44:34 ON 05 JUN 2006
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jun 2, 2006 (20060602/UP).

=> => d que stat l8
L6 STR



VAR G1=14/15/16/17

VAR G2=14/15/16/17

VAR G3=14/15/16/17

NODE ATTRIBUTES:

NSPEC IS R AT 14

NSPEC IS R AT 15

NSPEC IS R AT 16

NSPEC IS R AT 17

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE

L8 573 SEA FILE=REGISTRY SSS FUL L6

100.0% PROCESSED 4854 ITERATIONS

573 ANSWERS

SEARCH TIME: 00.00.01

=> d que nos l10

L6 STR

L8 573 SEA FILE=REGISTRY SSS FUL L6

L10 ANALYZE PLU=ON L8 1- LC : 11 TERMS


=> d l10 1-11

L10 ANALYZE L8 1- LC : 11 TERMS

TERM #	# OCC	# DOC	% DOC	LC
1	354	354	61.78	CA
2	354	354	61.78	CAPLUS
3	219	219	38.22	USPATFULL
4	185	185	32.29	CHEMCATS
5	168	168	29.32	CASREACT
6	55	55	9.60	BEILSTEIN
7	17	17	2.97	TOXCENTER
8	1	1	0.17	BIOSIS
9	1	1	0.17	PROUSDDR
10	1	1	0.17	SYNTHLINE
11	1	1	0.17	USPAT2

***** END OF L10***

=> d que stat l11
L6 STR



VAR G1=14/15/16/17

VAR G2=14/15/16/17

VAR G3=14/15/16/17

NODE ATTRIBUTES:

NSPEC IS R AT 14

NSPEC IS R AT 15

NSPEC IS R AT 16

NSPEC IS R AT 17

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE

L11 150 SEA FILE=BEILSTEIN SSS FUL L6

100.0% PROCESSED 1412 ITERATIONS

150 ANSWERS

SEARCH TIME: 00.00.05

=> d his l11-l14

(FILE 'REGISTRY' ENTERED AT 11:06:48 ON 05 JUN 2006)

FILE 'STNGUIDE' ENTERED AT 11:08:22 ON 05 JUN 2006

FILE 'BEILSTEIN' ENTERED AT 11:08:37 ON 05 JUN 2006

L11 150 S L6 FUL

L12 88 S L11 NOT RN/FA

L13 15 S L12 NOT BABSAN/FA

SAVE TEMP L11 WAR756BEIS/A

SAVE TEMP L13 WAR756BEIX/A

SELECT L11 1- BABSAN

FILE 'BABS' ENTERED AT 11:11:07 ON 05 JUN 2006

L14 22 S E13-E34/AN

=> d que nos l17


L14 22 SEA FILE=BABS ABB=ON PLU=ON (6487251/AN OR 5863646/AN OR
5577177/AN OR 6168489/AN OR 5577176/AN OR 6311218/AN OR
6170503/AN OR 5559630/AN OR 5690319/AN OR 6199365/AN OR
6254884/AN OR 6507792/AN OR 5559613/AN OR 6429378/AN OR
5563983/AN OR 6148796/AN OR 6348769/AN OR 6381124/AN OR
6392803/AN OR 6407489/AN OR 6443294/AN OR 6445593/AN)
L15 QUE ABB=ON PLU=ON AY<2004 OR PY<2004 OR PRY<2004 OR MY

<2004 OR REVIEW/DT

L17 19 SEA FILE=BABS ABB=ON PLU=ON L14 AND L15

=> d que stat l43

L1 1 SEA FILE=HCAPLUS ABB=ON PLU=ON US2004-771756/APPS
L3 TRANSFER PLU=ON L1 1- RN : 58 TERMS
L4 58 SEA FILE=REGISTRY ABB=ON PLU=ON L3
L6 STR



VAR G1=14/15/16/17

VAR G2=14/15/16/17

VAR G3=14/15/16/17

NODE ATTRIBUTES:

NSPEC IS R AT 14

NSPEC IS R AT 15

NSPEC IS R AT 16

NSPEC IS R AT 17

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE

L8 573 SEA FILE=REGISTRY SSS FUL L6

L15 QUE ABB=ON PLU=ON AY<2004 OR PY<2004 OR PRY<2004 OR MY
<2004 OR REVIEW/DT

L34 50 SEA FILE=HCAPLUS ABB=ON PLU=ON L8

L35 46 SEA FILE=HCAPLUS ABB=ON PLU=ON L34 AND L15

L37 47 SEA FILE=REGISTRY ABB=ON PLU=ON L8 AND L4

L38 24 SEA FILE=REGISTRY ABB=ON PLU=ON L37 AND BR/ELS

L39 15 SEA FILE=REGISTRY ABB=ON PLU=ON L38 AND ?QUINAZOL?/CNS

L40 1 SEA FILE=REGISTRY ABB=ON PLU=ON L39 AND C18H15BRN2/MF


L41 1 SEA FILE=HCAPLUS ABB=ON PLU=ON L40

L42 1 SEA FILE=HCAPLUS ABB=ON PLU=ON L41 AND L35

L43 46 SEA FILE=HCAPLUS ABB=ON PLU=ON L35 OR L42

=> d que stat l45

L6 STR



VAR G1=14/15/16/17

VAR G2=14/15/16/17

VAR G3=14/15/16/17

NODE ATTRIBUTES:

NSPEC IS R AT 14

NSPEC IS R AT 15

NSPEC IS R AT 16

NSPEC IS R AT 17

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE

L45 1 SEA FILE=WPIX SSS FUL L6

100.0% PROCESSED 131 ITERATIONS

1 ANSWERS

SEARCH TIME: 00.00.06

=> d his l45-l48

(FILE 'WPIX' ENTERED AT 11:34:54 ON 05 JUN 2006)

L45 1 S L6 FUL
SAVE TEMP L45 WAR756WPIS/A

L46 1 S L45/DCR
SELECT L45 1- SDCN

L47 1 S E35/DCN

L48 1 S L46 OR L47

=> d que nos l48

L6 STR

L45 1 SEA FILE=WPIX SSS FUL L6

L46 1 SEA FILE=WPIX ABB=ON PLU=ON L45/DCR

L47 1 SEA FILE=WPIX ABB=ON PLU=ON RAF9T7/DCN

L48 1 SEA FILE=WPIX ABB=ON PLU=ON L46 OR L47

=> d his l55

(FILE 'USPATFULL, USPAT2, CASREACT, TOXCENTER, BIOSIS, PROUSDDR,
CHEMCATS, SYNTHLINE' ENTERED AT 11:42:26 ON 05 JUN 2006)

L55 29 S L54 AND L15

=> d que nos l55

L6 STR

L8 573 SEA FILE=REGISTRY SSS FUL L6

L15 QUE ABB=ON PLU=ON AY<2004 OR PY<2004 OR PRY<2004 OR MY
<2004 OR REVIEW/DT

L54 502 SEA L8

L55 29 SEA L54 AND L15

=> d que nos l56

L1 1 SEA FILE=HCAPLUS ABB=ON PLU=ON US2004-771756/APPS

L3 TRANSFER PLU=ON L1 1- RN : 58 TERMS

L4 58 SEA FILE=REGISTRY ABB=ON PLU=ON L3
L6 STR
L8 573 SEA FILE=REGISTRY SSS FUL L6
L37 47 SEA FILE=REGISTRY ABB=ON PLU=ON L8 AND L4
L38 24 SEA FILE=REGISTRY ABB=ON PLU=ON L37 AND BR/ELS
L39 15 SEA FILE=REGISTRY ABB=ON PLU=ON L38 AND ?QUINAZOL?/CNS
L40 1 SEA FILE=REGISTRY ABB=ON PLU=ON L39 AND C18H15BRN2/MF
L56 1 SEA FILE=USPATFULL ABB=ON PLU=ON L40

=> d his 162

(FILE 'MEDLINE, BIOSIS, EMBASE, CABA, LIFESCI, DRUGU, DRUGB, VETU, VETB,
SCISEARCH, CONF, CONFSCI, DISSABS' ENTERED AT 11:47:28 ON 05 JUN 2006)
L62 2 S L61 AND L15

=> d que 162

L15 QUE ABB=ON PLU=ON AY<2004 OR PY<2004 OR PRY<2004 OR MY
<2004 OR REVIEW/DT
L27 QUE ABB=ON PLU=ON ?PYRROL?(4A)?AZOL?
L30 QUE ABB=ON PLU=ON ?CHEMOKIN? OR (CHEMO(W)KIN?)
L61 8 SEA L27 AND L30
L62 2 SEA L61 AND L15

=> d his 166

(FILE 'PASCAL, JICST-EPLUS' ENTERED AT 11:54:17 ON 05 JUN 2006)
L66 1 S L27 AND L30
SAVE TEMP L66 WAR756JP1B/A

FILE 'STNGUIDE' ENTERED AT 11:58:34 ON 05 JUN 2006

=> d que 166

L27 QUE ABB=ON PLU=ON ?PYRROL?(4A)?AZOL?
L30 QUE ABB=ON PLU=ON ?CHEMOKIN? OR (CHEMO(W)KIN?)
L66 1 SEA L27 AND L30

=> dup rem 143 117 148 155 162 166

DUPLICATE IS NOT AVAILABLE IN 'PROUSDDR, CHEMCATS, SYNTHLINE, CONF'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
FILE 'HCAPLUS' ENTERED AT 12:01:59 ON 05 JUN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BABS' ENTERED AT 12:01:59 ON 05 JUN 2006
COPYRIGHT (c) 2006 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften
licensed to Beilstein GmbH and MDL Information Systems GmbH

FILE 'WPIX' ENTERED AT 12:01:59 ON 05 JUN 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'USPATFULL' ENTERED AT 12:01:59 ON 05 JUN 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 12:01:59 ON 05 JUN 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CASREACT' ENTERED AT 12:01:59 ON 05 JUN 2006
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'TOXCENTER' ENTERED AT 12:01:59 ON 05 JUN 2006
COPYRIGHT (C) 2006 ACS

FILE 'BIOSIS' ENTERED AT 12:01:59 ON 05 JUN 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'SYNTHLINE' ENTERED AT 12:01:59 ON 05 JUN 2006
COPYRIGHT (C) 2006 Proux Science

FILE 'EMBASE' ENTERED AT 12:01:59 ON 05 JUN 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'PASCAL' ENTERED AT 12:01:59 ON 05 JUN 2006
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2006 INIST-CNRS. All rights reserved.

PROCESSING COMPLETED FOR L43

PROCESSING COMPLETED FOR L17

PROCESSING COMPLETED FOR L48

PROCESSING COMPLETED FOR L55

PROCESSING COMPLETED FOR L62

PROCESSING COMPLETED FOR L66

L67 58 DUP REM L43 L17 L48 L55 L62 L66 (40 DUPLICATES REMOVED)

ANSWERS '1-46' FROM FILE HCAPLUS

ANSWERS '47-53' FROM FILE USPATFULL

ANSWER '54' FROM FILE BIOSIS

ANSWER '55' FROM FILE SYNTHLINE

ANSWERS '56-57' FROM FILE EMBASE

ANSWER '58' FROM FILE PASCAL

=> file stnguide

FILE 'STNGUIDE' ENTERED AT 12:02:09 ON 05 JUN 2006
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Jun 2, 2006 (20060602/UP).

=> d ibib ed ab hitstr

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, USPATFULL, BIOSIS, SYNTHLINE, EMBASE, PASCAL' - CONTINUE? (Y)/N:y

L67 ANSWER 1 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2004:696376 HCAPLUS

DOCUMENT NUMBER: 141:225527

TITLE: Preparation of pyrroloquinazolines as modulators of chemokine activity

INVENTOR(S): Anderskewitz, Ralf; Dollinger, Horst; Heine, Claudia; Pouzet, Pascale Arielle Jane-josee; Birke, Franz; Bouyssou, Thierry

PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim Pharma GmbH & Co. Kg

SOURCE: PCT Int. Appl., 42 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004072074	A1	20040826	WO 2004-EP1043	20040205 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2005027122	A1	20050203	US 2004-771756	20040204 <--
CA 2515730	AA	20040826	CA 2004-2515730	20040205 <--
EP 1594873	A1	20051116	EP 2004-708347	20040205 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2006515002	T2	20060518	JP 2005-518417	20040205 <--
PRIORITY APPLN. INFO.:			EP 2003-3007	A 20030212 <--
			US 2003-499529P	P 20030902 <--
			WO 2004-EP1043	W 20040205

OTHER SOURCE(S): MARPAT 141:225527

ED Entered STN: 26 Aug 2004

AB The title compds. [I; R1, R2 = H, alkyl, alkenyl, cycloalkyl, etc.; or R1 and R2 together with the interjacent carbon atom form (un)substituted 3-8 membered cycloalkyl; or R1 and R2 form together :NR4; R3 = H, alkyl, alkenyl, aryl, etc.; R4 = H, CO2R5, COR5, CN, etc.; R5 = H, alkyl, cycloalkyl, aryl, etc.; or R2 and R3 together with the interjacent group form 5-8 membered ring; or R3 and R4 together with the interjacent group form 5-8 membered ring; E1, E2 = H or taken together form a double bond; X = H, halo, alkyl, cycloalkyl, aryl, etc.; the ring A may be substituted; Ar1, Ar2 = (un)substituted 6-10 membered homoarom. ring, 5-10 membered heteroarom. ring containing up to three heteroatoms selected from N, O and S; n = 1-4] and their pharmaceutically acceptable salts, which are effective modulators of chemokine activity, were prepared Thus, reacting 2-aminobenzylamine with γ -butyrolactone followed by treatment of the reaction mixture with POCl3, and then reacting the resulting 1,2,3,9-tetrahydropyrrolo[2,1-b]quinazoline with 2-bromobenzaldehyde

afforded 3-(2-bromobenzylidene)-1,2,3,9-tetrahydropyrrolo[2,1-b]quinazoline which showed K_i in the range 1-100 nM against CCR-3 receptor binding. The pharmaceutical composition comprising the compound I is claimed.


IT 82083-81-6P 745836-70-8P 745836-71-9P
 745836-72-0P 745836-73-1P 745836-74-2P
 745836-75-3P 745836-76-4P 745836-77-5P
 745836-78-6P 745836-79-7P 745836-80-0P
 745836-81-1P 745836-82-2P 745836-83-3P
 745836-84-4P 745836-85-5P 745836-86-6P
 745836-87-7P 745836-88-8P 745836-89-9P
 745836-90-2P 745836-91-3P 745836-92-4P
 745836-93-5P 745836-95-7P 745836-96-8P
 745836-97-9P 745836-98-0P 745836-99-1P
 745837-00-7P 745837-01-8P 745837-02-9P
 745837-03-0P 745837-04-1P 745837-05-2P
 745837-06-3P 745837-07-4P 745837-09-6P
 745837-10-9P 745837-11-0P 745837-12-1P
 745837-13-2P 745837-14-3P 745837-15-4P
 745837-36-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrroloquinazolines as modulators of chemokine activity)


RN 82083-81-6 HCAPLUS

CN Pyrrolo[2,1-b]quinazoline, 3-(2-furanylmethylene)-1,2,3,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 745836-70-8 HCAPLUS

CN Pyrrolo[2,1-b]quinazoline, 3-[(2-bromophenyl)methylene]-1,2,3,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 745836-71-9 HCAPLUS

CN Pyrrolo[2,1-b]quinazoline, 5,7-dibromo-3-[(2-chlorophenyl)methylene]-1,2,3,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 745836-72-0 HCAPLUS

CN Pyrrolo[2,1-b]quinazoline, 3-[(2-chlorophenyl)methylene]-1,2,3,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 745836-73-1 HCAPLUS

CN Pyrrolo[2,1-b]quinazoline, 7-bromo-3-[(2-chlorophenyl)methylene]-6-(1,1-dimethylethyl)-1,2,3,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 745836-74-2 HCAPLUS

CN Pyrrolo[2,1-b]quinazoline, 3-[(2,6-dichlorophenyl)methylene]-1,2,3,9-tetrahydro- (9CI) (CA INDEX NAME)



RN 745836-75-3 HCAPLUS


CN Pyrrolo[2,1-b]quinazoline, 3-[(2-fluorophenyl)methylene]-1,2,3,9-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 745836-76-4 HCAPLUS


CN Benzenamine, 3-chloro-4-[(1,2-dihydropyrrolo[2,1-b]quinazolin-3(9H)-ylidene)methyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 745836-77-5 HCAPLUS


CN Pyrrolo[2,1-b]quinazoline, 1,2,3,9-tetrahydro-3-[[2-(trifluoromethyl)phenyl]methylene]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 745836-78-6 HCAPLUS

CN Pyrrolo[2,1-b]quinazoline, 3-[(2-chlorophenyl)methylene]-1-ethyl-1,2,3,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 745836-79-7 HCAPLUS

CN Pyrrolo[2,1-b]quinazoline, 3-[(2-ethylphenyl)methylene]-1,2,3,9-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 745836-80-0 HCAPLUS
 CN Benzenamine, 4-[(1,2-dihydropyrrolo[2,1-b]quinazolin-3(9H)-ylidene)methyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 745836-81-1 HCAPLUS
 CN Pyrrolo[2,1-b]quinazoline, 3-[(3,4-dichlorophenyl)methylene]-1,2,3,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 745836-82-2 HCAPLUS
 CN Pyrrolo[2,1-b]quinazoline, 3-[(2-ethoxyphenyl)methylene]-1,2,3,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 745836-83-3 HCAPLUS
CN Pyrrolo[2,1-b]quinazoline, 1,2,3,9-tetrahydro-3-(2-thienylmethylene) -
(9CI) (CA INDEX NAME)



RN 745836-84-4 HCAPLUS
CN Pyrrolo[2,1-b]quinazoline, 1,2,3,9-tetrahydro-3-(3-thienylmethylene) -
(9CI) (CA INDEX NAME)




RN 745836-85-5 HCAPLUS
CN Pyrrolo[2,1-b]quinazoline, 3-([1,1'-biphenyl]-2-ylmethylene)-1,2,3,9-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 745836-86-6 HCAPLUS

CN Pyrrolo[2,1-b]quinazoline, 3-[(2-chloro-4-fluorophenyl)methylene]-1,2,3,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 745836-87-7 HCAPLUS

CN Pyrrolo[2,1-b]quinazoline, 1,2,3,9-tetrahydro-3-[(4-methoxy-3-methylphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 745836-88-8 HCAPLUS

CN Pyrrolo[2,1-b]quinazoline, 3-[(2,4-dichlorophenyl)methylene]-1,2,3,9-tetrahydro- (9CI) (CA INDEX NAME)



RN 745836-89-9 HCAPLUS


CN Benzaldehyde, 2-[amino(1,2-dihydropyrrolo[2,1-b]quinazolin-3(9H)-ylidene)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 745836-90-2 HCAPLUS


CN Pyrrolo[2,1-b]quinazoline, 1,2,3,9-tetrahydro-3-[[2-(trifluoromethoxy)phenyl]methylene]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 745836-91-3 HCAPLUS

CN Pyrrolo[2,1-b]quinazoline, 3-[(2-bromophenyl)methylene]-1-(4-fluorophenyl)-1,2,3,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 745836-92-4 HCAPLUS

CN Pyrrolo[2,1-b]quinazoline, 3-[(8-bromo-1-naphthalenyl)methylene]-1,2,3,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 745836-93-5 HCAPLUS

CN Pyrrolo[2,1-b]quinazoline, 3-[(2-bromophenyl)methylene]-1-butyl-1,2,3,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 745836-95-7 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-imine, 3-[(2-ethylphenyl)methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 745836-96-8 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-imine, 3-[(2-chlorophenyl)methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 745836-97-9 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-imine, 2,3-dihydro-3-[(2-iodophenyl)methylene]- (9CI) (CA INDEX NAME)




RN 745836-98-0 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-imine, 2,3-dihydro-3-[(4-methoxyphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 745836-99-1 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-imine, 3-[(2-bromophenyl)methylene]-2,3-dihydro-6,7-dimethoxy- (9CI) (CA INDEX NAME)




RN 745837-00-7 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-imine, 3-[(2-bromophenyl)methylene]-8-fluoro-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 745837-01-8 HCAPLUS

CN Pyrido[2,3-d]pyrrolo[1,2-a]pyrimidin-5(7H)-imine, 9-[(2-bromophenyl)methylene]-8,9-dihydro- (9CI) (CA INDEX NAME)




RN 745837-02-9 HCAPLUS

CN Methanamine, N-[3-[(2-bromophenyl)methylene]-2,3-dihydropyrrolo[2,1-b]quinazolin-9(1H)-ylidene]- (9CI) (CA INDEX NAME)




RN 745837-03-0 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-imine, 3-[(2-bromophenyl)methylene]-8-chloro-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 745837-04-1 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-imine, 3-[(2-bromophenyl)methylene]-2,3-dihydro-8-methyl- (9CI) (CA INDEX NAME)

BrC1=CC=CC=C1C(=O)C2CCN2C(=O)N3C(=O)N=CC=C3COC(=O)C1CC(=C2N3C(=N1)C(=N2)C4=CC=CC=C4N3)C(=C5C=CC(=C5)Br)C6=CC=CC=C6

Page 22




RN 745837-09-6 HCAPLUS

CN Formic acid, compd. with 5-[(2-bromophenyl)methylene]-1,5,6,7-tetrahydro-9H-pyrrolo[1,2-a]purin-9-imine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 745837-08-5

CMF C15 H12 Br N5



CM 2


CRN 64-18-6

CMF C H2 O2




RN 745837-10-9 HCAPLUS

CN Pyrrolo[1,2-a]thieno[2,3-d]pyrimidin-4(6H)-imine, 8-[(2-bromophenyl)methylene]-7,8-dihydro- (9CI) (CA INDEX NAME)




RN 745837-11-0 HCAPLUS

CN [1]Benzothieno[2,3-d]pyrrolo[1,2-a]pyrimidin-10(1H)-imine, 3-[(2-bromophenyl)methylene]-2,3,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)




RN 745837-12-1 HCAPLUS

CN Pyrrolo[1,2-a]thieno[2,3-d]pyrimidin-4(6H)-imine, 8-[(2-bromophenyl)methylene]-7,8-dihydro-2,3-dimethyl- (9CI) (CA INDEX NAME)




RN 745837-13-2 HCAPLUS

CN Pyrrolo[1,2-a]thieno[2,3-d]pyrimidin-4(6H)-imine, 8-[(2-bromophenyl)methylene]-3-(1,1-dimethylethyl)-7,8-dihydro- (9CI) (CA INDEX NAME)




RN 745837-14-3 HCAPLUS

CN Pyrrolo[1,2-a]thieno[2,3-d]pyrimidin-4(6H)-imine, 8-[(2-bromophenyl)methylene]-3-cyclopropyl-7,8-dihydro- (9CI) (CA INDEX NAME)




RN 745837-15-4 HCAPLUS

CN Furo[2,3-d]pyrrolo[1,2-a]pyrimidin-4(6H)-imine, 8-[(2-bromophenyl)methylene]-7,8-dihydro-2,3-dimethyl- (9CI) (CA INDEX NAME)



RN 745837-36-9 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-imine, 3-[(2-bromophenyl)methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




IT 745837-19-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrroloquinazolines as modulators of chemokine activity)

RN 745837-19-8 HCAPLUS

CN Pyrrolo[1,2-a]thieno[2,3-d]pyrimidine-8-methanol, α -(2-bromophenyl)-4,6,7,8-tetrahydro-4-imino- (9CI) (CA INDEX NAME)



=> d ibib ed ab hitstr 2-46

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, USPATFULL, BIOSIS, SYNTHLINE, EMBASE, PASCAL' - CONTINUE? (Y)/N:y

L67 ANSWER 2 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 2

ACCESSION NUMBER: 2003:656998 HCAPLUS

DOCUMENT NUMBER: 139:191372

TITLE: Antimalarial and antiproliferative pharmacophore models, novel tryptanthrin compounds having increased solubility, and methods of making and using thereof
INVENTOR(S): Nichols, Daniel A.; Hicks, Rickey P.; Bhattacharjee, Apurba K.

PATENT ASSIGNEE(S): U.S. Army Medical Research and Material Command, USA

SOURCE: PCT Int. Appl., 97 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003069303	A2	20030821	WO 2003-US3517	20030207 <--
WO 2003069303	A3	20031231		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003209012	A1	20030904	AU 2003-209012	20030207 <--
US 2004033934	A1	20040219	US 2003-359625	20030207 <--
PRIORITY APPLN. INFO.:			US 2002-355162P	P 20020209 <--
			US 2002-396911P	P 20020717 <--
			WO 2003-US3517	W 20030207 <--

ED Entered STN: 22 Aug 2003

AB Disclosed herein is a pharmacophore model for antimalarial activity and methods of making and using thereof. The pharmacophore comprises two hydrogen bond acceptor (lipid) functions and two hydrophobic (aromatic) functions. The pharmacophore model was made using a test set of tryptanthrin compds. which exhibit antimalarial activity. Also disclosed

are tryptanthrin compds. having greater solubility and bioactivity as compared to prior art tryptanthrin compds. and methods of making and using thereof. Also disclosed are methods of treating malaria in a subject.


IT 454699-59-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antimalarial and antiproliferative pharmacophore models, tryptanthrin compds. having increased solubility)

RN 454699-59-3 HCAPLUS

CN Indolo[2,1-b]quinazolin-12(6H)-one, 8-fluoro-4-methoxy-6-(phenylmethylene) - (9CI) (CA INDEX NAME)



L67 ANSWER 3 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 3

ACCESSION NUMBER: 2003:114417 HCAPLUS

DOCUMENT NUMBER: 139:7050

TITLE: A facile synthesis of simple alkaloids-synthesis of 2,3-polymethylene-4(3H)-quinazolinones and related alkaloids

AUTHOR(S): Lee, Eung Seok; Park, Jae-Gyu; Jahng, Yurngdong

CORPORATE SOURCE: College of Pharmacy, Yeungnam University, Kyongsan, 712-749, S. Korea

SOURCE: Tetrahedron Letters (2003), 44(9), 1883-1886

CODEN: TELEAY; ISSN: 0040-4039

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 139:7050

ED Entered STN: 14 Feb 2003

AB An efficient procedure for preparation of the simple alkaloids, 2,3-polymethylene-4(3H)-quinazolinones, luotonin A (I), tryptanthrin (II), and rutaecarpine has been established by the reaction of lactam-HCl salts with POCl₃ followed by cyclization with Me anthranilate.


IT 408321-71-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 2,3-polymethylene-4(3H)-quinazolinones and related alkaloids by the reaction of lactam-HCl salts with POCl₃ followed by cyclization with Me anthranilate)

RN 408321-71-1 HCAPLUS

CN Indolo[2,1-b]quinazolin-12(6H)-one, 6-(phenylmethylene)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L67 ANSWER 4 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 4

ACCESSION NUMBER: 2003:416522 HCAPLUS

DOCUMENT NUMBER: 139:149803

TITLE: Synthesis and COX-2 inhibitory activities of rutaecarpine homologues

AUTHOR(S): Chang, Hyeun Wook; Kim, Seung Ill; Jung, Hejin; Jahng, Yurngdong

CORPORATE SOURCE: College of Pharmacy, Yeungnam University, Kyongsan, 712-749, S. Korea

SOURCE: Heterocycles (2003), 60(6), 1359-1366

CODEN: HTCYAM; ISSN: 0385-5414

PUBLISHER: Japan Institute of Heterocyclic Chemistry

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 139:149803

ED Entered STN: 01 Jun 2003

AB Homologous series of rutaecarpine were prepared by structurally modifying the C-ring and were evaluated their inhibitory activities on COX-2. The inhibitory activity on COX-2 increased with the increase of methylene unit while the selectivity on COX-2 over COX-1 decreased to lead a loss in trimethylene bridged system.

IT 221186-21-6P 571172-27-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(synthesis and COX-2 inhibitory activities of rutaecarpine homologs from a polymethylenequinazolinone)

RN 221186-21-6 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-(phenylmethylene)-, (3E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 571172-27-5 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-(phenylmethylene)-,

(3Z) - (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L67 ANSWER 5 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 5

ACCESSION NUMBER: 2004:177227 HCAPLUS

DOCUMENT NUMBER: 140:406986

TITLE: A simple synthesis of tryptanthrin

AUTHOR(S): Son, Jong Keun; Park, Jae Gyu; Jahng, Yurngdong

CORPORATE SOURCE: College of Pharmacy, Yeungnam University, Kyongsan, 712-749, S. Korea

SOURCE: Heterocyclic Communications (2003), 9(6), 621-624

CODEN: HCOMEX; ISSN: 0793-0283

PUBLISHER: Freund Publishing House Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 140:406986

ED Entered STN: 04 Mar 2004

AB A simple synthetic procedure for tryptanthrin (I) was established from oxindole via indolo[2,1-b]quinazolin-12(6H)-one as a key intermediate.

IT 686289-50-9P 686289-51-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(simple synthesis of tryptanthrin from oxindole)

RN 686289-50-9 HCAPLUS

CN Indolo[2,1-b]quinazolin-12(6H)-one, 6-(phenylmethylene)-, (6E) - (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686289-51-0 HCAPLUS

CN Indolo[2,1-b]quinazolin-12(6H)-one, 6-(phenylmethylene)-, (6Z) - (9CI) (CA

INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L67 ANSWER 6 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 6

ACCESSION NUMBER: 2004:6781 HCAPLUS

DOCUMENT NUMBER: 141:135342

TITLE: Activation of the Ah receptor and Ah receptor signal transduction pathway by tryptophan-derived agonists

AUTHOR(S): Denison, Michael S.; Han, Dal-Ho; Heath-Pagliuso, Sharon; Scovill, John; Meijer, Laurent; Skaltounis, Leandros; Gillam, Elizabeth M. J.; Nagy, Scott R.

CORPORATE SOURCE: Department of Environmental Toxicology, University of California, Davis, CA, USA

SOURCE: Organohalogen Compounds (2003), 65, 90-93
CODEN: ORCOEP; ISSN: 1026-4892

PUBLISHER: International Symposium on Halogenated Environmental Organic Pollutants and Persistent Organic Pollutants, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 06 Jan 2004


AB A series of derivs. of several of the indole-containing ligands was examined to understand the structural diversity of Ah receptor (AhR) ligands and to determine whether key structural characteristics exist in this class naturally-occurring ligands. Tryptanthrins are a class of naturally occurring compds. found in plants as well as being a microbial metabolite that has some therapeutic uses. Results showed that tryptanthrins compds. were significantly more potent than the classical PAH inducers beta-naphthoflavone and 3-methylcholanthrene. Results also demonstrate that the substituted indirubins represent some of the most potent nonHAH AhR activators that been identified to date. Indole-containing compds. likely represent one major group of potent naturally-occurring activators of the AhR to which humans are exposed.

IT 408321-71-1

RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(activation of Ah receptor and Ah receptor signal transduction pathway by tryptophan-derived agonists)

RN 408321-71-1 HCAPLUS

CN Indolo[2,1-b]quinazolin-12(6H)-one, 6-(phenylmethylene)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L67 ANSWER 7 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 7

ACCESSION NUMBER: 2002:251288 HCAPLUS

DOCUMENT NUMBER: 137:210404

TITLE: Analysis of stereoelectronic properties, mechanism of action and pharmacophore of synthetic indolo[2,1-b]quinazoline-6,12-dione derivatives in relation to antileishmanial activity using quantum chemical, cyclic voltammetry and 3-D-QSAR CATALYST procedures

AUTHOR(S): Bhattacharjee, Apurba K.; Skanchy, David J.; Jennings, Barton; Hudson, Thomas H.; Brendle, James J.; Werbovetz, Karl A.

CORPORATE SOURCE: Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, MD, 20910, USA

SOURCE: Bioorganic & Medicinal Chemistry (2002), 10(6), 1979-1989

CODEN: BMECEP; ISSN: 0968-0896

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 04 Apr 2002

AB Several indolo[2,1-b]quinazoline-6,12-dione (tryptanthrin) derivs. exhibited remarkable activity at concns. below 100 ng/mL when tested against in vitro Leishmania donovani amastigotes. The in vitro toxicity studies indicate that the compds. are fairly well tolerated in both macrophage and neuronal lines. An anal. based on qual. and quant. structure-activity relationship studies between in vitro antileishmanial activity and mol. electronic structure of 27 analogs of indolo[2,1-b]quinazoline-6,12-dione is presented here by using a combination of semi-empirical AM1 quantum chemical, cyclic voltammetry and a pharmacophore generation (CATALYST) methods. A modest to good correlation is observed between activity and a few calculated mol. properties such as mol. d., octanol-water partition coefficient, MO energies, and redox potentials. Electron transfer seems to be a plausible path in the mechanism of action of the compds. A pharmacophore generated by using the 3-D QSAR of CATALYST produced a fairly accurate predictive model of antileishmanial activity of the tryptanthrins. The validity of the pharmacophore model extends to structurally different class of compds. that could open new frontiers for study. The carbonyl group of the five- and six-membered rings in the indolo[2,1-b]quinazoline-6,12-dione skeleton and the electron transfer ability to the carbonyl atom appear to be crucial for activity.


IT 454699-59-3

RL: ADV (Adverse effect, including toxicity); DMA (Drug mechanism of action); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(anal. of stereoelectronic properties, mechanism of action and pharmacophore of synthetic tryptanthrin derivs. in relation to antileishmanial activity using quantum chemical, cyclic voltammetry and 3-D-QSAR CATALYST procedures)

RN 454699-59-3 HCAPLUS

CN Indolo[2,1-b]quinazolin-12(6H)-one, 8-fluoro-4-methoxy-6-(phenylmethylene)-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L67 ANSWER 8 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 8

ACCESSION NUMBER: 2002:146295 HCAPLUS

DOCUMENT NUMBER: 136:291577

TITLE: Antitrypanosomal activities of tryptanthrins

AUTHOR(S): Scovill, John; Blank, Elizabeth; Konnick, Michael; Nenortas, Elizabeth; Shapiro, Theresa

CORPORATE SOURCE: Department of Chemistry, Bucknell University, Lewisburg, PA, 17837, USA

SOURCE: Antimicrobial Agents and Chemotherapy (2002), 46(3), 882-883

CODEN: AMACCQ; ISSN: 0066-4804

PUBLISHER: American Society for Microbiology

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 26 Feb 2002

AB New drugs and mol. targets are needed against Trypanosoma brucei, the protozoan that causes African sleeping sickness. Tryptanthrin (indolo[2,1-b]quinazoline-6,12-dione), a traditional antifungal agent, and 11 analogs were tested against T. brucei in vitro. The greatest activity was conferred by electron-withdrawing groups in the 8 position of the tryptanthrin ring system; the most potent compound had a 50% effective concentration of 0.40 μ M.


IT 408321-71-1

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antitrypanosomal activities of tryptanthrins against Trypanosoma brucei)

RN 408321-71-1 HCAPLUS

CN Indolo[2,1-b]quinazolin-12(6H)-one, 6-(phenylmethylene)-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L67 ANSWER 9 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 9

ACCESSION NUMBER: 2002:5125 HCAPLUS

DOCUMENT NUMBER: 136:319026

TITLE: A pyrroloquinazoline derivative with anti-inflammatory and analgesic activity by dual inhibition of cyclo-oxygenase-2 and 5-lipoxygenase

AUTHOR(S): Rioja, Inmaculada; Terencio, M. Carmen; Ubeda, Amalia; Molina, Pedro; Tarraga, Alberto; Gonzalez-Tejero, Antonia; Alcaraz, M. Jose

CORPORATE SOURCE: Facultad de Farmacia, Departamento de Farmacologia, Universidad de Valencia, Burjasot, Valencia, 46100, Spain

SOURCE: European Journal of Pharmacology (2002), 434(3), 177-185

CODEN: EJPHAZ; ISSN: 0014-2999

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 02 Jan 2002

AB In a previous study, we reported a new pyrroloquinazoline derivative, 3-(4'-acetoxy-3',5'-dimethoxy)benzylidene-1,2-dihydropyrrolo[2,1-b]quinazoline-9-one (PQ), which inhibited human purified 5-lipoxygenase activity and prostaglandin E2 release in lipopolysaccharide-stimulated RAW 264.7 cells. In the present work, we show that PQ inhibits cyclo-oxygenase-2 activity in intact cell assays (human monocytes) and purified enzyme preps. (ovine isoenzymes) without affecting cyclo-oxygenase-1 activity. This behavior was confirmed in vivo by using the zymosan-injected mouse air pouch model, where PQ caused a marked reduction in cell migration and leukotriene B4 levels at 4 h, as well as inhibition of prostaglandin E2 levels without affecting cyclo-oxygenase-2 expression at 24 h after zymosan stimulation. In addition, oral administration of this compound significantly reduced carrageenan-induced mouse paw edema and phenyl-p-benzoquinone-induced writhings in mice. These results indicate that oral PQ exerts analgesic and anti-inflammatory effects, which are related to dual inhibition of cyclo-oxygenase-2 and 5-lipoxygenase activities.


IT 371766-68-6

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pyrroloquinazoline derivative with antiinflammatory and analgesic activity by dual inhibition of cyclooxygenase-2 and 5-lipoxygenase)

RN 371766-68-6 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 3-[[4-(acetyloxy)-3,5-dimethoxyphenyl]methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L67 ANSWER 10 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 11

ACCESSION NUMBER: 2001:627724 HCAPLUS

DOCUMENT NUMBER: 135:338742

TITLE: Inhibition of leukocyte functions by the alkaloid isaindigotone from *Isatis indigotica* and some new synthetic derivatives

AUTHOR(S): Molina, Pedro; Tarraga, Alberto; Gonzalez-Tejero, Antonia; Rioja, Immaculada; Ubeda, Amalia; Terencio, M. Carmen; Alcaraz, M. Jose

CORPORATE SOURCE: Departamento de Quimica Organica Facultad de Quimica, Universidad de Murcia, Murcia, Spain

SOURCE: Journal of Natural Products (2001), 64(10), 1297-1300

CODEN: JNPRDF; ISSN: 0163-3864

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 135:338742

ED Entered STN: 30 Aug 2001

AB The alkaloid isaindigotone and seven derivs. have been synthesized to study their influence on several leukocyte functions and the generation of inflammatory mediators. Isaindigotone was found to be a scavenger of superoxide generated either by the hypoxanthine/xanthine oxidase system or stimulated human neutrophils. Isaindigotone and its acetylated derivative also inhibited 5-lipoxygenase activity and leukotriene B4 production in these cells, whereas none of the compds. affected degranulation. In RAW 264.7 macrophages stimulated with lipopolysaccharide, synthetic derivs. exerted higher inhibitory effects on PGE2 and NO generation when compared with isaindigotone. The presence of an acetoxyl group at C-4' favors the inhibition of NO and PGE2 production, whereas the fluoro substituent at C-4' or the absence of substituents on the aromatic ring of the benzylidene unit improves the inhibition of PGE2. Thus, this series of compds. can attenuate the production of mediators relevant to the inflammatory response.


IT 18549-16-1P 85620-22-0P 189316-00-5DP,
Isaindigotone, derivs. 189316-00-5P, Isaindigotone
371766-68-6P 371766-69-7P 371766-70-0P
371766-71-1P 371766-72-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(inhibition of leukocyte functions by alkaloid isaindigotone from
Isatis indigotica and by its synthetic derivs.)


RN 18549-16-1 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-(phenylmethylene)- (9CI)
(CA INDEX NAME)



RN 85620-22-0 HCAPLUS


CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-[(4-hydroxyphenyl)methylene]- (9CI) (CA INDEX NAME)



RN 189316-00-5 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-[(4-hydroxy-3,5-dimethoxyphenyl)methylene]-, (3E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 189316-00-5 HCAPLUS


CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-[(4-hydroxy-3,5-dimethoxyphenyl)methylene]-, (3E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 371766-68-6 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 3-[[4-(acetyloxy)-3,5-dimethoxyphenyl]methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 371766-69-7 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 3-[(3,5-dimethoxyphenyl)methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 371766-70-0 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-[[4-(trifluoromethyl)phenyl]methylene]- (9CI) (CA INDEX NAME)




RN 371766-71-1 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 3-[[4-fluorophenyl]methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 371766-72-2 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 3-[[4-(acetyloxy)phenyl]methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L67 ANSWER 11 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 12
 ACCESSION NUMBER: 2000:737821 HCAPLUS
 DOCUMENT NUMBER: 134:29603
 TITLE: A convenient divergent approach to the alkaloids isaindigotone and luotonin A
 AUTHOR(S): Molina, Pedro; Tarraga, Alberto; Gonzalez-Tejero, Antonia
 CORPORATE SOURCE: Departamento de Quimica Organica, Facultad de Quimica, Universidad de Murcia, Murcia, E-30071, Spain
 SOURCE: Synthesis (2000), (11), 1523-1525
 CODEN: SYNTBF; ISSN: 0039-7881
 PUBLISHER: Georg Thieme Verlag
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 134:29603
 ED Entered STN: 19 Oct 2000
 AB Deoxyvasicinone (I, X = CH₂) has been used as the key intermediate to prepare the alkaloids isaindigotone (II) and luotonin A (III). This intermediate is directly converted into isaindigotone by condensation with 4-acetoxy-3,5-dimethoxybenzaldehyde; alternatively oxidation with SeO₂ afforded the pyrrolo[2,1-b]quinazoline-3,9-dione (I, X = CO), a putative precursor of the luotonin A.
 IT 18549-16-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (divergent approach to the alkaloids isaindigotone and luotonin A)
 RN 18549-16-1 HCAPLUS
 CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-(phenylmethylene)- (9CI)
 (CA INDEX NAME)



IT 189316-00-5P, Isaindigotone
RL: SPN (Synthetic preparation); PREP (Preparation)
(divergent approach to the alkaloids isaindigotone and luotonin A)
RN 189316-00-5 HCAPLUS
CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-[(4-hydroxy-3,5-dimethoxyphenyl)methylene]-, (3E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L67 ANSWER 12 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 13
ACCESSION NUMBER: 1999:244150 HCAPLUS
DOCUMENT NUMBER: 131:44687
TITLE: Transformation of natural compounds. VII. Synthesis of α -piperazinylmethylenedeoxyvasicin-4-ones
AUTHOR(S): Elmuradov, B. Zh.; Shakhidoyatov, Kh. M.
CORPORATE SOURCE: Institute of the Chemistry of Plant Substances, Academy of Sciences of the Republic of Uzbekistan, Tashkent, Uzbekistan
SOURCE: Chemistry of Natural Compounds (Translation of Khimiya Prirodnikh Soedinenii) (1998), 34(3), 298-299
CODEN: CHNCA8; ISSN: 0009-3130
PUBLISHER: Consultants Bureau
DOCUMENT TYPE: Journal
LANGUAGE: English
ED Entered STN: 21 Apr 1999
AB α -(Piperazinylmethylene)deoxyvasicinones I [R = Me, Ph, C₆H₄Me-m, C₆H₄OMe-o, C₆H₄Cl-p, C₆H₄F-p, C₆HNO₂-p, C₆H₄CF₃-m, C₆H₃Me₂-2,3, CHPh₂, C(OH)Ph₂] have been synthesized by the interaction of α -(hydroxymethylene)deoxyvasicin-4-one with various N-substituted piperazines.
IT 227189-12-0P 227189-13-1P 227189-14-2P
227189-15-3P 227189-20-0P 227189-21-1P
227189-22-2P 227189-23-3P 227189-24-4P
227189-25-5P 227189-26-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis of α -piperazinylmethylenedeoxyvasicin-4-ones via condensation with piperazine derivs.)
RN 227189-12-0 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-[[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]methylene]- (9CI) (CA INDEX NAME)




RN 227189-13-1 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 3-[[4-(2,3-dimethylphenyl)-1-piperazinyl]methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 227189-14-2 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 3-[[4-(diphenylmethyl)-1-piperazinyl]methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 227189-15-3 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-[[4-(hydroxydiphenylmethyl)-1-piperazinyl]methylene]- (9CI) (CA INDEX NAME)




RN 227189-20-0 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-[(4-methyl-1-piperazinyl)methylene]- (9CI) (CA INDEX NAME)




RN 227189-21-1 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-[(4-phenyl-1-piperazinyl)methylene] - (9CI) (CA INDEX NAME)




RN 227189-22-2 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-[[4-(3-methylphenyl)-1-piperazinyl]methylene] - (9CI) (CA INDEX NAME)




RN 227189-23-3 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-[[4-(2-methoxyphenyl)-1-piperazinyl]methylene]- (9CI) (CA INDEX NAME)




RN 227189-24-4 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 3-[[4-(4-chlorophenyl)-1-piperazinyl]methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 227189-25-5 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 3-[[4-(4-fluorophenyl)-1-piperazinyl]methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)



RN 227189-26-6 HCAPLUS


CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-[[4-(4-nitrophenyl)-1-piperazinyl]methylene]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L67 ANSWER 13 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 14
 ACCESSION NUMBER: 1999:82507 HCAPLUS
 DOCUMENT NUMBER: 130:223469
 TITLE: Synthesis of 9-arylidene derivatives of deoxyvasicinone
 AUTHOR(S): Shakhidoyatov, Kh. M.; Kaisarov, I. K.
 CORPORATE SOURCE: Institute of the Chemistry of Plant Substances, Academy of Sciences of the Republic of Uzbekistan, Tashkent, Uzbekistan
 SOURCE: Chemistry of Natural Compounds (Translation of Khimiya Prirodnykh Soedinenii) (1998), 34(1), 59-61
 CODEN: CHNCA8; ISSN: 0009-3130
 PUBLISHER: Consultants Bureau
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 ED Entered STN: 09 Feb 1999
 AB A simple method has been developed for obtaining 9-arylidenedeoxyvasicinones by condensing deoxyvasicinone with aromatic aldehydes in the presence of glacial acetic acid. The yields of reaction products amount to 69-95%.
 IT 221186-21-6P 221186-22-7P 221186-23-8P
 221186-24-9P 221186-25-0P 221186-26-1P
 221186-27-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (synthesis of benzylidene derivs. of deoxyvasicinone)
 RN 221186-21-6 HCAPLUS
 CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-(phenylmethylene)-, (3E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 221186-22-7 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-[(3-nitrophenyl)methylene]-, (3E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 221186-23-8 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-[(4-nitrophenyl)methylene]-, (3E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 221186-24-9 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 3-[[4-(dimethylamino)phenyl]methylene]-2,3-dihydro-, (3E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 221186-25-0 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-[(2-hydroxyphenyl)methylene]-, (3E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 221186-26-1 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 3-[(5-bromo-2-hydroxyphenyl)methylene]-2,3-dihydro-, (3E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 221186-27-2 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-[(2-hydroxy-3-

methoxyphenyl)methylene]-, (3E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L67 ANSWER 14 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 15
 ACCESSION NUMBER: 1997:644530 HCAPLUS
 DOCUMENT NUMBER: 127:328882
 TITLE: New alkaloids from *Isatis indigotica*
 AUTHOR(S): Wu, Xiaoyun; Qin, Guowei; Cheung, Kung Kai; Cheng, Kin Fai
 CORPORATE SOURCE: Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 200031, Peop. Rep. China
 SOURCE: Tetrahedron (1997), 53(39), 13323-13328
 CODEN: TETRAB; ISSN: 0040-4020
 PUBLISHER: Elsevier
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 ED Entered STN: 11 Oct 1997
 AB From the roots of *Isatis indigotica*, two new alkaloids named isaindigotidione (I) and isaindigotone (II) were isolated. Their structures were elucidated by spectral and X-ray crystallog. analyses. I is the first discovered indolizino[7,6-c]quinoline derivative
 IT 189316-00-5P, Isaindigotone
 RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation)
 (new alkaloids from *Isatis indigotica*)
 RN 189316-00-5 HCAPLUS
 CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-[(4-hydroxy-3,5-dimethoxyphenyl)methylene]-, (3E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L67 ANSWER 15 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 16
 ACCESSION NUMBER: 1992:128860 HCAPLUS
 DOCUMENT NUMBER: 116:128860
 TITLE: Reactions with activated nitriles. Synthesis of new substituted pyridines, pyrano[2,3-d]imidazoles and pyrrolo[2,1-b]quinazolines
 AUTHOR(S): Hishmat, O. H.; Magd El Din, A. A.; Ismail, N. A.
 CORPORATE SOURCE: Nat. Prod. Dep., Natl. Res. Cent., Cairo, Egypt
 SOURCE: Organic Preparations and Procedures International (1992), 24(1), 33-7
 CODEN: OPPIAK; ISSN: 0030-4948
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 116:128860
 ED Entered STN: 03 Apr 1992
 AB Cyclization of $\text{ArNHCH:C(CN)CSNH}_2$ ($\text{Ar} = \text{Ph}, 4\text{-MeC}_6\text{H}_4, 4\text{-ClC}_6\text{H}_4$) with XCH_2CN ($\text{X} = \text{cyano}, \text{CO}_2\text{Et}, \text{COPh}$) gave pyridinethiones I. Reacting $\text{CH}_2(\text{CN})_2$ with quinazolines II ($\text{Ar} = \text{Ph}, 4\text{-MeC}_6\text{H}_4, 4\text{-ClC}_6\text{H}_4$) gave pyrroloquinazolinones III. Pyranoimidazoles IV ($\text{R} = \text{H}, \text{Ph}, \text{X} = \text{cyano}, \text{CO}_2\text{Et}, \text{COPh}$) were also prepared
 IT 139438-43-0P 139438-44-1P 139438-45-2P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
 RN 139438-43-0 HCAPLUS
 CN Pyrrolo[2,1-b]quinazoline-2-carbonitrile, 1-amino-1,2,3,9-tetrahydro-9-oxo-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 139438-44-1 HCAPLUS
 CN Pyrrolo[2,1-b]quinazoline-2-carbonitrile, 1-amino-1,2,3,9-tetrahydro-3-[(4-

methylphenyl)methyl]-9-oxo- (9CI) (CA INDEX NAME)




RN 139438-45-2 HCAPLUS

CN Pyrrolo[2,1-b]quinazoline-2-carbonitrile, 1-amino-3-[(4-chlorophenyl)methyl]-1,2,3,9-tetrahydro-9-oxo- (9CI) (CA INDEX NAME)




L67 ANSWER 16 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 17
 ACCESSION NUMBER: 1987:176718 HCAPLUS
 DOCUMENT NUMBER: 106:176718
 TITLE: New reactions of deoxyvasicinone
 AUTHOR(S): Dunn, A. D.; Kinnear, K. I.; Norrie, R.
 CORPORATE SOURCE: Dep. Mol. Life Sci., Dundee Coll. Technol., Dundee, DD1 1GH, UK
 SOURCE: Zeitschrift fuer Chemie (1986), 26(8), 290-2
 CODEN: ZECEAL; ISSN: 0044-2402
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 106:176718
 ED Entered STN: 29 May 1987
 AB Analogs of deoxyvasicinone, e.g. I (n = 1, 2, 3; R, R1, R2 = H, Me) were prepared by the cyclocondensation of aminopyridinecarboxylic acids with cyclic imidates II (n = 1, 2, 3; R, R1, R2 = H, Me). Condensation of I (n = 1; R - R2 = H, R = R1 = H, R2 = Me) with PhCHO gave benzylidene derivs. III (R = H, Me) in 22-69% yields.
 IT 107805-66-3P 107805-67-4P 107805-68-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 107805-66-3 HCAPLUS
 CN Pyrido[2,3-d]pyrrolo[1,2-a]pyrimidin-5(7H)-one, 8,9-dihydro-9-(phenylmethylene)- (9CI) (CA INDEX NAME)




RN 107805-67-4 HCAPLUS

CN Pyrido[3,4-d]pyrrolo[1,2-a]pyrimidin-5(7H)-one, 8,9-dihydro-9-(phenylmethylene)- (9CI) (CA INDEX NAME)



RN 107805-68-5 HCAPLUS

CN Pyrido[2,3-d]pyrrolo[1,2-a]pyrimidin-5(7H)-one, 8,9-dihydro-8-methyl-9-(phenylmethylene)- (9CI) (CA INDEX NAME)



L67 ANSWER 17 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 18

ACCESSION NUMBER: 1987:196368 HCAPLUS

DOCUMENT NUMBER: 106:196368

TITLE: New reactions of deoxyvasicinone. Part 4

AUTHOR(S): Dunn, A. D.; Kinnear, K. I.

CORPORATE SOURCE: Dundee Coll. Technol., Dundee, DD 1HG, UK

SOURCE: Journal of Heterocyclic Chemistry (1986), 23(1), 53-7

CODEN: JHTCAD; ISSN: 0022-152X

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 106:196368

ED Entered STN: 13 Jun 1987


AB Analogs of deoxyvasicinone (I) in which the pyrrole ring is substituted, enlarged, or attached to the a face of the quinazolone system were prepared and several reactions of these analogs with electrophilic reagents have been investigated.

IT 107954-47-2P 107954-48-3P 107954-49-4P
107954-50-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 107954-47-2 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-1-methyl-3-(phenylmethylene)- (9CI) (CA INDEX NAME)




RN 107954-48-3 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-1,1-dimethyl-3-(phenylmethylene)- (9CI) (CA INDEX NAME)




RN 107954-49-4 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-2-methyl-3-(phenylmethylene)- (9CI) (CA INDEX NAME)




RN 107954-50-7 HCAPLUS

CN Pyrrolo[2,1-b]quinazoline-1-carboxylic acid, 1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)-, ethyl ester (9CI) (CA INDEX NAME)




ACCESSION NUMBER: 1985:523753 HCAPLUS
DOCUMENT NUMBER: 103:123753
TITLE: New reactions of deoxyvasicinone. Part 3
AUTHOR(S): Dunn, A. D.; Kinnear, K. I.
CORPORATE SOURCE: Dundee Coll. Technol., Dundee, DD1 1HG, UK
SOURCE: Journal of Heterocyclic Chemistry (1985),
22(2), 311-12
CODEN: JHTCAD; ISSN: 0022-152X
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 103:123753
ED Entered STN: 19 Oct 1985
AB The reaction of deoxyvasicinone I with Bz2O, bis(dimethylamino)methane and
amyl nitrite are reported. Metalation of I is also described. Thus, I
was treated with Bz2O to give the adduct II.
IT 95235-23-7P 98262-87-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 95235-23-7 HCAPLUS
CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-(hydroxyphenylmethylene)-
, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 98262-87-4 HCAPLUS
CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 3-[(benzoyloxy)phenylmethylene]-2,3-
dihydro-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L67 ANSWER 19 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 20
ACCESSION NUMBER: 1984:407185 HCAPLUS
DOCUMENT NUMBER: 101:7185
TITLE: Amino derivatives of benzylidenepyrrolo[2,1-

INVENTOR(S): b]quinazolines and benzylidenepyrido[2,1-b]quinazolines and a drug containing them
Doria, Gianfederico; Passarotti, Carlo; Corno, Maria Luisa

PATENT ASSIGNEE(S): Farmitalia Carlo Erba S.p.A., Italy

SOURCE: Ger. Offen., 99 pp.
CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3326511	A1	19840209	DE 1983-3326511	19830722 <--
ES 524262	A1	19841116	ES 1983-524262	19830719 <--
IL 69274	A1	19860831	IL 1983-69274	19830719 <--
FI 8302649	A	19840206	FI 1983-2649	19830720 <--
FI 74471	B	19871030		
FI 74471	C	19880208		
AU 8317113	A1	19840209	AU 1983-17113	19830720 <--
AU 557305	B2	19861218		
ZA 8305288	A	19840328	ZA 1983-5288	19830720 <--
NO 8302662	A	19840206	NO 1983-2662	19830721 <--
SE 8304111	A	19840206	SE 1983-4111	19830722 <--
SE 461526	B	19900226		
SE 461526	C	19900621		
HU 31213	O	19840428	HU 1983-2600	19830722 <--
HU 188929	B	19860528		
CH 654307	A	19860214	CH 1983-4035	19830722 <--
BE 897358	A1	19840125	BE 1983-211222	19830725 <--
DK 8303400	A	19840206	DK 1983-3400	19830725 <--
FR 2531957	A1	19840224	FR 1983-12283	19830725 <--
FR 2531957	B1	19861205		
GB 2125039	A1	19840229	GB 1983-19929	19830725 <--
GB 2125039	B2	19850904		
NL 8302642	A	19840301	NL 1983-2642	19830725 <--
JP 59044388	A2	19840312	JP 1983-134515	19830725 <--
CA 1212379	A1	19861007	CA 1983-433127	19830725 <--
SU 1308197	A3	19870430	SU 1983-3624052	19830725 <--
AT 8302705	A	19911115	AT 1983-2705	19830725 <--
US 4579847	A	19860401	US 1984-681694	19841214 <--
PRIORITY APPLN. INFO.:			GB 1982-22591	A 19820805 <--
			US 1983-515646	A1 19830720 <--

OTHER SOURCE(S): CASREACT 101:7185

ED Entered STN: 07 Jul 1984


AB Title compds. (I) [m = 0, 1; n = 1, 2; R = H, alkyl, aryl, alkanoyl; R1 = halomethyl, (un)substituted aminomethyl, CO₂H or derivative, etc.; R2 = H, or C1-6 alkyl, R3-5 = H, halo, haloalkyl, OH, etc.; Z = bond, alkylene, phenylene, etc.] were prepared as antiasthmatics. Thus, 6-amino-3-benzylidene-1,2,3,9-tetrahydropyrrolo[2,1-b]quinazolin-9-one was treated with EtO₂CCOCl, and the ester saponified to give the 6-(carboxyamido) derivative II, which had antiasthmatic activity.

IT 85743-12-0

RL: RCT (Reactant); RACT (Reactant or reagent)
(acylation of)

RN 85743-12-0 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-2,3-dihydro-3-(phenylmethylene)- (9CI) (CA INDEX NAME)




IT 85743-13-1 85743-15-3 85743-16-4
 85743-17-5 85743-18-6 85743-19-7
 85743-20-0 85743-21-1 85743-22-2
 85743-23-3 90262-34-3 90262-35-4
 90262-36-5 90262-37-6 90262-38-7
 90262-39-8 90262-40-1 90262-41-2
 90262-42-3 90262-43-4 90262-44-5
 90262-45-6 90262-46-7 90262-47-8

RL: RCT (Reactant); RACT (Reactant or reagent)
 (acylation of, with ethoxalyl chloride)


RN 85743-13-1 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-2,3-dihydro-3-[(3,4,5-trimethoxyphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 85743-15-3 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-2,3-dihydro-3-[(2-methylphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 85743-16-4 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-2,3-dihydro-3-[(3-methylphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 85743-17-5 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-2,3-dihydro-3-[(4-methylphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 85743-18-6 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-2,3-dihydro-3-[(2-methoxyphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 85743-19-7 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-2,3-dihydro-3-[(3-methoxyphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 85743-20-0 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-2,3-dihydro-3-[(4-methoxyphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 85743-21-1 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-3-[(2,3-dimethoxyphenyl)methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 85743-22-2 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-3-[(4-fluorophenyl)methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 85743-23-3 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-3-(1,3-benzodioxol-5-ylmethylene)-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 90262-34-3 HCAPLUS


CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-3-[(2-chlorophenyl)methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 90262-35-4 HCAPLUS
 CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-3-[(3,4-dimethoxyphenyl)methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 90262-36-5 HCAPLUS
 CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-2,3-dihydro-3-[[3-(trifluoromethyl)phenyl]methylene]- (9CI) (CA INDEX NAME)



RN 90262-37-6 HCAPLUS
 CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-3-[(2,5-dimethylphenyl)methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 90262-38-7 HCAPLUS
 CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-3-[(2-ethoxyphenyl)methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 90262-39-8 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-3-[(3-ethoxyphenyl)methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 90262-40-1 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-3-[(4-ethoxyphenyl)methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 90262-41-2 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-3-[(4-chlorophenyl)methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 90262-42-3 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-3-[(3-chlorophenyl)methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 90262-43-4 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-3-[(3-ethoxy-2-methoxyphenyl)methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 90262-44-5 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-3-[(2,5-dimethoxyphenyl)methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 90262-45-6 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-3-[(2,3-diethoxyphenyl)methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 90262-46-7 HCAPLUS


CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-3-[(2,4-dichlorophenyl)methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)



RN 90262-47-8 HCAPLUS
 CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-3-[(2,6-dichlorophenyl)methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




IT 90262-33-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and antiasthmatic activity of)
 RN 90262-33-2 HCAPLUS
 CN Acetic acid, oxo[[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino] - (9CI) (CA INDEX NAME)




IT 90262-48-9P 90262-49-0P 90262-50-3P
 90262-51-4P 90262-52-5P 90262-53-6P
 90262-54-7P 90262-55-8P 90262-56-9P
 90262-57-0P 90262-58-1P 90262-59-2P
 90262-60-5P 90262-61-6P 90262-62-7P
 90262-63-8P 90262-64-9P 90262-65-0P
 90262-66-1P 90262-67-2P 90262-68-3P
 90262-69-4P 90262-70-7P 90262-71-8P
 90262-72-9P 90262-73-0P 90262-74-1P
 90262-75-2P 90262-76-3P 90262-77-4P
 90262-78-5P 90262-79-6P 90262-80-9P
 90262-81-0P 90262-82-1P 90262-83-2P
 90262-84-3P 90262-85-4P 90288-13-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and saponification of)
 RN 90262-48-9 HCAPLUS

CN Acetamide, 2-chloro-N-[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]- (9CI) (CA INDEX NAME)




RN 90262-49-0 HCAPLUS

CN Acetamide, 2,2,2-trifluoro-N-[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]- (9CI) (CA INDEX NAME)




RN 90262-50-3 HCAPLUS

CN Benzoic acid, 4-[(1,2-dihydro-6-nitro-9-oxopyrrolo[2,1-b]quinazolin-3(9H)-ylidene)methyl]- (9CI) (CA INDEX NAME)




RN 90262-51-4 HCAPLUS

CN Benzoic acid, 4-[(1,2-dihydro-6-nitro-9-oxopyrrolo[2,1-b]quinazolin-3(9H)-ylidene)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 90262-52-5 HCAPLUS

CN Benzoic acid, 4-[(6-amino-1,2-dihydro-9-oxopyrrolo[2,1-b]quinazolin-3(9H)-ylidene)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 90262-53-6 HCAPLUS

CN Acetic acid, oxo[[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 90262-54-7 HCAPLUS

CN Acetic acid, oxo[[1,2,3,9-tetrahydro-1-methyl-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 90262-55-8 HCAPLUS

CN Acetic acid, oxo[[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-7-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 90262-56-9 HCAPLUS

CN Butanoic acid, 4-oxo-4-[[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino]-, methyl ester (9CI)
(CA INDEX NAME)



RN 90262-57-0 HCAPLUS


CN Propanoic acid, 3-oxo-3-[[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino]-, ethyl ester (9CI)
(CA INDEX NAME)



RN 90262-58-1 HCAPLUS


CN 2-Butenoic acid, 4-oxo-4-[[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino]-, ethyl ester, (E,?)- (9CI) (CA INDEX NAME)

Double bond geometry as described by E or Z.




RN 90262-59-2 HCAPLUS

CN Benzoic acid, 3-[[[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 90262-60-5 HCAPLUS

CN Benzoic acid, 4-[[[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 90262-61-6 HCAPLUS

CN Acetic acid, oxo[[1,2,3,9-tetrahydro-3-[(2-methylphenyl)methylene]-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 90262-62-7 HCAPLUS

CN Acetic acid, oxo[[1,2,3,9-tetrahydro-3-[(3-methylphenyl)methylene]-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 90262-63-8 HCAPLUS

CN Acetic acid, oxo[[1,2,3,9-tetrahydro-3-[(4-methylphenyl)methylene]-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 90262-64-9 HCAPLUS

CN Acetic acid, oxo[[1,2,3,9-tetrahydro-3-[(2-methoxyphenyl)methylene]-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 90262-65-0 HCAPLUS

CN Acetic acid, oxo[[1,2,3,9-tetrahydro-3-[(3-methoxyphenyl)methylene]-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 90262-66-1 HCAPLUS


CN Acetic acid, oxo[[1,2,3,9-tetrahydro-3-[(4-methoxyphenyl)methylene]-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 90262-67-2 HCAPLUS


CN Acetic acid, [[3-[(4-fluorophenyl)methylene]-1,2,3,9-tetrahydro-9-

oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 90262-68-3 HCAPLUS

CN Acetic acid, [[3-[(2-chlorophenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 90262-69-4 HCAPLUS

CN Acetic acid, [[3-[(2,3-dimethoxyphenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 90262-70-7 HCAPLUS

CN Acetic acid, [[3-[(3,4-dimethoxyphenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 90262-71-8 HCAPLUS

CN Acetic acid, oxo[[1,2,3,9-tetrahydro-9-oxo-3-[[3-(trifluoromethyl)phenyl)methylene]pyrrolo[2,1-b]quinazolin-6-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 90262-72-9 HCAPLUS

CN Acetic acid, [[3-(1,3-benzodioxol-5-ylmethylene)-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 90262-73-0 HCAPLUS


CN Acetic acid, [[3-[(2,5-dimethylphenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 90262-74-1 HCAPLUS


CN Acetic acid, [[3-[(2-ethoxyphenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)

NAME)




RN 90262-75-2 HCAPLUS

CN Acetic acid, [[3-[(3-ethoxyphenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 90262-76-3 HCAPLUS

CN Acetic acid, [[3-[(4-ethoxyphenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 90262-77-4 HCAPLUS

CN Acetic acid, [[3-[(4-chlorophenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 90262-78-5 HCAPLUS

CN Acetic acid, [[3-[(3-chlorophenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 90262-79-6 HCAPLUS

CN Acetic acid, [[3-[(3-ethoxy-2-methoxyphenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 90262-80-9 HCAPLUS

CN Acetic acid, [[3-[(2,5-dimethoxyphenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 90262-81-0 HCAPLUS

CN Acetic acid, oxo[[1,2,3,9-tetrahydro-9-oxo-3-[(3,4,5-trimethoxyphenyl)methylene]pyrrolo[2,1-b]quinazolin-6-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 90262-82-1 HCAPLUS

CN Acetic acid, [[3-[(2,3-diethoxyphenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 90262-83-2 HCAPLUS

CN Acetic acid, [[3-[(2,6-diethoxyphenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 90262-84-3 HCAPLUS

CN Benzoic acid, 3-[[methyl[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 90262-85-4 HCAPLUS

CN Glycine, N-[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 90288-13-4 HCAPLUS

CN Acetic acid, [[3-[(2,4-dichlorophenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




IT 90262-86-5P 90263-40-4P 90263-41-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 90262-86-5 HCAPLUS


CN 2-Butenoic acid, 4-oxo-4-[[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino]-, methyl ester, (Z,?) - (9CI) (CA INDEX NAME)

Double bond geometry as described by E or Z.



RN 90263-40-4 HCAPLUS


CN Benzoic acid, 4-[(6-amino-1,2-dihydro-9-oxopyrrolo[2,1-b]quinazolin-3(9H)-ylidene)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 90263-41-5 HCAPLUS

CN Benzoic acid, 4-[(6-amino-1,2-dihydro-9-oxopyrrolo[2,1-b]quinazolin-3(9H)-ylidene)methyl]- (9CI) (CA INDEX NAME)




IT 90262-88-7P 90262-89-8P 90262-90-1P
 90262-91-2P 90262-92-3P 90262-93-4P
 90262-94-5P 90262-95-6P 90262-96-7P
 90262-97-8P 90262-98-9P 90262-99-0P
 90263-00-6P 90263-01-7P 90263-02-8P
 90263-03-9P 90263-04-0P 90263-05-1P
 90263-06-2P 90263-07-3P 90263-08-4P
 90263-09-5P 90263-10-8P 90263-11-9P
 90263-12-0P 90263-13-1P 90263-14-2P
 90263-15-3P 90263-16-4P 90263-17-5P
 90263-18-6P 90263-19-7P 90263-20-0P
 90263-21-1P 90263-22-2P 90263-23-3P
 90263-24-4P 90263-25-5P 90263-26-6P
 90263-27-7P 90263-28-8P 90263-29-9P
 90263-30-2P 90263-31-3P 90263-32-4P
 90263-33-5P 90263-34-6P 90263-35-7P
 90263-36-8P 90263-37-9P 90263-38-0P
 90263-39-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as antiasthmatic)


RN 90262-88-7 HCAPLUS

CN Acetic acid, oxo[[1,2,3,9-tetrahydro-1-methyl-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino]- (9CI) (CA INDEX NAME)




RN 90262-89-8 HCAPLUS

CN Acetic acid, oxo[[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-7-yl]amino]- (9CI) (CA INDEX NAME)



RN 90262-90-1 HCAPLUS


CN Butanoic acid, 4-oxo-4-[[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino]-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 90262-91-2 HCAPLUS


CN Butanoic acid, 4-oxo-4-[[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino]- (9CI) (CA INDEX NAME)



RN 90262-92-3 HCAPLUS

CN Propanoic acid, 3-oxo-3-[[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino]-


(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino] - (9CI) (CA INDEX NAME)



RN 90262-93-4 HCAPLUS


CN 2-Butenoic acid, 4-oxo-4-[[[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino]-, (E,?) - (9CI) (CA INDEX NAME)

Double bond geometry as described by E or Z.




RN 90262-94-5 HCAPLUS

CN Benzoic acid, 3-[[[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 90262-95-6 HCAPLUS

CN Benzoic acid, 4-[[[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 90262-96-7 HCAPLUS

CN Carbamic acid, [1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 90262-97-8 HCAPLUS


CN Benzoic acid, 2-[[[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 90262-98-9 HCAPLUS

CN 3-Cyclohexene-1-carboxylic acid, 6-[[[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino]carbonyl]-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 90262-99-0 HCAPLUS


CN 2-Butenoic acid, 4-oxo-4-[[[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino]-, (Z,?) - (9CI) (CA INDEX NAME)

Double bond geometry as described by E or Z.




RN 90263-00-6 HCAPLUS

CN 2-Butenoic acid, 2,3-dichloro-4-oxo-4-[[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino]- (9CI) (CA INDEX NAME)




RN 90263-01-7 HCAPLUS

CN Acetic acid, oxo[[1,2,3,9-tetrahydro-3-[(2-methylphenyl)methylene]-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]- (9CI) (CA INDEX NAME)




RN 90263-02-8 HCAPLUS

CN Acetic acid, oxo[[1,2,3,9-tetrahydro-3-[(3-methylphenyl)methylene]-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]- (9CI) (CA INDEX NAME)




RN 90263-03-9 HCAPLUS

CN Acetic acid, oxo[[1,2,3,9-tetrahydro-3-[(4-methylphenyl)methylene]-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]- (9CI) (CA INDEX NAME)




RN 90263-04-0 HCAPLUS

CN Acetic acid, oxo[[1,2,3,9-tetrahydro-3-[(2-methoxyphenyl)methylene]-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]- (9CI) (CA INDEX NAME)




RN 90263-05-1 HCAPLUS

CN Acetic acid, oxo[[1,2,3,9-tetrahydro-3-[(3-methoxyphenyl)methylene]-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]- (9CI) (CA INDEX NAME)




RN 90263-06-2 HCAPLUS

CN Acetic acid, oxo[[1,2,3,9-tetrahydro-3-[(4-methoxyphenyl)methylene]-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]- (9CI) (CA INDEX NAME)




RN 90263-07-3 HCAPLUS

CN Acetic acid, [[3-[(4-fluorophenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo- (9CI) (CA INDEX NAME)




RN 90263-08-4 HCAPLUS

CN Acetic acid, [[3-[(2-chlorophenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo- (9CI) (CA INDEX NAME)




RN 90263-09-5 HCAPLUS

CN Acetic acid, [[3-[(2,3-dimethoxyphenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo- (9CI) (CA INDEX NAME)




RN 90263-10-8 HCAPLUS

CN Acetic acid, [[3-[(3,4-dimethoxyphenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo- (9CI) (CA INDEX NAME)




RN 90263-11-9 HCAPLUS

CN Acetic acid, [[3-[(3-ethoxy-2-methoxyphenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo- (9CI) (CA INDEX NAME)




RN 90263-12-0 HCAPLUS

CN Acetic acid, [[3-[(2,5-dimethylphenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo- (9CI) (CA INDEX NAME)




RN 90263-13-1 HCAPLUS

CN Acetic acid, [[3-[(2-ethoxyphenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo- (9CI) (CA INDEX NAME)




RN 90263-14-2 HCAPLUS

CN Acetic acid, [[3-[(3-ethoxyphenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo- (9CI) (CA INDEX NAME)




RN 90263-15-3 HCAPLUS

CN Acetic acid, [[3-[(4-ethoxyphenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo- (9CI) (CA INDEX NAME)




RN 90263-16-4 HCAPLUS

CN Acetic acid, [[3-[(4-chlorophenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo- (9CI) (CA INDEX NAME)




RN 90263-17-5 HCAPLUS

CN Acetic acid, [[3-[(3-chlorophenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo- (9CI) (CA INDEX NAME)




RN 90263-18-6 HCAPLUS

CN Acetic acid, [[3-[(2,3-diethoxyphenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo- (9CI) (CA INDEX NAME)




RN 90263-19-7 HCAPLUS

CN Acetic acid, [[3-[(3,4-dichlorophenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo- (9CI) (CA INDEX NAME)




RN 90263-20-0 HCAPLUS

CN Acetic acid, [[3-[(2,4-dichlorophenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo- (9CI) (CA INDEX NAME)




RN 90263-21-1 HCAPLUS

CN Acetic acid, [[3-[(2,6-dichlorophenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo- (9CI) (CA INDEX NAME)




RN 90263-22-2 HCAPLUS

CN Acetic acid, [[3-[(1,3-benzodioxol-5-yl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo- (9CI) (CA INDEX NAME)




RN 90263-23-3 HCAPLUS

CN Acetic acid, oxo[[1,2,3,9-tetrahydro-9-oxo-3-[[3-(trifluoromethyl)phenyl]methylene]pyrrolo[2,1-b]quinazolin-6-yl]amino]- (9CI) (CA INDEX NAME)




RN 90263-24-4 HCAPLUS

CN Acetic acid, [[3-[(2,5-dimethoxyphenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo- (9CI) (CA INDEX NAME)




RN 90263-25-5 HCAPLUS

CN Acetic acid, oxo[[1,2,3,9-tetrahydro-9-oxo-3-[(3,4,5-trimethoxyphenyl)methylene]pyrrolo[2,1-b]quinazolin-6-yl]amino]- (9CI) (CA INDEX NAME)




RN 90263-26-6 HCAPLUS

CN Benzoic acid, 4-[[6-[(carboxycarbonyl)amino]-1,2-dihydro-9-oxopyrrolo[2,1-b]quinazolin-3(9H)-ylidene]methyl]-, 1-methyl ester (9CI) (CA INDEX NAME)




RN 90263-27-7 HCAPLUS

CN Benzoic acid, 4-[[6-[(carboxycarbonyl)amino]-1,2-dihydro-9-oxopyrrolo[2,1-b]quinazolin-3(9H)-ylidene]methyl]- (9CI) (CA INDEX NAME)



RN 90263-28-8 HCAPLUS


CN Benzoic acid, 3-[[methyl[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino]carbonyl]-, monosodium salt (9CI) (CA INDEX NAME)



● Na


RN 90263-29-9 HCAPLUS

CN Benzoic acid, 3-[[methyl[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 90263-30-2 HCAPLUS

CN Acetic acid, [methyl[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino]oxo- (9CI) (CA INDEX NAME)



RN 90263-31-3 HCAPLUS

CN Benzoic acid, 2-[[[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino]carbonyl]-, monosodium salt (9CI) (CA INDEX NAME)




● Na

RN 90263-32-4 HCAPLUS

CN 3-Cyclohexene-1-carboxylic acid, 6-[[[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino]carbonyl]-, monosodium salt, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




● Na

RN 90263-33-5 HCAPLUS


CN 2-Butenoic acid, 4-oxo-4-[[[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino]carbonyl]-, monosodium salt, (Z,?) - (9CI) (CA INDEX NAME)

Double bond geometry as described by E or Z.




● Na


RN 90263-34-6 HCAPLUS
 CN 1-Piperidinepropanamide, N-[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl] - (9CI) (CA INDEX NAME)



RN 90263-35-7 HCAPLUS
 CN 4-Morpholineacetamide, N-[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl] - (9CI) (CA INDEX NAME)




RN 90263-36-8 HCAPLUS
 CN Glycine, N-[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 90263-37-9 HCAPLUS


CN Glycine, N-[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]- (9CI) (CA INDEX NAME)



RN 90263-38-0 HCAPLUS


CN Benzoic acid, 4-[[6-[(3-carboxy-1-oxo-2-propenyl)amino]-1,2-dihydro-9-oxopyrrolo[2,1-b]quinazolin-3(9H)-ylidene]methyl]-, (Z,?) - (9CI) (CA INDEX NAME)

Double bond geometry as described by E or Z.



RN 90263-39-1 HCAPLUS

CN 2-Butenoic acid, 4-oxo-4-[[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino]-, 2-(diethylamino)ethyl ester (9CI) (CA INDEX NAME)



L67 ANSWER 20 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 21

ACCESSION NUMBER: 1985:39496 HCAPLUS

DOCUMENT NUMBER: 102:39496

TITLE: New derivatives of pyrrolo and pyrido[2,1-b]quinazoline as antiulcer agents

AUTHOR(S): Doria, G.; Passarotti, C.; Magrini, R.; Sala, R.; Sberze, P.; Tibolla, M.; Arcari, G.; Ceserani, R.; Castello, R.

CORPORATE SOURCE: Dep. Chem. Res. Dev., Farmitalia Carlo Erba S.p.A., Milan, Italy

SOURCE: Farmaco, Edizione Scientifica (1984), 39(11), 968-78

CODEN: FRPSAX; ISSN: 0430-0920

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 102:39496

ED Entered STN: 09 Feb 1985

AB 1,2,3,9-Tetrahydro-9-oxopyrrolo[2,1-b]quinazolines I (R = 6- or 7-CO₂H; R₁ = H, Me, F) or 6,7,8,9-tetrahydro-11-oxo-11H-pyrido[2,1-b]quinazolines II (R = 2- or 3-CO₂H; R₁ = H, Me, or F) were prepared and were effective antiulcer agents and gastric antisecretory agents in rats. Thus, 3-benzylidene-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazoline-7-carboxylic acid (I; R = 7-CO₂H; R₁ = H) [85742-73-0] prepared by refluxing 3-benzylidene-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazoline-7-carboxylic acid Me ester [85742-72-9] in HCl and acetic acid was effective in inhibiting restraint-induced ulcers and gastric acid secretion. 6-Benzylidene-6,7,8,9-tetrahydro-11-oxo-11H-pyrido[2,1-b]quinazoline-3-carboxylic acid (II; R = 3-CO₂H; R₁ = H) [85743-06-2] prepared by refluxing 1,2,3,9-tetrahydro-9-oxopyr[2,1-b]quinazoline-6-carboxylic acid Me ester [55762-24-8] with benzaldehyde [100-52-7] in anhydrous MeOH containing Na methylete was also an effective inhibitor of gastric

acid secretion and ulcer formation. These compds. lacked anticholinergic activity and had a low toxicity. Structure-activity relations are given.

IT 18549-16-1DP, analogs 85742-73-0P 85742-74-1P

85742-75-2P 85742-76-3P 85742-77-4P


85742-81-0P 85742-83-2P 85743-04-0P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation and antiulcer and gastric acid inhibitory activity of, structure in relation to)


RN 18549-16-1 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-(phenylmethylene)- (9CI)
(CA INDEX NAME)




RN 85742-73-0 HCAPLUS

CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)- (9CI) (CA INDEX NAME)




RN 85742-74-1 HCAPLUS

CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 1,2,3,9-tetrahydro-3-[(3-methylphenyl)methylene]-9-oxo- (9CI) (CA INDEX NAME)




RN 85742-75-2 HCAPLUS

CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 1,2,3,9-tetrahydro-3-[(4-methylphenyl)methylene]-9-oxo- (9CI) (CA INDEX NAME)




RN 85742-76-3 HCAPLUS

CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 3-[(2,5-dimethylphenyl)methylene]-1,2,3,9-tetrahydro-9-oxo- (9CI) (CA INDEX NAME)




RN 85742-77-4 HCAPLUS

CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 3-[(2,4-dimethylphenyl)methylene]-1,2,3,9-tetrahydro-9-oxo- (9CI) (CA INDEX NAME)




RN 85742-81-0 HCAPLUS

CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 1,2,3,9-tetrahydro-3-[(2-methylphenyl)methylene]-9-oxo- (9CI) (CA INDEX NAME)




RN 85742-83-2 HCAPLUS

CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 3-[(4-fluorophenyl)methylene]-1,2,3,9-tetrahydro-9-oxo- (9CI) (CA INDEX NAME)



RN 85743-04-0 HCAPLUS

CN Pyrrolo[2,1-b]quinazoline-6-carboxylic acid, 1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)- (9CI) (CA INDEX NAME)




IT 85742-72-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and de-esterification of)

RN 85742-72-9 HCAPLUS

CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)-, methyl ester (9CI) (CA INDEX NAME)



L67 ANSWER 21 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 22

ACCESSION NUMBER: 1983:438481 HCAPLUS

DOCUMENT NUMBER: 99:38481

TITLE: Substituted pyrrolo[2,1-b]quinazolines,
pyrido[2,1-b]quinazolines and pharmaceutical
compositions containing these compounds

PATENT ASSIGNEE(S): Farmitalia Carlo Erba S.p.A., Italy

SOURCE: Neth. Appl., 37 pp.

CODEN: NAXXAN

DOCUMENT TYPE: Patent

LANGUAGE: Dutch

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
NL 8202602	A	19830117	NL 1982-2602	19820628 <--
AT 7807753	A	19840815	AT 1978-7753	19781030 <--
AT 377586	B	19850410		
US 4428952	A	19840131	US 1982-387181	19820610 <--
AU 8284922	A1	19830106	AU 1982-84922	19820616 <--
AU 552065	B2	19860522		
CH 657618	A	19860915	CH 1982-3785	19820618 <--
ZA 8204502	A	19830427	ZA 1982-4502	19820624 <--
AT 8202475	A	19860115	AT 1982-2475	19820625 <--
AT 381092	B	19860825		
GB 2103207	A	19830216	GB 1982-18609	19820628 <--
GB 2103207	B2	19850109		
IL 66146	A1	19851231	IL 1982-66146	19820628 <--
BE 893694	A1	19821229	BE 1982-208486	19820629 <--
DK 8202927	A	19821231	DK 1982-2927	19820629 <--
SE 8204034	A	19821231	SE 1982-4034	19820629 <--
SE 448096	B	19870119		
SE 448096	C	19870430		
JP 58008082	A2	19830118	JP 1982-110921	19820629 <--
DE 3224213	A1	19830127	DE 1982-3224213	19820629 <--
CA 1183135	A1	19850226	CA 1982-406308	19820629 <--
SU 1279530	A1	19861223	SU 1982-3459054	19820629 <--
FI 8202329	A	19821231	FI 1982-2329	19820630 <--
FI 73997	B	19870831		
FI 73997	C	19871210		
FR 2508457	A1	19821231	FR 1982-11493	19820630 <--
FR 2508457	B1	19850830		

PRIORITY APPLN. INFO.: GB 1981-20126 A 19810630 <--

OTHER SOURCE(S): CASREACT 99:38481; MARPAT 99:38481

ED Entered STN: 12 May 1984


AB The title compds. I [n = 1,2; R, R1 = H, halogen, alkyl, cyano, carbamoyl, (un)esterified CO₂H, amino, CH₂OH; R2 = H, alkyl; R3 = Ph, substituted Ph] were prepared Thus 3,4-(HO₂C)2C₆H₃NH₂ was converted its monoester and cyclized with 2-piperidinone to give II (X = H₂, R₄ = Me) which was treated with PhCHO, followed by hydrolysis with HOAc, to give II (X = CHPh, R₄ = H). This compound has an antiulcer ED₅₀ of 8 mg/kg and a gastric secretion-inhibiting ED₅₀ 15 mg/kg, both orally in rats.

IT 85742-73-0P 85743-04-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antiulcer activity of)


RN 85742-73-0 HCAPLUS

CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)- (9CI) (CA INDEX NAME)



RN 85743-04-0 HCAPLUS

CN Pyrrolo[2,1-b]quinazoline-6-carboxylic acid, 1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)- (9CI) (CA INDEX NAME)




IT 85743-45-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and dehydration of)

RN 85743-45-9 HCAPLUS

CN Pyrrolo[2,1-b]quinazoline-7-carboxamide, 1,2,3,9-tetrahydro-3-[(2-methylphenyl)methylene]-9-oxo- (9CI) (CA INDEX NAME)




IT 85742-72-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and hydrolysis of)

RN 85742-72-9 HCAPLUS

CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)-, methyl ester (9CI) (CA INDEX NAME)




IT 65636-75-1P 85743-26-6P 85743-30-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and reduction of)


RN 65636-75-1 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-6-nitro-3-(phenylmethylene)- (9CI) (CA INDEX NAME)




RN 85743-26-6 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-1-methyl-6-nitro-3-(phenylmethylene)- (9CI) (CA INDEX NAME)



RN 85743-30-2 HCAPLUS


CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 1,2,3,9-tetrahydro-3-[(2-methylphenyl)methylene]-9-oxo-, methyl ester (9CI) (CA INDEX NAME)



IT 85742-74-1P 85742-75-2P 85742-76-3P
 85742-77-4P 85742-78-5P 85742-79-6P
 85742-80-9P 85742-81-0P 85742-82-1P
 85742-83-2P 85742-84-3P 85742-85-4P
 85742-86-5P 85742-87-6P 85742-88-7P
 85742-89-8P 85742-90-1P 85742-91-2P
 85742-92-3P 85742-93-4P 85742-94-5P
 85743-07-3P 85743-08-4P 85743-09-5P
 85743-10-8P 85743-11-9P 85743-12-0P
 85743-13-1P 85743-14-2P 85743-15-3P
 85743-16-4P 85743-17-5P 85743-18-6P
 85743-19-7P 85743-20-0P 85743-21-1P
 85743-22-2P 85743-23-3P 85743-24-4P
 85743-27-7P 85743-31-3P 85743-32-4P
 85743-33-5P 85743-34-6P 85743-35-7P
 85743-38-0P 85743-39-1P 85743-40-4P
 85743-41-5P 85743-42-6P 85743-46-0P
 85743-47-1P 85743-48-2P 85743-49-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)


RN 85742-74-1 HCAPLUS

CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 1,2,3,9-tetrahydro-3-[(3-methylphenyl)methylene]-9-oxo- (9CI) (CA INDEX NAME)




RN 85742-75-2 HCAPLUS

CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 1,2,3,9-tetrahydro-3-[(4-methylphenyl)methylene]-9-oxo- (9CI) (CA INDEX NAME)




RN 85742-76-3 HCAPLUS


CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 3-[(2,5-dimethylphenyl)methylene]-1,2,3,9-tetrahydro-9-oxo- (9CI) (CA INDEX NAME)




RN 85742-77-4 HCAPLUS
CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 3-[(2,4-dimethylphenyl)methylene]-1,2,3,9-tetrahydro-9-oxo- (9CI) (CA INDEX NAME)




RN 85742-78-5 HCAPLUS
CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 1,2,3,9-tetrahydro-3-[(3-methoxyphenyl)methylene]-9-oxo- (9CI) (CA INDEX NAME)



RN 85742-79-6 HCAPLUS
CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 3-[(3-chlorophenyl)methylene]-1,2,3,9-tetrahydro-9-oxo- (9CI) (CA INDEX NAME)




RN 85742-80-9 HCAPLUS
CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 3-[(2,6-dichlorophenyl)methylene]-1,2,3,9-tetrahydro-9-oxo- (9CI) (CA INDEX NAME)




RN 85742-81-0 HCAPLUS

CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 1,2,3,9-tetrahydro-3-[(2-methylphenyl)methylene]-9-oxo- (9CI) (CA INDEX NAME)




RN 85742-82-1 HCAPLUS

CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 3-[(2,4-dichlorophenyl)methylene]-1,2,3,9-tetrahydro-9-oxo- (9CI) (CA INDEX NAME)




RN 85742-83-2 HCAPLUS

CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 3-[(4-fluorophenyl)methylene]-1,2,3,9-tetrahydro-9-oxo- (9CI) (CA INDEX NAME)




RN 85742-84-3 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 7-chloro-2,3-dihydro-3-(phenylmethylene)- (9CI) (CA INDEX NAME)




RN 85742-85-4 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 7-chloro-2,3-dihydro-3-[(2-methylphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 85742-86-5 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 7-chloro-2,3-dihydro-3-[(3-methylphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 85742-87-6 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 7-chloro-3-[(4-fluorophenyl)methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 85742-88-7 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 7-chloro-3-[(2,6-dichlorophenyl)methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 85742-89-8 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 7-chloro-2,3-dihydro-3-[(2-methoxyphenyl)methylene] - (9CI) (CA INDEX NAME)




RN 85742-90-1 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 7-chloro-2,3-dihydro-3-[(3-methoxyphenyl)methylene] - (9CI) (CA INDEX NAME)




RN 85742-91-2 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 7-chloro-3-[(3,4-dimethoxyphenyl)methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 85742-92-3 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 7-chloro-2,3-dihydro-3-[(2,3,4-trimethoxyphenyl)methylene] - (9CI) (CA INDEX NAME)




RN 85742-93-4 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 7-chloro-2,3-dihydro-3-[(2,4,5-trimethoxyphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 85742-94-5 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 7-chloro-2,3-dihydro-3-[(3,4,5-trimethoxyphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 85743-07-3 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-7-methyl-3-(phenylmethylene)- (9CI) (CA INDEX NAME)




RN 85743-08-4 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-chloro-2,3-dihydro-3-(phenylmethylene)- (9CI) (CA INDEX NAME)




RN 85743-09-5 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 5,7-dichloro-2,3-dihydro-3-(phenylmethylene)- (9CI) (CA INDEX NAME)




RN 85743-10-8 HCAPLUS

CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 1,2,3,9-tetrahydro-1-methyl-9-oxo-3-(phenylmethylene)- (9CI) (CA INDEX NAME)




RN 85743-11-9 HCAPLUS

CN Acetamide, N-(1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl)- (9CI) (CA INDEX NAME)




RN 85743-12-0 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-2,3-dihydro-3-(phenylmethylene)- (9CI) (CA INDEX NAME)




RN 85743-13-1 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-2,3-dihydro-3-[(3,4,5-trimethoxyphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 85743-14-2 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-3-[(3,4-dichlorophenyl)methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 85743-15-3 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-2,3-dihydro-3-[(2-methylphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 85743-16-4 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-2,3-dihydro-3-[(3-methylphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 85743-17-5 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-2,3-dihydro-3-[(4-methylphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 85743-18-6 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-2,3-dihydro-3-[(2-methoxyphenyl)methylene]- (9CI) (CA INDEX NAME)



RN 85743-19-7 HCAPLUS


CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-2,3-dihydro-3-[(3-methoxyphenyl)methylene]- (9CI) (CA INDEX NAME)



RN 85743-20-0 HCAPLUS


CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-2,3-dihydro-3-[(4-methoxyphenyl)methylene]- (9CI) (CA INDEX NAME)

2/3




RN 85743-21-1 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-3-[(2,3-dimethoxyphenyl)methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 85743-22-2 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-3-[(4-fluorophenyl)methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 85743-23-3 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-3-(1,3-benzodioxol-5-ylmethylene)-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 85743-24-4 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 7-amino-2,3-dihydro-3-(phenylmethylene)- (9CI) (CA INDEX NAME)




RN 85743-27-7 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-2,3-dihydro-1-methyl-3-(phenylmethylene)- (9CI) (CA INDEX NAME)




RN 85743-31-3 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-7-(hydroxymethyl)-3-[(2-methylphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 85743-32-4 HCAPLUS

CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 1,2,3,9-tetrahydro-3-[(2-methylphenyl)methylene]-9-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 85743-33-5 HCAPLUS

CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 3-[(4-fluorophenyl)methylene]-1,2,3,9-tetrahydro-9-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 85743-34-6 HCAPLUS

CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 1,2,3,9-tetrahydro-1-methyl-9-oxo-3-(phenylmethylene)-, methyl ester (9CI) (CA INDEX NAME)




RN 85743-35-7 HCAPLUS

CN Pyrrolo[2,1-b]quinazoline-6-carboxylic acid, 1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)-, methyl ester (9CI) (CA INDEX NAME)




RN 85743-38-0 HCAPLUS

CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 1,2,3,9-tetrahydro-3-[(3-methylphenyl)methylene]-9-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 85743-39-1 HCAPLUS

CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 1,2,3,9-tetrahydro-3-[(4-methylphenyl)methylene]-9-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 85743-40-4 HCAPLUS

CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 1,2,3,9-tetrahydro-3-[(3-methoxyphenyl)methylene]-9-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 85743-41-5 HCAPLUS

CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 3-[(2,4-dimethylphenyl)methylene]-1,2,3,9-tetrahydro-9-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 85743-42-6 HCAPLUS

CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 3-[(2,5-dimethylphenyl)methylene]-1,2,3,9-tetrahydro-9-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 85743-46-0 HCAPLUS

CN Pyrrolo[2,1-b]quinazoline-7-carbonitrile, 1,2,3,9-tetrahydro-3-[(2-methylphenyl)methylene]-9-oxo- (9CI) (CA INDEX NAME)




RN 85743-47-1 HCAPLUS

CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 2-(diethylamino)-1,2,3,9-tetrahydro-3-[(2-methylphenyl)methylene]-9-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 85743-48-2 HCAPLUS

CN Pyrrolo[2,1-b]quinazoline-6-carboxylic acid, 2-(diethylamino)-1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)-, ethyl ester (9CI) (CA INDEX NAME)



RN 85743-49-3 HCAPLUS

CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)-, sodium salt (9CI) (CA INDEX NAME)




● Na

L67 ANSWER 22 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 23
ACCESSION NUMBER: 1983:614134 HCAPLUS
DOCUMENT NUMBER: 99:214134
TITLE: Cyanine dyes from deoxyvasicinone derivatives
AUTHOR(S): Andrianova, S. V.; Dil'manova, K.; Kovtun, T. V.;
Stetsenko, A. V.
CORPORATE SOURCE: Kiev. Gos. Univ., Kiev, USSR
SOURCE: Ukrainskii Khimicheskii Zhurnal (Russian Edition) (
1983), 49(9), 978-80
CODEN: UKZHAU; ISSN: 0041-6045
DOCUMENT TYPE: Journal
LANGUAGE: Russian
ED Entered STN: 12 May 1984
AB The alkaloid deoxyvasicinone (I) [530-53-0] from *Peganum harmala* was
quaternized with Et p-toluenesulfonate and condensed (at position 3) with
HC(OEt)₃ to give the sym. cyanine perchlorate [87886-76-8],
 λ_{max} 532 nm. Similar conventional condensations gave 4 unsym.
cyanines, a merocyanine, and a styryl dye. The merocyanine (a rhodamine
derivative) showed pos. solvatochromism: the color of a CHCl₃ solution was
deeper
than that of an EtOH solution
IT 87886-76-8P 87886-81-5P 87886-82-6P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and visible absorption of)
RN 87886-76-8 HCAPLUS
CN Pyrrolo[2,1-b]quinazolinium, 4-ethyl-3-[(4-ethyl-1,2,4,9-tetrahydro-9-
oxopyrrolo[2,1-b]quinazolin-3-yl)methylene]-1,2,3,9-tetrahydro-9-oxo-,
perchlorate (9CI) (CA INDEX NAME)

CM 1

CRN 87886-75-7


CMF C27 H27 N4 O2



CM 2


CRN 14797-73-0

CMF Cl O4




RN 87886-81-5 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(4H)-one, 4-ethyl-3-[(3-ethyl-4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-1,2-dihydro- (9CI) (CA INDEX NAME)



RN 87886-82-6 HCAPLUS

CN Pyrrolo[2,1-b]quinazolinium, 3-[[4-(dimethylamino)phenyl]methylene]-4-ethyl-1,2,3,9-tetrahydro-9-oxo-, iodide (9CI) (CA INDEX NAME)

● I⁻

L67 ANSWER 23 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 24

ACCESSION NUMBER: 1983:505211 HCAPLUS

DOCUMENT NUMBER: 99:105211

TITLE: New reactions of deoxyvasicinone

AUTHOR(S): Dunn, A. D.; Guy, E. L. M.; Kinnear, K. I.

CORPORATE SOURCE: Dundee Coll. Technol., Dundee, DD1 1HG, UK

SOURCE: Journal of Heterocyclic Chemistry (1983), 20(3), 779-80

CODEN: JHTCAD; ISSN: 0022-152X


DOCUMENT TYPE: Journal

LANGUAGE: English


ED Entered STN: 12 May 1984

AB Deoxyvasicinone (I; R = R1 = H) reacted at the 3 position of the pyrrolidine ring with ClCO2R2 (R2 = Et, Bu) and benzoyl chloride to give, e.g., I [RR1 = C(OEt)OCO2Et]. D exchange also occurred at this site.


IT 86988-80-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 86988-80-9 HCAPLUS
 CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 3-(chlorophenylmethylene)-2,3-dihydro-
 (9CI) (CA INDEX NAME)



L67 ANSWER 24 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 25
 ACCESSION NUMBER: 1982:406605 HCAPLUS
 DOCUMENT NUMBER: 97:6605
 TITLE: Synthesis of vasicinone derivatives
 AUTHOR(S): Sharma, V. K.; Jain, M. P.
 CORPORATE SOURCE: Reg. Res. Lab., Jammu Tawi, 180 001, India
 SOURCE: Indian Journal of Chemistry, Section B: Organic
 Chemistry Including Medicinal Chemistry (1982
), 21B(1), 75-6
 CODEN: IJSBDB; ISSN: 0376-4699
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 ED Entered STN: 12 May 1984
 AB The vasicinone derivs. I [R = (un)substituted Ph, 2-furyl] were prepd in
 40-80% yield by the condensation of aromatic aldehydes with deoxyvasicinone.
 IT 18549-16-1P 64791-88-4P 64791-92-0P
 82083-65-6P 82083-66-7P 82083-67-8P
 82083-68-9P 82083-69-0P 82083-70-3P
 82083-72-5P 82083-73-6P 82083-74-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 18549-16-1 HCAPLUS
 CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-(phenylmethylene)- (9CI)
 (CA INDEX NAME)




RN 64791-88-4 HCAPLUS
 CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-[(3-nitrophenyl)methylene]- (9CI) (CA INDEX NAME)




RN 64791-92-0 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-[(2-hydroxyphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 82083-65-6 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-[(4-methoxyphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 82083-66-7 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-[(4-methylphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 82083-67-8 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 3-[(4-chlorophenyl)methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 82083-68-9 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 3-[(4-aminophenyl)methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 82083-69-0 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 3-[(3,4-dimethoxyphenyl)methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)



RN 82083-70-3 HCAPLUS


CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 3-[(3,4-dihydroxyphenyl)methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)



RN 82083-72-5 HCAPLUS


CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-[(4-hydroxy-3-

methoxyphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 82083-73-6 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-[(3-hydroxy-4-methoxyphenyl)methylene]- (9CI) (CA INDEX NAME)



RN 82083-74-7 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 3-(1,3-benzodioxol-5-ylmethylene)-2,3-dihydro- (9CI) (CA INDEX NAME)



L67 ANSWER 25 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 26

ACCESSION NUMBER: 1982:406604 HCAPLUS

DOCUMENT NUMBER: 97:6604

TITLE: Synthesis of vasicine analogs

AUTHOR(S): Gupta, V. N.; Jain, M. P.; Atal, C. K.; Bhardawaj, M.

CORPORATE SOURCE: Reg. Res. Lab., Jammu Tawi, India

SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1982), 21B(1), 74-5

CODEN: IJSBDB; ISSN: 0376-4699

DOCUMENT TYPE: Journal


LANGUAGE: English

ED Entered STN: 12 May 1984


AB Vasicine analogs I [R = (un)substituted Ph, 2-furyl] were prepared in 24-80% yield by the condensation of deoxyvasicine with aromatic aldehydes. I were

screened for bronchodilator and uterine activity.


IT 82083-75-8P 82083-76-9P 82083-77-0P
 82083-78-1P 82083-79-2P 82083-80-5P
 82083-81-6P 82083-82-7P 82083-83-8P
 82083-84-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 82083-75-8 HCAPLUS
 CN Pyrrolo[2,1-b]quinazoline, 1,2,3,9-tetrahydro-3-(phenylmethylene)- (9CI)
 (CA INDEX NAME)




RN 82083-76-9 HCAPLUS
 CN Pyrrolo[2,1-b]quinazoline, 1,2,3,9-tetrahydro-3-[(4-methoxyphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 82083-77-0 HCAPLUS
 CN Pyrrolo[2,1-b]quinazoline, 3-[(4-chlorophenyl)methylene]-1,2,3,9-tetrahydro- (9CI) (CA INDEX NAME)



RN 82083-78-1 HCAPLUS
 CN Pyrrolo[2,1-b]quinazoline, 1,2,3,9-tetrahydro-3-[(3-nitrophenyl)methylene]- (9CI) (CA INDEX NAME)




RN 82083-79-2 HCAPLUS
 CN Pyrrolo[2,1-b]quinazoline, 1,2,3,9-tetrahydro-3-[(4-methylphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 82083-80-5 HCAPLUS

CN Phenol, 2-[(1,2-dihydropyrrolo[2,1-b]quinazolin-3(9H)-ylidene)methyl]-(9CI) (CA INDEX NAME)




RN 82083-81-6 HCAPLUS

Pyrrulo[2,1-b]quinazoline, 3-(2-furanylmethylene)-1,2,3,9-tetrahydro-	
(9CI) (CA INDEX NAME)	




RN 82083-82-7 HCAPLUS

CN	Pyrrolo[2,1-b]quinazoline, 3-(1,3-benzodioxol-5-ylmethylene)-1,2,3,9-tetrahydro- (9CI) (CA INDEX NAME)
----	--




RN 82083-83-8 HCAPLUS

CN Phenol, 4-[(1,2-dihydropyrrolo[2,1-b]quinazolin-3(9H)-ylidene)methyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 82083-84-9 HCAPLUS

CN Phenol, 5-[(1,2-dihydropyrrolo[2,1-b]quinazolin-3(9H)-ylidene)methyl]-2-methoxy- (9CI) (CA INDEX NAME)



L67 ANSWER 26 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 27

ACCESSION NUMBER: 1981:192253 HCAPLUS

DOCUMENT NUMBER: 94:192253

TITLE: Synthesis of potential fungicides in the quinazoline series

AUTHOR(S): Shakhidoyatov, Kh. M.; Oripov, E. O.; Yun, L. M.; Yamankulov, M. Ya.; Kadyrov, Ch. Sh.

CORPORATE SOURCE: USSR

SOURCE: Fungitsidy (1980), 66-81. Editor(s): Mel'nikov, N. N. Izd. Fan Uzb. SSR: Tashkent, USSR. CODEN: 44UOAK

DOCUMENT TYPE: Conference

LANGUAGE: Russian

OTHER SOURCE(S): CASREACT 94:192253

ED Entered STN: 12 May 1984

AB Acylaminoquinazolines I (R = MeO, Me, Me2CHCH2, Ph, benzyl, PhCH:CH, p-O2NC6H4, p-MeOC6H4, p-tolyl, 3,5-xylyl) were obtained in 20-69% yield by acylation of the resp. amine. Pyrimidoquinazolines II (R1-3 = H; R1-2 = H, R3 = Me; R1 = Me, R2-3 = H; R1-2 = Me, Ph, R3 = H) were obtained in 61-90% yield by cycloaddn. of R1CR2:CR3CO2H with the amine. Polymethylenedihydroquinazolones III (n = 1, 2, 3) were brominated, chlorosulfonated, nitrated and formylated to give 6.1-100% expected products. Aminomethylene derivative IV (X = e.g., NO2; n = 1, 2, 3; NR4R5 = piperidino, morpholino; R4 = R5 = H, Me; R4 = H, R5 = OH, Bu, Me2CHCH2, CMe3) were also prepared. Condensation of III (n = 1) with 26 aldehydes and ketones gave V e.g., R6 = Ph, R7 = H). The prepared compds. had low fungicidal activity (no data).

IT 18549-16-1P 64791-88-4P 64791-89-5P

64791-90-8P 64791-91-9P 64791-92-0P

64791-93-1P 64791-95-3P 64791-96-4P

64791-97-5P 64791-98-6P 69185-63-3P


69185-64-4P 69185-65-5P 69185-66-6P

77478-86-5P 77478-87-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as potential fungicide)


RN 18549-16-1 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-(phenylmethylene)- (9CI)
(CA INDEX NAME)




RN 64791-88-4 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-[(3-nitrophenyl)methylene]- (9CI) (CA INDEX NAME)




RN 64791-89-5 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-[(4-nitrophenyl)methylene]- (9CI) (CA INDEX NAME)




RN 64791-90-8 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 3-[(4-bromophenyl)methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 64791-91-9 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 3-[[4-(dimethylamino)phenyl]methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 64791-92-0 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-[(2-hydroxyphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 64791-93-1 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 3-[(5-bromo-2-hydroxyphenyl)methylene]-
2,3-dihydro- (9CI) (CA INDEX NAME)




RN 64791-95-3 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 3-(2-furanylmethylene)-2,3-dihydro-
(9CI) (CA INDEX NAME)




RN 64791-96-4 HCAPLUS

Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-[(5-iodo-2-furanyl)methylene]- (9CI) (CA INDEX NAME)




RN 64791-97-5 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-[hydroxy(3-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 64791-98-6 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-[hydroxy(4-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 69185-63-3 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-(1-piperidinylmethylene)- (9CI) (CA INDEX NAME)




RN 69185-64-4 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-(4-morpholinylmethylene)- (9CI) (CA INDEX NAME)




RN 69185-65-5 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-7-nitro-3-(1-piperidinylmethylene)- (9CI) (CA INDEX NAME)




RN 69185-66-6 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-(4-morpholinylmethylene)-7-nitro- (9CI) (CA INDEX NAME)




RN 77478-86-5 HCAPLUS


CN 11H-Pyrido[2,1-b]quinazolin-11-one, 6,7,8,9-tetrahydro-6-[(1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-3-yl)methylene]- (9CI) (CA INDEX NAME)




RN 77478-87-6 HCAPLUS
 CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-[(2-hydroxy-3-methoxyphenyl)methylene]- (9CI) (CA INDEX NAME)



L67 ANSWER 27 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 28
 ACCESSION NUMBER: 1979:87388 HCAPLUS
 DOCUMENT NUMBER: 90:87388
 TITLE: Some reactions of α -hydroxy- and α -dimethylaminoformylidene-2,3-polymethylene-3,4-dihydro-4-quinazolinones
 AUTHOR(S): Oripov, E.; Yun, L. M.; Shakhidoyatov, Kh. M.; Kadyrov, Ch. Sh.
 CORPORATE SOURCE: Inst. Khim. Rastit. Veshchestv, Tashkent, USSR
 SOURCE: Khimiya Prirodnikh Soedinenii (1978), (5), 603-9
 CODEN: KPSUAR; ISSN: 0023-1150
 DOCUMENT TYPE: Journal
 LANGUAGE: Russian
 OTHER SOURCE(S): CASREACT 90:87388
 ED Entered STN: 12 May 1984
 AB Acylation of the title compds. by (RCO)₂O (R = Me, Pr, Ph) gave 49-86% I (Z = O₂CR, X = H, 6-O₂N, 7-O₂N, n = 1-3). Amination of the title compds. by RR₁NH [R = H, R₁ = H, OH, Bu, CH₂CH₂CHMe₂, CMe₃, Ph, p-tolyl, PhNH, 2,4-(O₂N)₂C₆H₃NH; R = R₁ = Me; RR₁ = (CH₂)₅, (CH₂)₂₀(CH₂)₂] gave 31-92% I (Z = NRR₁). Addnl. obtained were II (n = 1, 2) by hydrolysis of the title compds.
 IT 69185-63-3P 69185-64-4P 69185-65-5P
 69185-66-6P 69185-67-7P 69185-74-6P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
 RN 69185-63-3 HCAPLUS
 CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-(1-piperidinylmethylene)- (9CI) (CA INDEX NAME)




RN 69185-64-4 HCAPLUS
 CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-(4-morpholinylmethylene)- (9CI) (CA INDEX NAME)




RN 69185-65-5 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-7-nitro-3-(1-piperidinylmethylene)- (9CI) (CA INDEX NAME)




RN 69185-66-6 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-(4-morpholinylmethylene)-7-nitro- (9CI) (CA INDEX NAME)




RN 69185-67-7 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-6-nitro-3-(1-piperidinylmethylene)- (9CI) (CA INDEX NAME)




RN 69185-74-6 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 3-[(1,2-dihydro-9-oxopyrrolo[2,1-b]quinazolin-3(9H)-ylidene)methyl]-2,3-dihydro- (9CI) (CA INDEX NAME)



L67 ANSWER 28 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2001:847194 HCAPLUS
 DOCUMENT NUMBER: 136:118618
 TITLE: Concise and Efficient Synthesis of Bioactive Natural
 Products Pegamine, Deoxyvasicinone, and (-)-Vasicinone
 AUTHOR(S): Mhaske, Santosh B.; Argade, Narshinha P.
 CORPORATE SOURCE: Division of Organic Chemistry (Synthesis), National
 Chemical Laboratory, Pune, 411 008, India
 SOURCE: Journal of Organic Chemistry (2001), 66(26),
 9038-9040
 CODEN: JOCEAH; ISSN: 0022-3263
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 136:118618
 ED Entered STN: 22 Nov 2001
 AB The authors have demonstrated a most concise, efficient, and practical
 synthesis of naturally occurring bioactive quinazolinone alkaloids
 pegamine (I), deoxyvasicinone (II, R = H), (-)-vasicinone (II, R = OH),
 for the first time starting from succinic anhydride and
 (S)-acetoxysuccinic anhydride. A formal synthesis of rutecarpine,
 isaindigotone, and luotonins A and B has been implied. The present
 approach also provides a new general method for designing several
 quinazolinone derivs. using a variety of cyclic anhydrides for structure
 activity relationship studies.
 IT 189316-00-5P, Isaindigotone
 RL: PNU (Preparation, unclassified); PREP (Preparation)
 (formal synthesis of)
 RN 189316-00-5 HCAPLUS
 CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-[(4-hydroxy-3,5-
 dimethoxyphenyl)methylene]-, (3E)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 64 THERE ARE 64 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L67 ANSWER 29 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2000:227660 HCAPLUS
 DOCUMENT NUMBER: 132:260669
 TITLE: Indolo[2,1-b]quinazole-6,12-dione antimalarial compounds and methods using them for treating malaria
 INVENTOR(S): Pitzer, Kevin K.; Scovill, John P.; Kyle, Dennis E.; Gerena, Lucia
 PATENT ASSIGNEE(S): WRAIR (Walter Reid Army Institute of Research), USA
 SOURCE: PCT Int. Appl., 41 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000018769	A2	20000406	WO 1999-US22569	19990928 <--
WO 2000018769	A3	20000908		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2317711	AA	20000406	CA 1999-2317711	19990928 <--
AU 9965023	A1	20000417	AU 1999-65023	19990928 <--
AU 765401	B2	20030918		
EP 1032574	A2	20000906	EP 1999-952979	19990928 <--
EP 1032574	A3	20001220		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US 6284772	B1	20010904	US 1999-407196	19990928 <--
ZA 2000003315	A	20010711	ZA 2000-3315	20000630 <--
US 2001034350	A1	20011025	US 2001-850996	20010508 <--
US 6531487	B2	20030311		

US 2003191138 A1 20031009 US 2003-384979 20030310 <--
 PRIORITY APPLN. INFO.: US 1998-102399P P 19980930 <--
 US 1999-407196 A3 19990928 <--
 WO 1999-US22569 W 19990928 <--
 US 2001-850996 A3 20010508 <--

OTHER SOURCE(S): MARPAT 132:260669

ED Entered STN: 07 Apr 2000

AB Compds., compns. and methods are provided for treating malaria parasites in vitro and in vivo by administering indolo[2,1-b]quinazoline-6,12-dione compds. I [A-H = C, N, or A and B or C and D can be taken together to be N or S, with proviso that not more than three of A-H are other than C; R1-R8 independently selected from, but not limited to, F, Cl, Br, I, alkyl, CF3, CH3O, COOCH3, COOCH2CH3, nitro, aryl, heteroaryl, cyano, amino, dialkylaminoalkyl, 1-(4-alkylpiperazinyl), and pharmaceutically acceptable salts thereof; X = any atom (especially O) or any side chain necessary to make the indolo[2,1-b]quinazoline-6,12-dione compound a prodrug]. The compds. include a side chain having a structure where a carbon-nitrogen double bond bears substituents that make the prodrug more water soluble and bioavailable.


IT 263239-55-0

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(indoloquinazoledione antimalarial compds., methods, and combinations)

RN 263239-55-0 HCAPLUS

CN Indolo[2,1-b]quinazolin-12(6H)-one, 4-methoxy-6-(phenylmethylene)- (9CI)
 (CA INDEX NAME)



L67 ANSWER 30 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1998:508176 HCAPLUS

DOCUMENT NUMBER: 129:245112

TITLE: Utilization of 2-(2-carboxyethyl)-4(3H)-quinazolinethione in the synthesis of condensed and noncondensed heterocycles

AUTHOR(S): Amine, M. S.; Eissa, A. M. F.; Shaaban, A. F.; El-Sawy, A.; El-Sayed, R.

CORPORATE SOURCE: Chemistry Department, Faculty of Science, Benha University, Benha, Egypt

SOURCE: Indian Journal of Heterocyclic Chemistry (1998), 7(4), 289-292

CODEN: IJCHEI; ISSN: 0971-1627

PUBLISHER: Prof. R. S. Varma

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 17 Aug 1998

AB Reactions of the title compound under different reaction conditions have yielded condensed and noncondensed heterocyclic systems, e.g., I and II (R

= H, OMe). Their structures have been ascertained on the basis of IR, NMR and mass spectral data. The antibacterial activity of the products was examined


IT 213203-14-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(2-(2-carboxyethyl)-4(3H)-quinazolinethione in preparation of condensed and noncondensed heterocycles)

RN 213203-14-6 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-1(2H)-one, 3,9-dihydro-3-[(4-methoxyphenyl)methylene]-9-thioxo- (9CI) (CA INDEX NAME)




IT 213203-13-5P

RL: SPN (Synthetic preparation); PREP (Preparation)

(2-(2-carboxyethyl)-4(3H)-quinazolinethione in preparation of condensed and noncondensed heterocycles)

RN 213203-13-5 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-1(2H)-one, 3,9-dihydro-3-(phenylmethylene)-9-thioxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L67 ANSWER 31 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1997:225199 HCAPLUS


DOCUMENT NUMBER: 126:314807

TITLE: Chemical studies of ban-lan-gen. 2. Alkaloids from Isatis indigotica

AUTHOR(S): Deng, Ke Min; Wu, Xiao Yun; Yang, Gen Jin; Qin, Guo Wei

CORPORATE SOURCE: Shanghai Inst. Mater. Med., Chinese Acad. Sci.,
Shanghai, 200031, Peop. Rep. China
SOURCE: Chinese Chemical Letters (1997), 8(3),
237-238
CODEN: CCLEE7
PUBLISHER: Chinese Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
ED Entered STN: 07 Apr 1997
AB Isaindigotone (I) and 3-(2'-hydroxyphenyl)-4(3H)-quinazolinone (II) were
isolated from the roots of I. indigotica. I was elucidated as a new
alkaloid. II was discovered for the 1st time from a natural source.
IT 189316-00-5, Isaindigotone
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP
(Properties); BIOL (Biological study); OCCU (Occurrence)
(alkaloids from Isatis indigotica)
RN 189316-00-5 HCAPLUS
CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-[(4-hydroxy-3,5-
dimethoxyphenyl)methylene]-, (3E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L67 ANSWER 32 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1996:281574 HCAPLUS
DOCUMENT NUMBER: 124:317160
TITLE: Preparation of pyrroloimidazoles as photochromic
compounds.
INVENTOR(S): Kawase, Ichiro; Tanaka, Masao
PATENT ASSIGNEE(S): Dainippon Ink & Chemicals, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 18 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08012677	A2	19960116	JP 1994-150942	19940701 <--
PRIORITY APPLN. INFO.:			JP 1994-150942	19940701 <--

OTHER SOURCE(S): MARPAT 124:317160
 ED Entered STN: 14 May 1996
 AB The title compds. I [A = (un)substituted divalent aromatic moiety; one of R2 - R4 is (un)substituted aromatic heterocyclic ring, the other two and R1 are independently alkyl, etc.; further details on R1 - R4 are given] are claimed. The title compound II (preparation given) became red-violet under UV light. The title compds. showed good durability.
 IT **176308-21-7P**
 RL: SPN (Synthetic preparation); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
 (preparation of pyrroloimidazoles as photochromic compds.)
 RN 176308-21-7 HCAPLUS
 CN 10H-Pyrrolo[1,2-a]perimidin-10-one, 8-[1-(2,5-dimethyl-3-furanyl)ethylidene]-8,9-dihydro-9-(1-methylethylidene)-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L67 ANSWER 33 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1997:24438 HCAPLUS
 DOCUMENT NUMBER: 126:157463
 TITLE: Heterocyclic compounds from 3-(4-phenylbenzoyl)propionic acid
 AUTHOR(S): Soliman, A. Y.; Bakeer, H. M.; Attia, I. A.
 CORPORATE SOURCE: Science Department, Faculty of Teachers, Alhasa, 31982, Saudi Arabia
 SOURCE: Chinese Journal of Chemistry (1996), 14(6), 532-540
 CODEN: CJOCEV; ISSN: 1001-604X
 PUBLISHER: Science Press
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 ED Entered STN: 15 Jan 1997
 AB 3-(4-Phenylbenzoyl)propionic acid was used as the starting material for the synthesis of furanones I (Ar = Ph, 4-ClC6H4, 4-MeOC6H4), pyrrolinones II (R = Cl, H, OMe, R' = Me, Et, 4-MeC6H4, Ph), pyridazinone III, benzoxazinone IV and quinazolinones, e.g., V. The behavior of the derivs. of furanones and benzoxazinones toward different nucleophiles is reported.
 IT **186788-24-9P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of heterocyclic compds. from (phenylbenzoyl)propionic acid)
 RN 186788-24-9 HCAPLUS
 CN Pyrrolo[2,1-b]quinazolin-9(3H)-one, 1-[1,1'-biphenyl]-4-yl-3-[(4-chlorophenyl)methylene]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L67 ANSWER 34 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1986:74879 HCAPLUS

DOCUMENT NUMBER: 104:74879

TITLE: Preformulation stability studies on deoxyvasicinebenzylidene (DVB)

AUTHOR(S): Gupta, V. N.; Jain, M. P.; Atal, C. K.; Rao, V. B.; Nagavi, B. G.

CORPORATE SOURCE: Reg. Res. Lab., Jammu Tawi, 180 001, India

SOURCE: Indian Drugs (1985), 22(12), 644-6

CODEN: INDRBA; ISSN: 0019-462X

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 08 Mar 1986

AB DVB (I) [82083-75-8] degradation in solution under various conditions of temperature and pH followed 1st-order kinetics. I did not show any decompose

in solid state. I was most stable in solution at pH 4.5 having a shelf life of 2.53 yr. The stability of I at pH values >6.0 was independent of H⁺ and OH⁻ concns.


IT 82083-75-8

RL: PRP (Properties)

(stability of, in solids and solns.)

RN 82083-75-8 HCAPLUS

CN Pyrrolo[2,1-b]quinazoline, 1,2,3,9-tetrahydro-3-(phenylmethylene)- (9CI) (CA INDEX NAME)



L67 ANSWER 35 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1985:123475 HCAPLUS

DOCUMENT NUMBER: 102:123475

TITLE: (Z)-3-(α -Hydroxybenzylidene)-1,2,3,9-tetrahydropyrrolo[2,1-b]quinazolin-9-one, C₁₈H₁₄N₂O₂

AUTHOR(S): Barnes, John C.; Low, John N.; Paton, John D.; Dunn, Allan D.; Kinnear, Kenneth I.

CORPORATE SOURCE: Chem. Dep., Univ. Dundee, Dundee, DD1 4HN, UK
 SOURCE: Acta Crystallographica, Section C: Crystal Structure
 Communications (1985), C41(2), 282-4
 CODEN: ACSCEE; ISSN: 0108-2701

DOCUMENT TYPE: Journal
 LANGUAGE: English

ED Entered STN: 06 Apr 1985


AB The title compound is monoclinic, space group P21/c, with a 11.309(5), b 11.121(5), c 11.672(5) Å, and β 110.23(5)°; Z = 4 for dc = 1.4002. The final R = 0.0689 for 1115 reflections. The OH proton is involved in H bonding to the sp²-hybridized N atom of the quinazoline ring. The Ph group is close to coplanar with the pyrroloquinazolinone fragment giving the maximum extended π bonding. Atomic coordinates are given.

IT 95235-23-7
 RL: PRP (Properties)
 (structure of)

RN 95235-23-7 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-(hydroxyphenylmethylene)-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L67 ANSWER 36 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1983:198523 HCAPLUS

DOCUMENT NUMBER: 98:198523

TITLE: Synthesis of vasicine and vasicinone derivatives for oxytocic and bronchodilatory activity

AUTHOR(S): Rao, M. N. A.; Krishnan, S.; Jain, M. P.; Anand, K. K.

CORPORATE SOURCE: Reg. Res. Lab., Jammu Tawi, 180 001, India

SOURCE: Indian Journal of Pharmaceutical Sciences (1982), 44(6), 151-3
 CODEN: IJSIDW; ISSN: 0250-474X

DOCUMENT TYPE: Journal

LANGUAGE: English


ED Entered STN: 12 May 1984

AB The title derivs. I [X = H₂, O, X₁ = RCH (R = m-HOC₆H₄, p-HOC₆H₄, PhCH:CH, (MeO)₂C₆H₃, H, Me, Pr, Bu, Me₂CHCH₂, MeCH:CH)] were prepared by condensation of I (X₁ = H₂) with RCHO. Some I had oxytocic activity at 10⁻³ mg/mL and none showed bronchodilator activity at 3 x 10⁻² mg/mL.

IT 85620-12-8P 85620-13-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and oxytocic activity of)


RN 85620-12-8 HCAPLUS

CN Phenol, 3-[(1,2-dihydropyrrolo[2,1-b]quinazolin-3(9H)-ylidene)methyl]- (9CI) (CA INDEX NAME)



RN 85620-13-9 HCAPLUS

CN Phenol, 4-[(1,2-dihydropyrrolo[2,1-b]quinazolin-3(9H)-ylidene)methyl]-(9CI) (CA INDEX NAME)




IT 85620-21-9P 85620-22-0P 85620-23-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 85620-21-9 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-[(3-hydroxyphenyl)methylene]-(9CI) (CA INDEX NAME)




RN 85620-22-0 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-[(4-hydroxyphenyl)methylene]-(9CI) (CA INDEX NAME)




RN 85620-23-1 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-[(3,4,5-trimethoxyphenyl)methylene]-(9CI) (CA INDEX NAME)




L67 ANSWER 37 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1978:501913 HCAPLUS
 DOCUMENT NUMBER: 89:101913
 TITLE: Agent for influencing plant growth and development
 INVENTOR(S): Bergner, Christoph; Groeger, Detlef; John, Siegfried;
 Jung, Barbara; Schreiber, Klaus; Sembdner, Guenther
 PATENT ASSIGNEE(S): Akademie der Wissenschaften der DDR, Ger. Dem. Rep.
 SOURCE: Ger. (East), 9 pp.
 CODEN: GEXXA8
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DD 128758	Z	19771207	DD 1976-196573	19761223 <--
PRIORITY APPLN. INFO.:			DD 1976-196573	A 19761223 <--
ED Entered STN: 12 May 1984				
AB Vasicinone derivs. are plant-growth inhibitors. Thus, 10-3M 7-nitrodeoxyvasicinone (I) [55727-51-0] inhibited the growth of spring rye seedlings by 17%. The synthesis of the derivs. is given.				
IT 41759-33-5P 65636-73-9P 65636-74-0P 65636-75-1P 65636-76-2P				
RL: SPN (Synthetic preparation); PREP (Preparation) (preparation and plant growth-inhibiting activity of)				
RN 41759-33-5 HCAPLUS				
CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-[(2-nitrophenyl)methylene] - (9CI) (CA INDEX NAME)				




RN 65636-73-9 HCAPLUS
 CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-(2-pyridinylmethylene) - (9CI) (CA INDEX NAME)




RN 65636-74-0 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-(4-pyridinylmethylene)-
(9CI) (CA INDEX NAME)




RN 65636-75-1 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-6-nitro-3-
(phenylmethylene)- (9CI) (CA INDEX NAME)



RN 65636-76-2 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-7-nitro-3-
(phenylmethylene)- (9CI) (CA INDEX NAME)



L67 ANSWER 38 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1978:424589 HCAPLUS


DOCUMENT NUMBER: 89:24589

TITLE: Synthesis and carbon-13 NMR spectroscopy of some
pyrrolo[2,1-b]quinazolines


AUTHOR(S): Johne, S.; Jung, B.; Groeger, D.; Radeglia, R.

CORPORATE SOURCE: Inst. Biochem. Pflanzen, DAW, Halle/Saale, Ger. Dem.


Rep.
 SOURCE: Journal fuer Praktische Chemie (Leipzig) (1977
), 319(6), 919-26
 CODEN: JPCEAO; ISSN: 0021-8383
 DOCUMENT TYPE: Journal
 LANGUAGE: German
 ED Entered STN: 12 May 1984
 AB Peganine and vasicinone derivs. I (X = CH, N; X1 = O, H2; R = OH, H, Cl;
 R1 = H, NO2; R2 = H, NO2) were prepared by reaction of anthranilic acid
 derivs. with either 4-aminobutyric acid or 2-methoxy-Δ1-pyrroline.
 C-3 substituted deoxyvasicinones were prepared also. The 13C NMR of all C
 atoms in peganine were assigned.
 IT 41759-33-5P 65636-73-9P 65636-74-0P
 65636-75-1P 65636-76-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 41759-33-5 HCAPLUS
 CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-[(2-
 nitrophenyl)methylene] - (9CI) (CA INDEX NAME)



RN 65636-73-9 HCAPLUS
 CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-(2-pyridinylmethylene) -
 (9CI) (CA INDEX NAME)




RN 65636-74-0 HCAPLUS
 CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-(4-pyridinylmethylene) -
 (9CI) (CA INDEX NAME)




RN 65636-75-1 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-6-nitro-3-(phenylmethylene)- (9CI) (CA INDEX NAME)



RN 65636-76-2 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-7-nitro-3-(phenylmethylene)- (9CI) (CA INDEX NAME)



L67 ANSWER 39 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1978:7166 HCAPLUS

DOCUMENT NUMBER: 88:7166

TITLE: Quinazolines. XI. Condensation of deoxyvasicinone with aldehydes

AUTHOR(S): Shakhidoyatov, Kh. M.; Yamankulov, M. Ya.; Kadyrov, Ch. Sh.

CORPORATE SOURCE: Inst. Khim. Rastit. Veshchestv, Tashkent, USSR

SOURCE: Khimiya Prirodnikh Soedinenii (1977), (4), 552-6

CODEN: KPSUAR; ISSN: 0023-1150

DOCUMENT TYPE: Journal

LANGUAGE: Russian

ED Entered STN: 12 May 1984


AB Deoxyvasicinone derivs. I [R = Ph, m-, p-O2NC6H4, p-BrC6H4, p-Me2NC6H4, o-HOC6H4, 2,5-(HO)BrC6H3, 2,3-(HO)MeC6H3, 2-furyl, 5-iodo-2-furyl] were obtained in 17-98% yields by condensation of deoxyvasicinone with RCHO 0.5-4 h at 150-200°.

IT 64791-97-5P 64791-98-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation and dehydration of)

RN 64791-97-5 HCAPLUS


CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-[hydroxy(3-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 64791-98-6 HCAPLUS
 CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-[hydroxy(4-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)




IT 18549-16-1P 64791-88-4P 64791-89-5P
 64791-90-8P 64791-91-9P 64791-92-0P
 64791-93-1P 64791-94-2P 64791-95-3P
 64791-96-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 18549-16-1 HCAPLUS
 CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-(phenylmethylene)- (9CI)
 (CA INDEX NAME)



RN 64791-88-4 HCAPLUS
 CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-[(3-nitrophenyl)methylene]- (9CI) (CA INDEX NAME)




RN 64791-89-5 HCAPLUS
 CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-[(4-nitrophenyl)methylene]- (9CI) (CA INDEX NAME)




RN 64791-90-8 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 3-[(4-bromophenyl)methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 64791-91-9 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 3-[[4-(dimethylamino)phenyl]methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 64791-92-0 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-[(2-hydroxyphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 64791-93-1 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 3-[(5-bromo-2-hydroxyphenyl)methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 64791-94-2 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-[(2-hydroxy-3-methylphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 64791-95-3 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 3-(2-furanylmethylene)-2,3-dihydro- (9CI) (CA INDEX NAME)



RN 64791-96-4 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-[(5-iodo-2-furanyl)methylene]- (9CI) (CA INDEX NAME)



L67 ANSWER 40 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1975:4452 HCAPLUS

DOCUMENT NUMBER: 82:4452

TITLE: Pseudorutecarpine


INVENTOR(S): Kametani, Tetsuji

PATENT ASSIGNEE(S): Japan Chemipha Co., Ltd.

SOURCE: Jpn. Kokai Tokkyo Koho, 3 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 49085100	A2	19740815	JP 1972-128970	19721222 <--
JP 50029480	B4	19750923		

PRIORITY APPLN. INFO.: JP 1972-128970 A 19721222 <--
 ED Entered STN: 12 May 1984
 AB Pseudorutecarpine (I) was prepared by reacting 3-(2-nitrobenzylidene)-1,2,3,9-tetrahydropyrrolo[2,1-b]quinazolin-9-one (II) with trialkyl phosphites. Thus, 1.9 g II was refluxed with 2 g (EtO)₃P 20 hr at 170° under N and SiO₂ to give 0.1 g I. I had analgesic and hypotensive actions.
 IT 41759-33-5
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reaction of, with trialkyl phosphites)
 RN 41759-33-5 HCAPLUS
 CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-[(2-nitrophenyl)methylene]- (9CI) (CA INDEX NAME)



L67 ANSWER 41 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1975:16864 HCAPLUS
 DOCUMENT NUMBER: 82:16864
 TITLE: 3-(2-Alkylaminobenzal)-1,2,3,9-tetrahydropyrrolo[2,1-b]quinazolin-9-ones
 INVENTOR(S): Kametani, Tetsuji
 PATENT ASSIGNEE(S): Japan Chemipha Co., Ltd.
 SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 49085096	A2	19740815	JP 1972-128969	19721222 <--
JP 51002478	B4	19760126		

PRIORITY APPLN. INFO.: JP 1972-128969 A 19721222 <--
 ED Entered STN: 12 May 1984
 AB Analgesic and hypotensive title compds. (I; R₁ = lower alkyl; R₂ = H, acyl) were prepared by treating 3-(2-nitrobenzylidene)-1,2,3,9-tetrahydropyrrolo[2,1-b]quinazolin-9-one (II) with trialkyl phosphites


followed by acylation, if needed. E.g., refluxing 1.9 g II with 2 g (EtO)₃P 20 hr at 170° under N gave 0.8 g I (R1 Et, R2 = H) (III). Heating 100 mg III with Ac₂O 3 hr gave 65 mg I (R1 = Et, R2 = Ac).

IT 41759-34-6P 41759-35-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 41759-34-6 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 3-[[2-(ethylamino)phenyl]methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)



RN 41759-35-7 HCAPLUS

CN Acetamide, N-[2-[(1,2-dihydro-9-oxopyrrolo[2,1-b]quinazolin-3(9H)-ylidene)methyl]phenyl]- (9CI) (CA INDEX NAME)




IT 41759-33-5

RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with trialkyl phosphites)

RN 41759-33-5 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-[(2-nitrophenyl)methylene]- (9CI) (CA INDEX NAME)




L67 ANSWER 42 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN


ACCESSION NUMBER: 1973:97850 HCAPLUS

DOCUMENT NUMBER: 78:97850


TITLE: Synthesis of heterocyclic compounds. CDXCIX.
Synthesis of pseudorutecarpine with triethyl phosphite
AUTHOR(S): Kametani, Tetsuji; Yamanaka, Tohru; Nyu, Kiyosato
CORPORATE SOURCE: Pharm. Inst., Tohoku Univ., Sendai, Japan
SOURCE: Journal of Heterocyclic Chemistry (1972),
9(6), 1281-2
CODEN: JHTCAD; ISSN: 0022-152X
DOCUMENT TYPE: Journal
LANGUAGE: English
ED Entered STN: 12 May 1984
AB Pseudorutecarpine (I) was synthesized by nitrene reaction of
3-(2-nitrobenzylidene)-1,2,3,9-tetrahydropyrrolo[2,1-b]quinazolin-9-one.
IT 41759-33-5P 41759-34-6P 41759-35-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 41759-33-5 HCAPLUS
CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-[(2-nitrophenyl)methylene]- (9CI) (CA INDEX NAME)



RN 41759-34-6 HCAPLUS
CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 3-[[2-(ethylamino)phenyl]methylene]-
2,3-dihydro- (9CI) (CA INDEX NAME)



RN 41759-35-7 HCAPLUS
CN Acetamide, N-[2-[(1,2-dihydro-9-oxopyrrolo[2,1-b]quinazolin-3(9H)-ylidene)methyl]phenyl]- (9CI) (CA INDEX NAME)



L67 ANSWER 43 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1969:47397 HCAPLUS

DOCUMENT NUMBER: 70:47397

TITLE: Chemistry of azacyclols. II. Synthesis and properties of C-acyl derivatives of anhydrooxa- and anhydroazacyclols

AUTHOR(S): Shkrob, A. M.; Krylova, Yu. I.; Antonov, V. K.; Shemyakin, M. M.

CORPORATE SOURCE: Inst. Khim. Prir. Soedin., Moscow, USSR

SOURCE: Zhurnal Obshchei Khimii (1968), 38(9), 2030-46

CODEN: ZOKHA4; ISSN: 0044-460X

DOCUMENT TYPE: Journal

LANGUAGE: Russian

OTHER SOURCE(S): CASREACT 70:47397

ED Entered STN: 12 May 1984

AB Anhydro derivs. of aromatic oxa and aza cyclols were shown to be able to acylate to form C-acyl derivs. The C-acetyl derivs. of the aza cyclols on further acylation gave pyrones. Hydration converted the C-acyl derivs. into unstable aza cyclols, which by retroaldol cleavage give quinazolinones. Refluxing 2 hrs. I(n = 1) in AcOH-AcONa gave 58% 1,2-dihydro-3-acetyl-9H-pyrrolo[2,1-b][1,3]benzoxazin-9-one, m. 256-8°, also formed from N-salicyloylbutyrolactam and Ac2O at 130°. Heating II in Ac2O 2.5 hrs. gave 1,2,3,10-tetrahydro-4-acetylpyrido[2,1-b][1,3]benzoxazin-10-one, m. 170-1°, in 55% yield and more soluble (26%) N-(o-acetylsalicyloyl)valerolactam, m. 111-12°. The latter also formed by heating acetylsalicylic acid with SOCl2 and treating the product with valerolactam in MePh. From appropriate analogy of II was similarly prepared 73% N-(O-acetylsalicyloyl)caprolactam, m. 81-2°. 3-Carbethoxyvalerolactam and Et3N in Et2O treated with o-Ph-CH2OC6H4COCl gave 63% 1-(o-benzyloxybenzoyl)-3-carbethoxyvalerolactam, m. 85-6°, which on hydrogenolysis over Pd gave 25% III, m. 88-91°: Appropriately substituted O-methyl lactams and anthranilic acid mixed in Me2CO at 5° gave after final heating to 40° 1 hr. the following acylamidines: 1,2,3,9-tetrahydropyrrolo[2,1-b]quinazolin-9-one, m. 109-10° (HCl salt, m. 298-302°); 1,2,3,4-tetrahydro-1H-pyrido[2,1-b]quinazolin-10-one, m. 99-100° (HCl salt, m. 269-72°); and 1,2,3,4,5,11-hexahydroazepino[2,1-b]quinazolin-11-one (IV), m. 96-7° (HCl salt, m. 221-4°). These and Me tosylate heated in MePh 4 hrs. gave (V) toluenesulfonate of 1,2,3,9-tetrahydro-4-methylpyrrolo[2,1-b]quinazolin-9-onium m. 177-8° and 1,2,3,4-tetrahydro-5-methyl-1H-pyrido[2,1-b]quinazolin-10-onium (VI), m. 185-6°. The acylamidines and MeI in 10 hrs. at 120° gave 1,2,3,9-tetrahydro-4-methylpyrrolo[2,1-b]quinazolin-9-on-4-ium iodide, m. 289-90°; 1,2,3,4,5,11-hexahydro-6-methylazepino-[2,1-b]quinazolin-11-onium iodide (VII) m. 231-3°. The latter


heated with pyridine 0.5 hr. gave 52% IV. V heated 20 min. with AcONa-Ac2O gave after purification on Al2O3 80% 1,2-dihydro-3-acetyl-4-methyl - 9H - pyrrolo[2,1 -b]quinazolin - 9 - one (VIII) m. 163-4°; the N-CD3 analog was prepared similarly as well as the COCD3 analog. The product heated in Ac2O at 150° 8 hrs. gave 2,3-dihydro-1-(N-acetyl-N-methylantranoyl)-4-methylpyrrolo[2,1-b]pyran-6-one, m. 243-5°. VI acetylated similarly gave 1,2,3,10-tetrahydro-4-acetyl-5-methylpyrido[2,1-b]-quinazolin-10-one, m. 162-4°, and 65% 1,2,3,4-tetrahydro-1-(N-acetyl-N-methylantranoyl)-5-methylpyrido[2,3-b]pyran-7-one, m. 245-7°, also prepared by acetylation of the preceding product under similar conditions in 60% yield. Heating the tosylates V and VI with BzCl in pyridine at 100° 3 hrs. gave: 33% 1,2-dihydro-3-benzoyl-4 - methyl - 9H - pyrrolo[2,1 -b]quinazolin - 9-one (IX) m. 223-5° (the D tagged N-Me analog prepared similarly); 90% 1,2,3,10-tetrahydro-4-benzoyl-5-methylpyrido[2,1-b]-quinazolin-10-one (X) m. 191-2°. N-Methylisatic anhydride heated with 3-carbethoxyvalerolactam 1 hr. at 190° gave 21% 1,2,3,10-tetrahydro-4-carbethoxy-5-methylpyrido[2,1-b]quinazolin-10-one (XI) m. 130-1°, 10% 1-methyl-3-(4-carbethoxybutyl)quinazoline-2,4-dione, m. 78-9°; and 13% 1,2,3,4,5,10-hexahydro-1-(N-methylantranoyl)-10-methylpyrido[2,3 - b]quinolin - 5 - one, m. 204-6°, the latter also being prepared by C-acylation of the tosylate VI with Et chlorocarbonate in the presence of K2CO3. Hydrolysis in 80% aqueous EtOH converted VIII into 1-methyl-3-(4-oxo-amyl)quinazoline-2,4-dione, m. 110-11°; similarly IX and X gave 1-methyl-3-(4-phenyl-4-oxobutyl)quinazoline-2,4-dione, m. 140-1°, and 1-methyl-3-(5-phenyl-5-oxopentyl)quinazoline-2,4-dione, m. 89-90°, while XI gave 1-methyl-3-(4-carbethoxybutyl)-quinazoline-2,4-dione, m. 78-9°. The products were characterized by mass spectra and ir spectra.

IT 16015-62-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 16015-62-6 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 3-benzoyl-2,4-dihydro-4-methyl- (8CI)
(CA INDEX NAME)



L67 ANSWER 44 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1967:473732 HCAPLUS

DOCUMENT NUMBER: 67:73732

TITLE: Alkaloids of anisotes sessiliflorus. Five new 4-quinazolinone alkaloids

AUTHOR(S): Arndt, Reinhard R.; Eggers, S. H.; Jordaan, A.

CORPORATE SOURCE: Council Sci. Ind. Res., Pretoria, S. Afr.

SOURCE: Tetrahedron (1967), 23(8), 3521-3532

CODEN: TETRAB; ISSN: 0040-4020

DOCUMENT TYPE: Journal

LANGUAGE: English


ED Entered STN: 12 May 1984

AB The structures of 5 new 4-quinazolone alkaloids I-V were elucidated by the extensive use of spectrographic techniques and a few selected chemical reactions.

IT **18549-16-1P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 18549-16-1 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-(phenylmethylene)- (9CI)
 (CA INDEX NAME)



L67 ANSWER 45 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1967:500091 HCAPLUS

DOCUMENT NUMBER: 67:100091

TITLE: Synthesis of stable derivatives of azacyclols

AUTHOR(S): Shkrob, A. M.; Krylova, Yu. I.; Antonov, V. K.

CORPORATE SOURCE: U.S.S.R. Acad. Sci., Moscow, USSR

SOURCE: Tetrahedron Letters (1967), (28), 2701-6

CODEN: TELEAY; ISSN: 0040-4039

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 12 May 1984

AB Attempts to prepare the azacyclols (I, R = Me, n = 1, 2, and 3) by way of the N-anthranoyllactams or the salts (II, X = TsO, n = 1, m. 177-8°; X = I, n = 1, m. 289-90°; X = TsO, n = 2, m. 185-6°; X = I, n = 3) showed that I immediately underwent either isomerization to the cyclodiamides (III, n = 3, m. 163-6°) or dehydration to the unstable anhydro compds. (IV). It was found possible to prepare stable derivs. of I, the ortho amides (V), by intramol. addition of nucleophilic residues to the double bond of the anhydro compds. (VI). VI were synthesized by acrylation of IV. Treatment of the salts II by acylating agents in the presence of bases gave stable C-acylated anhydro compds. (VII, R = Me, n = 1, m. 163-4°; R = Me, n = 2, m. 162-4°; R = Ph, n = 1, m. 223-5°; R = Ph, n = 2, m. 191-2°). The properties of these anhydro compds. were similar to those of the known compound VII (R = OEt, n = 2, m. 131-2°). VII underwent hydration on heating in aqueous alc. but the resultant azacyclols (VIII) were unstable and underwent retro-aldol fission yielding the quinazolinedione derivs. (IX, R = Me, n = 1, m. 110-11°; R = Ph, n = 1, m. 140-1°; R = Ph, n = 2, m. 89-90°; R = OEt, n = 2, m. 78-9°) (CA 51: 4262g) with structure confirmed by N.M.R. and mass spectra. The hydration of VII provided an example of addition to the double bond in anhydroazacyclols, and a similar intramol. reaction was observed on refluxing the salts II with excess Ac₂O in the presence of K₂CO₃ or NaOAc. Under these drastic conditions the initially formed VII react further to give the pyrone derivs. X (n = 1, 2, and 3), m. 243-5°, 245-7°, and 172-4°, resp. The structure of X followed from the ir, N.M.R., and mass spectra. The reaction mechanism was schematically outlined. The ease of conversion of VII (R = Me) was in the order n = 1 < n = 2 < n = 3. Intramol. nucleophilic addition occurred on


acylation of the anhydrocyclools IV with N-methylisatoic anhydride (XI). In the presence of bases XI reacted with the salts II with intermediate formation of ortho-amides (XII, R = H, n = 1), m. 196-8°, and production of the N-anthranoyl compds. (XIII, R = H, n = 1, 2, and 3), m. 290-3°, 204-6°, and 178-80°, resp. The structure of XIII was supported by ir and mass spectra and confirmed by hydrolysis to XIV (R = H, n = 1, 2, and 3), m. 278-80°, 249-51°, and 248-9°, resp. Acylation of XIV with XI regenerated XIII. The labeled compound XIII (R = D, n = 1), obtained from the salt IIa (R = D, X = I) contained the N-CD₃ group in the anthranoyl moiety split off by hydrolysis or on mass spectrometric fragmentation. Compds. XII (R = H, n = 1; R = D, n = 1) were isolated from acylation of the butyrolactam (XV, n = 1) or the salts IIa (R = H, n = 1; R = D, n = 1), and are the 1st examples of stable azacyclopentol derivs. On heating above the m.p. they isomerized to the corresponding N-anthranoyl compds. XIII, by thermal syn-1,2-elimination. Results of mass spectrometric fragmentation of XII (R = D, n = 1) were rationalized.

IT 16015-62-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 16015-62-6 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 3-benzoyl-2,4-dihydro-4-methyl- (8CI)
(CA INDEX NAME)



L67 ANSWER 46 OF 58 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1935:33603 HCAPLUS

DOCUMENT NUMBER: 29:33603

ORIGINAL REFERENCE NO.: 29:4365a-c

TITLE: Structure of vasicine. III. Position of the hydroxyl group

AUTHOR(S): Morris, R. C.; Hanford, W. E.; Adams, R.

SOURCE: Journal of the American Chemical Society (1935), 57, 951-4

CODEN: JACSAT; ISSN: 0002-7863

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

ED Entered STN: 16 Dec 2001


AB Oxidation of vasicine (I) with H₂O₂ in Me₂CO gives 2,3-(α -hydroxytrimethylene)-4-quinazolone (II), m. 213-4°; a mixture with I m. 168-70° and this may be the product reported by Ghose (C. A. 27, 510). Oxidation of desoxyvasicine (III) gives 2,3-trimethylene-4-quinazolone (IV), m. 110-10.5°; benzal derivative, yellow, m. 137-9°. II and SOCl₂ give the α -Cl derivative, m. 109°, which is reduced by Zn and AcOH to III. o-(γ -Phenoxybutyrylamino) benzamide, m. 150°; heating to 230-5° gives 2-(γ -phenoxypropyl)-4-quinazolone, light yellow, m. 181°; the action of HBr followed by alkali gives IV. Oxidation of IV with Pb(OAc)₄ in C₆H₆ gives II. These facts indicate that the HO in I is on the CH₂

attached to the 2-C atom.

IT 18549-16-1, Pyrrolo[2,1-b]quinazolin-9(1)-one,
3-benzal-2,3-dihydro-
(preparation of)

RN 18549-16-1 HCAPLUS

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-3-(phenylmethylene) - (9CI)
(CA INDEX NAME)



=> d ibib ab hitstr 47

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, USPATFULL, BIOSIS, SYNTHLINE, EMBASE, PASCAL' - CONTINUE? (Y)/N:y

L67 ANSWER 47 OF 58 USPATFULL on STN

DUPLICATE 10

ACCESSION NUMBER: 2001:188716 USPATFULL

TITLE: Indolo[2,1-b]quinazolin-6,12-dione antimalarial
compounds and methods of treating malaria therewith

INVENTOR(S): Pitzer, Kevin K., Pasadena, MD, United States
Scovill, John P., Walkersville, MD, United States
Kyle, Dennis E., Gaithersburg, MD, United States
Gerena, Lucia, Silver Spring, MD, United States

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2001034350	A1	20011025	<--
	US 6531487	B2	20030311	
APPLICATION INFO.:	US 2001-850996	A1	20010508 (9)	<--
RELATED APPLN. INFO.:	Division of Ser. No. US 1999-407196, filed on 28 Sep 1999, PENDING			

	NUMBER	DATE	
PRIORITY INFORMATION:	US 1998-102399P	19980930 (60)	<--
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Caroline Nash, Nash & Titus, LLC, 3415 Brookeville Road, Brookeville, MD, 20833		
NUMBER OF CLAIMS:	43		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1023		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds, compositions and methods are provided for treating malaria parasites in vitro and in vivo by administering indolo[2,1-b]quinazolin-6,12-dione compounds of Formula I. ##STR1##


wherein A, B, C, D, E, F, G and H are independently selected from carbon and nitrogen, or A and B or C and D can be taken together to be nitrogen

or sulfur, with the proviso that not more than three of A, B, C, D, E, F, G and H are other than carbon; wherein R.sub.1 through R.sub.8 are independently selected from the group consisting of, but not limited to, the halogens (F, Cl, Br, and I), alkyl groups, trifluoromethyl groups, methoxyl groups, the carboxy methyl or carboxy ethyl group (COOCH.sub.3 or COOCH.sub.2CH.sub.3), nitro, aryl, heteroaryl, cyano, amino, dialkylaminoalkyl, 1-(4-alkylpiperazinyl), and the pharmaceutically acceptable salts thereof; and wherein X is independently selected from the group consisting of any atom especially oxygen, or any side chain necessary to make the indolo[2,1-b]quinazoline-6,12-dione compound a "prodrug" as the term is understood by one of ordinary skill in the art of medicinal chemistry. In other words, a side chain having a structure where a carbon-nitrogen double bond bears substituents that make the prodrug more water soluble and bioavailable.

IT 263239-55-0

(indoloquinazoledione antimalarial compds., methods, and combinations)

RN 263239-55-0 USPATFULL

CN Indolo[2,1-b]quinazolin-12(6H)-one, 4-methoxy-6-(phenylmethylene)- (9CI)
(CA INDEX NAME)

=> d ibib ab hitstr 48-53

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, USPATFULL, BIOSIS, SYNTHLINE, EMBASE, PASCAL' - CONTINUE? (Y)/N:y

L67 ANSWER 48 OF 58 USPATFULL on STN

ACCESSION NUMBER: 2005:31684 USPATFULL

TITLE: Pyrrolidinohydrochinazolines

INVENTOR(S): Anderskewitz, Ralf, Laupheim, GERMANY, FEDERAL REPUBLIC OF

Dollinger, Horst, Schemmerhofen, GERMANY, FEDERAL REPUBLIC OF

Heine, Claudia, Biberach, GERMANY, FEDERAL REPUBLIC OF
Pouzet, Pascale Arielle Jane-Josee, Biberach, GERMANY, FEDERAL REPUBLIC OF

Bouyssou, Thierry, Mietingen, GERMANY, FEDERAL REPUBLIC OF

PATENT ASSIGNEE(S): Birke, Franz, Ingelheim, GERMANY, FEDERAL REPUBLIC OF
Boehringer Ingelheim International GmbH, Ingelheim, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005027122	A1	20050203
APPLICATION INFO.:	US 2004-771756	A1	20040204 (10)

	NUMBER	DATE	
	-----	-----	
PRIORITY INFORMATION:	EP 2003-3007	20030212	<--
	US 2003-499529P	20030902 (60)	<--
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877		
NUMBER OF CLAIMS:	11		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1343		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			
AB	Disclosed are compounds of formula (I): ##STR1##		


or stereoisomers or pharmaceutically acceptable salts thereof, wherein the groups Ar.sup.1, Ar.sup.2, A, R.sup.1, R.sup.2, R.sup.3, E.sup.1, E.sup.2, X and n are as defined in the description and claims, which are effective modulators of chemokine activity.

IT 82083-81-6P 745836-70-8P 745836-71-9P
 745836-72-0P 745836-73-1P 745836-74-2P
 745836-75-3P 745836-76-4P 745836-77-5P
 745836-78-6P 745836-79-7P 745836-80-0P
 745836-81-1P 745836-82-2P 745836-83-3P
 745836-84-4P 745836-85-5P 745836-86-6P
 745836-87-7P 745836-88-8P 745836-89-9P
 745836-90-2P 745836-91-3P 745836-92-4P
 745836-93-5P 745836-95-7P 745836-96-8P
 745836-97-9P 745836-98-0P 745836-99-1P
 745837-00-7P 745837-01-8P 745837-02-9P
 745837-03-0P 745837-04-1P 745837-05-2P
 745837-06-3P 745837-07-4P 745837-09-6P
 745837-10-9P 745837-11-0P 745837-12-1P
 745837-13-2P 745837-14-3P 745837-15-4P
 745837-36-9P

(preparation of pyrroloquinazolines as modulators of chemokine activity)


RN 82083-81-6 USPATFULL

CN Pyrrolo[2,1-b]quinazoline, 3-(2-furanylmethylene)-1,2,3,9-tetrahydro-
 (9CI) (CA INDEX NAME)




RN 745836-70-8 USPATFULL

CN Pyrrolo[2,1-b]quinazoline, 3-[(2-bromophenyl)methylene]-1,2,3,9-tetrahydro-
 (9CI) (CA INDEX NAME)




RN 745836-71-9 USPATFULL

CN Pyrrolo[2,1-b]quinazoline, 5,7-dibromo-3-[(2-chlorophenyl)methylene]-1,2,3,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 745836-72-0 USPATFULL

CN Pyrrolo[2,1-b]quinazoline, 3-[(2-chlorophenyl)methylene]-1,2,3,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 745836-73-1 USPATFULL

CN Pyrrolo[2,1-b]quinazoline, 7-bromo-3-[(2-chlorophenyl)methylene]-6-(1,1-dimethylethyl)-1,2,3,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 745836-74-2 USPATFULL

CN Pyrrolo[2,1-b]quinazoline, 3-[(2,6-dichlorophenyl)methylene]-1,2,3,9-tetrahydro- (9CI) (CA INDEX NAME)



RN 745836-75-3 USPATFULL


CN Pyrrolo[2,1-b]quinazoline, 3-[(2-fluorophenyl)methylene]-1,2,3,9-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 745836-76-4 USPATFULL


CN Benzenamine, 3-chloro-4-[(1,2-dihydropyrrolo[2,1-b]quinazolin-3(9H)-ylidene)methyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 745836-77-5 USPATFULL


CN Pyrrolo[2,1-b]quinazoline, 1,2,3,9-tetrahydro-3-[[2-(trifluoromethyl)phenyl)methylene]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 745836-78-6 USPATFULL

CN Pyrrolo[2,1-b]quinazoline, 3-[(2-chlorophenyl)methylene]-1-ethyl-1,2,3,9-tetrahydro- (9CI) (CA INDEX NAME)



RN 745836-79-7 USPATFULL


CN Pyrrolo[2,1-b]quinazoline, 3-[(2-ethylphenyl)methylene]-1,2,3,9-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 745836-80-0 USPATFULL

CN Benzenamine, 4-[(1,2-dihydropyrrolo[2,1-b]quinazolin-3(9H)-ylidene)methyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 745836-81-1 USPATFULL


CN Pyrrolo[2,1-b]quinazoline, 3-[(3,4-dichlorophenyl)methylene]-1,2,3,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 745836-82-2 USPATFULL
CN Pyrrolo[2,1-b]quinazoline, 3-[(2-ethoxyphenyl)methylene]-1,2,3,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 745836-83-3 USPATFULL
CN Pyrrolo[2,1-b]quinazoline, 1,2,3,9-tetrahydro-3-(2-thienylmethylene) - (9CI) (CA INDEX NAME)



RN 745836-84-4 USPATFULL
CN Pyrrolo[2,1-b]quinazoline, 1,2,3,9-tetrahydro-3-(3-thienylmethylene) - (9CI) (CA INDEX NAME)




RN 745836-85-5 USPATFULL
CN Pyrrolo[2,1-b]quinazoline, 3-([1,1'-biphenyl]-2-ylmethylene)-1,2,3,9-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 745836-86-6 USPATFULL

CN Pyrrolo[2,1-b]quinazoline, 3-[(2-chloro-4-fluorophenyl)methylene]-1,2,3,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 745836-87-7 USPATFULL

CN Pyrrolo[2,1-b]quinazoline, 1,2,3,9-tetrahydro-3-[(4-methoxy-3-methylphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 745836-88-8 USPATFULL

CN Pyrrolo[2,1-b]quinazoline, 3-[(2,4-dichlorophenyl)methylene]-1,2,3,9-tetrahydro- (9CI) (CA INDEX NAME)



RN 745836-89-9 USPATFULL


CN Benzaldehyde, 2-[amino(1,2-dihydropyrrolo[2,1-b]quinazolin-3(9H)-ylidene)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 745836-90-2 USPATFULL


CN Pyrrolo[2,1-b]quinazoline, 1,2,3,9-tetrahydro-3-[[2-(trifluoromethoxy)phenyl]methylene]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 745836-91-3 USPATFULL

CN Pyrrolo[2,1-b]quinazoline, 3-[(2-bromophenyl)methylene]-1-(4-fluorophenyl)-1,2,3,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 745836-92-4 USPATFULL

CN Pyrrolo[2,1-b]quinazoline, 3-[(8-bromo-1-naphthalenyl)methylene]-1,2,3,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 745836-93-5 USPATFULL

CN Pyrrolo[2,1-b]quinazoline, 3-[(2-bromophenyl)methylene]-1-butyl-1,2,3,9-tetrahydro- (9CI) (CA INDEX NAME)




RN 745836-95-7 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-imine, 3-[(2-ethylphenyl)methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 745836-96-8 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-imine, 3-[(2-chlorophenyl)methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 745836-97-9 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-imine, 2,3-dihydro-3-[(2-iodophenyl)methylene]- (9CI) (CA INDEX NAME)




RN 745836-98-0 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-imine, 2,3-dihydro-3-[(4-methoxyphenyl)methylene]- (9CI) (CA INDEX NAME),




RN 745836-99-1 USPTAFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-imine, 3-[(2-bromophenyl)methylene]-2,3-dihydro-6,7-dimethoxy- (9CI) (CA INDEX NAME)




RN 745837-00-7 USPTAFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-imine, 3-[(2-bromophenyl)methylene]-8-fluoro-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 745837-01-8 USPTAFULL

CN Pyrido[2,3-d]pyrrolo[1,2-a]pyrimidin-5(7H)-imine, 9-[(2-bromophenyl)methylene]-8,9-dihydro- (9CI) (CA INDEX NAME)




RN 745837-02-9 USPATFULL

CN Methanamine, N-[3-[(2-bromophenyl)methylene]-2,3-dihydropyrrolo[2,1-b]quinazolin-9(1H)-ylidene]- (9CI) (CA INDEX NAME)




RN 745837-03-0 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-imine, 3-[(2-bromophenyl)methylene]-8-chloro-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 745837-04-1 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-imine, 3-[(2-bromophenyl)methylene]-2,3-dihydro-8-methyl- (9CI) (CA INDEX NAME)




RN 745837-05-2 USPATFULL

CN Cyanamide, [3-[(2-bromophenyl)methylene]-2,3-dihydropyrrolo[2,1-b]quinazolin-9(1H)-ylidene]- (9CI) (CA INDEX NAME)




RN 745837-06-3 USPATFULL

CN Pyrrolo[2,1-b]quinazoline-1-carboxylic acid, 3-[(2-bromophenyl)methylene]-1,2,3,9-tetrahydro-9-imino-, methyl ester (9CI) (CA INDEX NAME)



RN 745837-07-4 USPATFULL

CN Pyrrolo[2,1-b]quinazoline-1-carboxamide, 3-[(2-bromophenyl)methylene]-1,2,3,9-tetrahydro-9-imino- (9CI) (CA INDEX NAME)




RN 745837-09-6 USPATFULL

CN Formic acid, compd. with 5-[(2-bromophenyl)methylene]-1,5,6,7-tetrahydro-9H-pyrrolo[1,2-a]purin-9-imine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 745837-08-5


CMF C15 H12 Br N5



CM 2


CRN 64-18-6

CMF C H2 O2



RN 745837-10-9 USPATFULL


CN Pyrrolo[1,2-a]thieno[2,3-d]pyrimidin-4(6H)-imine, 8-[(2-bromophenyl)methylene]-7,8-dihydro- (9CI) (CA INDEX NAME)



RN 745837-11-0 USPATFULL


CN [1]Benzothieno[2,3-d]pyrrolo[1,2-a]pyrimidin-10(1H)-imine, 3-[(2-bromophenyl)methylene]-2,3,6,7,8,9-hexahydro- (9CI) (CA INDEX NAME)

NAME)




RN 745837-12-1 USPATFULL

CN Pyrrolo[1,2-a]thieno[2,3-d]pyrimidin-4(6H)-imine, 8-[(2-bromophenyl)methylene]-7,8-dihydro-2,3-dimethyl- (9CI) (CA INDEX NAME)




RN 745837-13-2 USPATFULL

CN Pyrrolo[1,2-a]thieno[2,3-d]pyrimidin-4(6H)-imine, 8-[(2-bromophenyl)methylene]-3-(1,1-dimethylethyl)-7,8-dihydro- (9CI) (CA INDEX NAME)




RN 745837-14-3 USPATFULL

CN Pyrrolo[1,2-a]thieno[2,3-d]pyrimidin-4(6H)-imine, 8-[(2-bromophenyl)methylene]-3-cyclopropyl-7,8-dihydro- (9CI) (CA INDEX NAME)




RN 745837-15-4 USPATFULL

CN Furo[2,3-d]pyrrolo[1,2-a]pyrimidin-4(6H)-imine, 8-[(2-bromophenyl)methylene]-7,8-dihydro-2,3-dimethyl- (9CI) (CA INDEX NAME)



RN 745837-36-9 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-imine, 3-[(2-bromophenyl)methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




IT 745837-19-8P

(preparation of pyrroloquinazolines as modulators of chemokine activity)

RN 745837-19-8 USPATFULL

CN Pyrrolo[1,2-a]thieno[2,3-d]pyrimidine-8-methanol, α -(2-bromophenyl)-4,6,7,8-tetrahydro-4-imino- (9CI) (CA INDEX NAME)



L67 ANSWER 49 OF 58 USPATFULL on STN

ACCESSION NUMBER: 2004:44941 USPATFULL

TITLE: Antimalarial and antiproliferative pharmacophore models, novel tryptanthrin compounds having increased solubility, and methods of making and using thereof

INVENTOR(S): Nichols, Daniel A., Sparrows Point, MD, UNITED STATES
Hicks, Rickey P., Woodbridge, VA, UNITED STATES
Bhattacharjee, Apurba K., Silver Spring, MD, UNITED STATES

	NUMBER	KIND	DATE		
PATENT INFORMATION:	US 2004033934	A1	20040219		
APPLICATION INFO.:	US 2003-359625	A1	20030207	(10)	<--

	NUMBER	DATE		
PRIORITY INFORMATION:	US 2002-355162P	20020209	(60)	<--
	US 2002-396911P	20020717	(60)	<--

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: Suzannah K. Sundby, Esq., Smith, Gambrell & Russell, LLP, Suite 800, 1850 M Street, NW, Washington, DC, 20036

NUMBER OF CLAIMS: 39

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 18 Drawing Page(s)

LINE COUNT: 3074


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed herein is a pharmacophore model for antimalarial activity and methods of making and using thereof. The pharmacophore comprises two hydrogen bond acceptor (lipid) functions and two hydrophobic (aromatic) functions. The pharmacophore model was made using a test set of tryptanthrin compounds which exhibit antimalarial activity. Also disclosed are tryptanthrin compounds having greater solubility and bioactivity as compared to prior art tryptanthrin compounds and methods of making and using thereof. Also disclosed are methods of treating malaria in a subject.

IT 454699-59-3
(antimalarial and antiproliferative pharmacophore models, tryptanthrin compds. having increased solubility)

RN 454699-59-3 USPATFULL

CN Indolo[2,1-b]quinazolin-12(6H)-one, 8-fluoro-4-methoxy-6-(phenylmethylene)-(9CI) (CA INDEX NAME)



L67 ANSWER 50 OF 58 USPATFULL on STN

ACCESSION NUMBER: 2003:271530 USPATFULL

TITLE: Indolo[2,1-b]quinazoline-6,12-dione antimalarial compounds and methods of treating malaria therewith

INVENTOR(S): Pitzer, Kevin K., Pasadena, MD, UNITED STATES
 Scovill, John P., Walkersville, MD, UNITED STATES
 Kyle, Dennis E., Gaithersburg, MD, UNITED STATES
 Gerena, Lucia, Silver Spring, MD, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003191138	A1	20031009	<--
APPLICATION INFO.:	US 2003-384979	A1	20030310	(10) <--
RELATED APPLN. INFO.:	Division of Ser. No. US 2001-850996, filed on 8 May 2001, GRANTED, Pat. No. US 6531487 Division of Ser. No. US 1999-407196, filed on 28 Sep 1999, GRANTED, Pat. No. US 6284772			

	NUMBER	DATE	
PRIORITY INFORMATION:	US 1998-102399P	19980930	(60) <--
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Caroline Nash, Nash & Titus, LLC, 3415 Brookeville Road, Brookeville, MD, 20833		
NUMBER OF CLAIMS:	43		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1041		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds, compositions and methods are provided for treating malaria parasites in vitro and in vivo by administering indolo[2,1-b]quinazoline-6,12-dione compounds of Formula I. ##STR1##

wherein A, B, C, D, E, F, G and H are independently selected from carbon and nitrogen, or A and B or C and D can be taken together to be nitrogen or sulfur, with the proviso that not more than three of A, B, C, D, E, F, G and H are other than carbon; wherein R.sub.1 through R.sub.8 are independently selected from the group consisting of, but not limited to, the halogens (F, Cl, Br, and I), alkyl groups, trifluoromethyl groups, methoxyl groups, the carboxy methyl or carboxy ethyl group (COOCH.sub.3 or COOCH.sub.2CH.sub.3), nitro, aryl, heteroaryl, cyano, amino, dialkylaminoalkyl, 1-(4-alkylpiperazinyl), and the pharmaceutically acceptable salts thereof; and wherein X is independently selected from the group consisting of any atom especially oxygen, or any side chain necessary to make the indolo[2,1-b]quinazoline-6,12-dione compound a "prodrug" as the term is understood by one of ordinary skill in the art of medicinal chemistry. In other words, a side chain having a structure where a carbon-nitrogen double bond bears substituents that make the


prodrug more water soluble and bioavailable.

IT 263239-55-0

(indoloquinazoledione antimalarial compds., methods, and combinations)

RN 263239-55-0 USPATFULL

CN Indolo[2,1-b]quinazolin-12(6H)-one, 4-methoxy-6-(phenylmethylene)- (9CI)
(CA INDEX NAME)



L67 ANSWER 51 OF 58 USPATFULL on STN

ACCESSION NUMBER: 2001:147979 USPATFULL

TITLE: Indolo[2,1-B] quinazole-6,12-dione antimalarial compounds and methods of treating malaria therewith

INVENTOR(S): Pitzer, Kevin K., Pasadena, MD, United States
Scovill, John P., Walkersville, MD, United States
Kyle, Dennis E., Gaithersburg, MD, United States
Gerena, Lucia, Silver Spring, MD, United States

PATENT ASSIGNEE(S): The United States of America as represented by the Secretary of the Army, Washington, DC, United States (U.S. government)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6284772	B1	20010904	<--
APPLICATION INFO.:	US 1999-407196		19990928 (9)	<--

	NUMBER	DATE	
PRIORITY INFORMATION:	US 1998-102399P	19980930 (60)	<--
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Weddington, Kevin E.		
LEGAL REPRESENTATIVE:	Arwine, Elizabeth, Harris, Charles H.Nash & Titus, LLC		
NUMBER OF CLAIMS:	13		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1018		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds, compositions and methods are provided for treating malaria parasites in vitro and in vivo by administering indolo[2,1-b]quinazoline-6,12-dione compounds of Formula I. ##STR1##

wherein A, B, C, D, E, F, G and H are independently selected from carbon and nitrogen, or A and B or C and D can be taken together to be nitrogen or sulfur, with the proviso that not more than three of A, B, C, D, E, F, G and 14 are other than carbon; wherein R.sub.1 through R.sub.8 are independently selected from the group consisting of, but not limited to, the halogens (F, Cl, Br, and I), alkyl groups, trifluoromethyl groups, methoxyl groups, the carboxy methyl or carboxy ethyl group (COOCH.sub.3 or COOCH.sub.2 CH.sub.3), nitro, aryl, heteroaryl, cyano, amino, dialkylaminoalkyl, 1-(4-alkylpiperazinyl), and the pharmaceutically


acceptable salts thereof; and wherein X is independently selected from the group consisting of any atom especially oxygen, or any side chain necessary to make the indolo[2,1-b]quinazoline-6,12-dione compound a "prodrug" as the term is understood by one of ordinary skill in the art of medicinal chemistry. In other words, a side chain having a structure where a carbon-nitrogen double bond bears substituents that make the prodrug more water soluble and bioavailable.

IT 263239-55-0

(indoloquinazoledione antimalarial compds., methods, and combinations)

RN 263239-55-0 USPATFULL

CN Indolo[2,1-b]quinazolin-12(6H)-one, 4-methoxy-6-(phenylmethylene)- (9CI)
(CA INDEX NAME)



L67 ANSWER 52 OF 58 USPATFULL on STN

ACCESSION NUMBER: 86:18662 USPATFULL

TITLE: Amino derivatives of benzylidene-pyrrolo[2,1-b]quinazolines useful for treating conditions of allergic origin

INVENTOR(S): Doria, Gianfederico, Milan, Italy
Passarotti, Carlo, Gallarate, Italy
Corno, Maria L., Milan, Italy

PATENT ASSIGNEE(S): Farmitalia Carlo Erba S.p.A., Milan, Italy (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4579847		19860401 <--
APPLICATION INFO.:	US 1984-681694		19841214 (6) <--
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1983-515646, filed on 20 Jul 1983, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1982-22591	19820805 <--
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Daus, Donald G.	
ASSISTANT EXAMINER:	Rivers, D. G.	
LEGAL REPRESENTATIVE:	Murray and Whisenhunt	
NUMBER OF CLAIMS:	7	
EXEMPLARY CLAIM:	1,5,6	
LINE COUNT:	1740	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB Amino derivatives of benzylidene-Pyrrolo[2,1-b] Quinazolines are provided, together with pharmaceutical compositions containing them. The compounds and the compositions have pharmaceutical utility and are particularly useful as anti allergy agents.

IT 85743-12-0

(acylation of)

RN 85743-12-0 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-2,3-dihydro-3-(phenylmethylene)- (9CI) (CA INDEX NAME)



IT 85743-13-1 85743-15-3 85743-16-4

85743-17-5 85743-18-6 85743-19-7

85743-20-0 85743-21-1 85743-22-2

85743-23-3 90262-34-3 90262-35-4

90262-36-5 90262-37-6 90262-38-7

90262-39-8 90262-40-1 90262-41-2


90262-42-3 90262-43-4 90262-44-5

90262-45-6 90262-46-7 90262-47-8

(acylation of, with ethoxalyl chloride)


RN 85743-13-1 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-2,3-dihydro-3-[(3,4,5-trimethoxyphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 85743-15-3 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-2,3-dihydro-3-[(2-methylphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 85743-16-4 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-2,3-dihydro-3-[(3-methylphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 85743-17-5 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-2,3-dihydro-3-[(4-methylphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 85743-18-6 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-2,3-dihydro-3-[(2-methoxyphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 85743-19-7 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-2,3-dihydro-3-[(3-methoxyphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 85743-20-0 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-2,3-dihydro-3-[(4-methoxyphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 85743-21-1 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-3-[(2,3-dimethoxyphenyl)methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 85743-22-2 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-3-[(4-fluorophenyl)methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 85743-23-3 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-3-[(1,3-benzodioxol-5-yl)methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 90262-34-3 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-3-[(2-chlorophenyl)methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 90262-35-4 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-3-[(3,4-dimethoxyphenyl)methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 90262-36-5 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-2,3-dihydro-3-[[3-(trifluoromethyl)phenyl]methylene]- (9CI) (CA INDEX NAME)




RN 90262-37-6 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-3-[(2,5-dimethylphenyl)methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 90262-38-7 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-3-[(2-ethoxyphenyl)methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 90262-39-8 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-3-[(3-ethoxyphenyl)methylene]-
2,3-dihydro- (9CI) (CA INDEX NAME)




RN 90262-40-1 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-3-[(4-ethoxyphenyl)methylene]-
2,3-dihydro- (9CI) (CA INDEX NAME)




RN 90262-41-2 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-3-[(4-chlorophenyl)methylene]-
2,3-dihydro- (9CI) (CA INDEX NAME)




RN 90262-42-3 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-3-[(3-chlorophenyl)methylene]-
2,3-dihydro- (9CI) (CA INDEX NAME)




RN 90262-43-4 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-3-[(3-ethoxy-2-methoxyphenyl)methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 90262-44-5 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-3-[(2,5-dimethoxyphenyl)methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 90262-45-6 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-3-[(2,3-diethoxyphenyl)methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 90262-46-7 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-3-[(2,4-dichlorophenyl)methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)



RN 90262-47-8 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-3-[(2,6-dichlorophenyl)methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




IT 90262-33-2P

(preparation and antiasthmatic activity of)

RN 90262-33-2 USPATFULL

CN Acetic acid, oxo[[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino]- (9CI) (CA INDEX NAME)



IT 90262-48-9P 90262-49-0P 90262-50-3P

90262-51-4P 90262-52-5P 90262-53-6P

90262-54-7P 90262-55-8P 90262-56-9P

90262-57-0P 90262-58-1P 90262-59-2P

90262-60-5P 90262-61-6P 90262-62-7P

90262-63-8P 90262-64-9P 90262-65-0P

90262-66-1P 90262-67-2P 90262-68-3P

90262-69-4P 90262-70-7P 90262-71-8P

90262-72-9P 90262-73-0P 90262-74-1P

90262-75-2P 90262-76-3P 90262-77-4P

90262-78-5P 90262-79-6P 90262-80-9P


90262-81-0P 90262-82-1P 90262-83-2P

90262-84-3P 90262-85-4P 90288-13-4P

(preparation and saponification of)


RN 90262-48-9 USPATFULL

CN Acetamide, 2-chloro-N-[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]- (9CI) (CA INDEX NAME)




RN 90262-49-0 USPATFULL

CN Acetamide, 2,2,2-trifluoro-N-[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl] - (9CI) (CA INDEX NAME)




RN 90262-50-3 USPATFULL

CN Benzoic acid, 4-[(1,2-dihydro-6-nitro-9-oxopyrrolo[2,1-b]quinazolin-3(9H)-ylidene)methyl] - (9CI) (CA INDEX NAME)




RN 90262-51-4 USPATFULL

CN Benzoic acid, 4-[(1,2-dihydro-6-nitro-9-oxopyrrolo[2,1-b]quinazolin-3(9H)-ylidene)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 90262-52-5 USPATFULL

CN Benzoic acid, 4-[(6-amino-1,2-dihydro-9-oxopyrrolo[2,1-b]quinazolin-3(9H)-ylidene)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 90262-53-6 USPATFULL

CN Acetic acid, oxo[[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 90262-54-7 USPATFULL

CN Acetic acid, oxo[[1,2,3,9-tetrahydro-1-methyl-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 90262-55-8 USPATFULL

CN Acetic acid, oxo[[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-7-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 90262-56-9 USPATFULL

CN Butanoic acid, 4-oxo-4-[[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 90262-57-0 USPATFULL


CN Propanoic acid, 3-oxo-3-[[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 90262-58-1 USPATFULL


CN 2-Butenoic acid, 4-oxo-4-[[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino]-, ethyl ester, (E,?) - (9CI) (CA INDEX NAME)

Double bond geometry as described by E or Z.




RN 90262-59-2 USPATFULL

CN Benzoic acid, 3-[[[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 90262-60-5 USPATFULL

CN Benzoic acid, 4-[[[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 90262-61-6 USPATFULL

CN Acetic acid, oxo[[1,2,3,9-tetrahydro-3-[(2-methylphenyl)methylene]-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 90262-62-7 USPATFULL

CN Acetic acid, oxo[[1,2,3,9-tetrahydro-3-[(3-methylphenyl)methylene]-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 90262-63-8 USPATFULL

CN Acetic acid, oxo[[1,2,3,9-tetrahydro-3-[(4-methylphenyl)methylene]-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 90262-64-9 USPATFULL

CN Acetic acid, oxo[[1,2,3,9-tetrahydro-3-[(2-methoxyphenyl)methylene]-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 90262-65-0 USPATFULL

CN Acetic acid, oxo[[1,2,3,9-tetrahydro-3-[(3-methoxyphenyl)methylene]-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 90262-66-1 USPATFULL

CN Acetic acid, oxo[[1,2,3,9-tetrahydro-3-[(4-methoxyphenyl)methylene]-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 90262-67-2 USPATFULL

CN Acetic acid, [[3-[(4-fluorophenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 90262-68-3 USPATFULL

CN Acetic acid, [[3-[(2-chlorophenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 90262-69-4 USPATFULL

CN Acetic acid, [[3-[(2,3-dimethoxyphenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 90262-70-7 USPATFULL

CN Acetic acid, [[3-[(3,4-dimethoxyphenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 90262-71-8 USPATFULL

CN Acetic acid, oxo[[1,2,3,9-tetrahydro-9-oxo-3-[[3-(trifluoromethyl)phenyl]methylene]pyrrolo[2,1-b]quinazolin-6-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 90262-72-9 USPATFULL

CN Acetic acid, [[3-(1,3-benzodioxol-5-ylmethylene)-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 90262-73-0 USPATFULL

CN Acetic acid, [[3-[(2,5-dimethylphenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 90262-74-1 USPATFULL

CN Acetic acid, [[3-[(2-ethoxyphenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 90262-75-2 USPATFULL

CN Acetic acid, [[3-[(3-ethoxyphenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 90262-76-3 USPATFULL

CN Acetic acid, [[3-[(4-ethoxyphenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 90262-77-4 USPATFULL

CN Acetic acid, [[3-[(4-chlorophenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 90262-78-5 USPATFULL

CN Acetic acid, [[3-[(3-chlorophenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 90262-79-6 USPATFULL

CN Acetic acid, [[3-[(3-ethoxy-2-methoxyphenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 90262-80-9 USPATFULL

CN Acetic acid, [[3-[(2,5-dimethoxyphenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 90262-81-0 USPATFULL

CN Acetic acid, oxo[[1,2,3,9-tetrahydro-9-oxo-3-[(3,4,5-trimethoxyphenyl)methylene]pyrrolo[2,1-b]quinazolin-6-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 90262-82-1 USPATFULL

CN Acetic acid, [[3-[(2,3-diethoxyphenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 90262-83-2 USPATFULL

CN Acetic acid, [[3-[(2,6-dichlorophenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 90262-84-3 USPATFULL

CN Benzoic acid, 3-[[methyl[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 90262-85-4 USPATFULL


CN Glycine, N-[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 90288-13-4 USPATFULL

CN Acetic acid, [[3-[(2,4-dichlorophenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo-, ethyl ester (9CI) (CA

INDEX NAME)




IT 90262-86-5P 90263-40-4P 90263-41-5P

(preparation of)

RN 90262-86-5 USPATFULL


CN 2-Butenoic acid, 4-oxo-4-[[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino]-, methyl ester, (Z,?) - (9CI) (CA INDEX NAME)

Double bond geometry as described by E or Z.



RN 90263-40-4 USPATFULL


CN Benzoic acid, 4-[(6-amino-1,2-dihydro-9-oxopyrrolo[2,1-b]quinazolin-3(9H)-ylidene)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 90263-41-5 USPATFULL

CN Benzoic acid, 4-[(6-amino-1,2-dihydro-9-oxopyrrolo[2,1-b]quinazolin-3(9H)-ylidene)methyl]- (9CI) (CA INDEX NAME)




IT 90262-88-7P 90262-89-8P 90262-90-1P
 90262-91-2P 90262-92-3P 90262-93-4P
 90262-94-5P 90262-95-6P 90262-96-7P
 90262-97-8P 90262-98-9P 90262-99-0P
 90263-00-6P 90263-01-7P 90263-02-8P
 90263-03-9P 90263-04-0P 90263-05-1P
 90263-06-2P 90263-07-3P 90263-08-4P
 90263-09-5P 90263-10-8P 90263-11-9P
 90263-12-0P 90263-13-1P 90263-14-2P
 90263-15-3P 90263-16-4P 90263-17-5P
 90263-18-6P 90263-19-7P 90263-20-0P
 90263-21-1P 90263-22-2P 90263-23-3P
 90263-24-4P 90263-25-5P 90263-26-6P
 90263-27-7P 90263-28-8P 90263-29-9P
 90263-30-2P 90263-31-3P 90263-32-4P
 90263-33-5P 90263-34-6P 90263-35-7P
 90263-36-8P 90263-37-9P 90263-38-0P
 90263-39-1P

(preparation of, as antiasthmatic)


RN 90262-88-7 USPATFULL

CN Acetic acid, oxo[[1,2,3,9-tetrahydro-1-methyl-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino] - (9CI) (CA INDEX NAME)




RN 90262-89-8 USPATFULL

CN Acetic acid, oxo[[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-7-yl]amino] - (9CI) (CA INDEX NAME)



RN 90262-90-1 USPATFULL


CN Butanoic acid, 4-oxo-4-[[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino]-, monosodium salt (9CI) (CA INDEX NAME)



● Na


RN 90262-91-2 USPATFULL

CN Butanoic acid, 4-oxo-4-[[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino]- (9CI) (CA INDEX NAME)



RN 90262-92-3 USPATFULL


CN Propanoic acid, 3-oxo-3-[[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino]- (9CI) (CA INDEX NAME)



RN 90262-93-4 USPATFULL


CN 2-Butenoic acid, 4-oxo-4-[[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino]-, (E,?) - (9CI) (CA INDEX NAME)

Double bond geometry as described by E or Z.




RN 90262-94-5 USPATFULL

CN Benzoic acid, 3-[[[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 90262-95-6 USPATFULL

CN Benzoic acid, 4-[[[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 90262-96-7 USPATFULL

CN Carbamic acid, [1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 90262-97-8 USPATFULL


CN Benzoic acid, 2-[[[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 90262-98-9 USPATFULL

CN 3-Cyclohexene-1-carboxylic acid, 6-[[[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino]carbonyl]-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 90262-99-0 USPATFULL


CN 2-Butenoic acid, 4-oxo-4-[[[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino]-, (Z,?) - (9CI) (CA INDEX NAME)

Double bond geometry as described by E or Z.




RN 90263-00-6 USPATFULL

CN 2-Butenoic acid, 2,3-dichloro-4-oxo-4-[[[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino]- (9CI) (CA INDEX NAME)




RN 90263-01-7 USPATFULL

CN Acetic acid, oxo[[1,2,3,9-tetrahydro-3-[(2-methylphenyl)methylene]-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]- (9CI) (CA INDEX NAME)




RN 90263-02-8 USPATFULL

CN Acetic acid, oxo[[1,2,3,9-tetrahydro-3-[(3-methylphenyl)methylene]-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]- (9CI) (CA INDEX NAME)




RN 90263-03-9 USPATFULL

CN Acetic acid, oxo[[1,2,3,9-tetrahydro-3-[(4-methylphenyl)methylene]-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]- (9CI) (CA INDEX NAME)




RN 90263-04-0 USPATFULL

CN Acetic acid, oxo[[1,2,3,9-tetrahydro-3-[(2-methoxyphenyl)methylene]-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]- (9CI) (CA INDEX NAME)




RN 90263-05-1 USPATFULL

CN Acetic acid, oxo[[1,2,3,9-tetrahydro-3-[(3-methoxyphenyl)methylene]-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]- (9CI) (CA INDEX NAME)




RN 90263-06-2 USPATFULL

CN Acetic acid, oxo[[1,2,3,9-tetrahydro-3-[(4-methoxyphenyl)methylene]-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]- (9CI) (CA INDEX NAME)




RN 90263-07-3 USPATFULL

CN Acetic acid, [[3-[(4-fluorophenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo- (9CI) (CA INDEX NAME)




RN 90263-08-4 USPATFULL

CN Acetic acid, [[3-[(2-chlorophenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo- (9CI) (CA INDEX NAME)




RN 90263-09-5 USPATFULL

CN Acetic acid, [[3-[(2,3-dimethoxyphenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo- (9CI) (CA INDEX NAME)




RN 90263-10-8 USPATFULL

CN Acetic acid, [[3-[(3,4-dimethoxyphenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo- (9CI) (CA INDEX NAME)




RN 90263-11-9 USPATFULL

CN Acetic acid, [[3-[(3-ethoxy-2-methoxyphenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo- (9CI) (CA INDEX NAME)




RN 90263-12-0 USPATFULL

CN Acetic acid, [[3-[(2,5-dimethylphenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo- (9CI) (CA INDEX NAME)




RN 90263-13-1 USPATFULL

CN Acetic acid, [[3-[(2-ethoxyphenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo- (9CI) (CA INDEX NAME)




RN 90263-14-2 USPATFULL

CN Acetic acid, [[3-[(3-ethoxyphenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo- (9CI) (CA INDEX NAME)




RN 90263-15-3 USPATFULL

CN Acetic acid, [[3-[(4-chlorophenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo- (9CI) (CA INDEX NAME)




RN 90263-16-4 USPATFULL

CN Acetic acid, [[3-[(4-chlorophenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo- (9CI) (CA INDEX NAME)




RN 90263-17-5 USPATFULL

CN Acetic acid, [[3-[(3-chlorophenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo- (9CI) (CA INDEX NAME)




RN 90263-18-6 USPATFULL

CN Acetic acid, [[3-[(2,3-diethoxyphenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo- (9CI) (CA INDEX NAME)




RN 90263-19-7 USPATFULL

CN Acetic acid, [[3-[(3,4-dichlorophenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo- (9CI) (CA INDEX NAME)




RN 90263-20-0 USPATFULL

CN Acetic acid, [[3-[(2,4-dichlorophenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo- (9CI) (CA INDEX NAME)




RN 90263-21-1 USPATFULL

CN Acetic acid, [[3-[(2,6-dichlorophenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo- (9CI) (CA INDEX NAME)




RN 90263-22-2 USPATFULL

CN Acetic acid, [[3-[(1,3-benzodioxol-5-yl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo- (9CI) (CA INDEX NAME)




RN 90263-23-3 USPATFULL

CN Acetic acid, oxo[[1,2,3,9-tetrahydro-9-oxo-3-[[3-(trifluoromethyl)phenyl]methylene]pyrrolo[2,1-b]quinazolin-6-yl]amino]- (9CI) (CA INDEX NAME)




RN 90263-24-4 USPATFULL

CN Acetic acid, [[3-[(2,5-dimethoxyphenyl)methylene]-1,2,3,9-tetrahydro-9-oxopyrrolo[2,1-b]quinazolin-6-yl]amino]oxo- (9CI) (CA INDEX NAME)




RN 90263-25-5 USPATFULL

CN Acetic acid, oxo[[1,2,3,9-tetrahydro-9-oxo-3-[(3,4,5-trimethoxyphenyl)methylene]pyrrolo[2,1-b]quinazolin-6-yl]amino]- (9CI)
(CA INDEX NAME)




RN 90263-26-6 USPATFULL

CN Benzoic acid, 4-[[6-[(carboxycarbonyl)amino]-1,2-dihydro-9-oxopyrrolo[2,1-b]quinazolin-3(9H)-ylidene]methyl]-, 1-methyl ester (9CI) (CA INDEX NAME)




RN 90263-27-7 USPATFULL

CN Benzoic acid, 4-[[6-[(carboxycarbonyl)amino]-1,2-dihydro-9-oxopyrrolo[2,1-b]quinazolin-3(9H)-ylidene]methyl]- (9CI) (CA INDEX NAME)



RN 90263-28-8 USPATFULL


CN Benzoic acid, 3-[[methyl[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino]carbonyl]-, monosodium salt (9CI) (CA INDEX NAME)



● Na


RN 90263-29-9 USPATFULL

CN Benzoic acid, 3-[[methyl[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 90263-30-2 USPATFULL

CN Acetic acid, [methyl[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino]oxo- (9CI) (CA INDEX NAME)



RN 90263-31-3 USPATFULL

CN Benzoic acid, 2-[[[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino]carbonyl]-, monosodium salt (9CI) (CA INDEX NAME)




● Na

RN 90263-32-4 USPATFULL

CN 3-Cyclohexene-1-carboxylic acid, 6-[[[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino]carbonyl]-, monosodium salt, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




● Na

RN 90263-33-5 USPATFULL

CN 2-Butenoic acid, 4-oxo-4-[[[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino]-, monosodium salt, (Z,?) - (9CI) (CA INDEX NAME)


Double bond geometry as described by E or Z.



● Na


RN 90263-34-6 USPATFULL

CN 1-Piperidinepropanamide, N-[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]- (9CI) (CA INDEX NAME)




RN 90263-35-7 USPATFULL

CN 4-Morpholineacetamide, N-[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]- (9CI) (CA INDEX NAME)



RN 90263-36-8 USPATFULL


CN Glycine, N-[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 90263-37-9 USPATFULL


CN Glycine, N-[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]- (9CI) (CA INDEX NAME)



RN 90263-38-0 USPATFULL


CN Benzoic acid, 4-[[6-[(3-carboxy-1-oxo-2-propenyl)amino]-1,2-dihydro-9-oxopyrrolo[2,1-b]quinazolin-3(9H)-ylidene]methyl]-, (Z,?) - (9CI) (CA INDEX NAME)

Double bond geometry as described by E or Z.



RN 90263-39-1 USPATFULL

CN 2-Butenoic acid, 4-oxo-4-[[1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl]amino]-, 2-(diethylamino)ethyl ester (9CI) (CA INDEX NAME)



L67 ANSWER 53 OF 58 USPATFULL on STN

ACCESSION NUMBER: 84:5957 USPATFULL

TITLE: Substituted pyrrolo[2,1-b]quinazolines and pyrido[2,1-b]quinazolines useful for the treatment of or the prevention of gastrointestinal ulcers

INVENTOR(S): Doria, Gianfederico, Milan, Italy
Passarotti, Carlo, Gallarate, Italy
Arcari, Giuliana, Milan, Italy

PATENT ASSIGNEE(S): Farmitalia Carlo Erba S.p.A., Milan, Italy (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4428952		19840131	<--
APPLICATION INFO.:	US 1982-387181		19820610 (6)	<--

NUMBER DATE

PRIORITY INFORMATION: GB 1981-20126 19810630 <--
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Daus, Donald G.
ASSISTANT EXAMINER: Rivers, Diana G.
LEGAL REPRESENTATIVE: Murray and Whisenhunt
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1,13,14
LINE COUNT: 1202


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Substituted Pyrrolo [2,1-b] and Pyrido [2, 1 b] Quinazolines are provided, together with pharmaceutical compositions, containing them. The compounds have pharmaceutical utility, and are particularly useful for the treatment of or prevention of the formation of gastrointestinal ulcers.

IT 85742-73-0P 85743-04-0P
(preparation and antiulcer activity of)


RN 85742-73-0 USPATFULL

CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)- (9CI) (CA INDEX NAME)



RN 85743-04-0 USPATFULL


CN Pyrrolo[2,1-b]quinazoline-6-carboxylic acid, 1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)- (9CI) (CA INDEX NAME)



IT 85743-45-9P
(preparation and dehydration of)

RN 85743-45-9 USPATFULL

CN Pyrrolo[2,1-b]quinazoline-7-carboxamide, 1,2,3,9-tetrahydro-3-[(2-methylphenyl)methylene]-9-oxo- (9CI) (CA INDEX NAME)




IT 85742-72-9P

(preparation and hydrolysis of)

RN 85742-72-9 USPATFULL

CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)-, methyl ester (9CI) (CA INDEX NAME)




IT 65636-75-1P 85743-26-6P 85743-30-2P

(preparation and reduction of)


RN 65636-75-1 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-6-nitro-3-(phenylmethylene)- (9CI) (CA INDEX NAME)



RN 85743-26-6 USPATFULL


CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-1-methyl-6-nitro-3-(phenylmethylene)- (9CI) (CA INDEX NAME)



RN 85743-30-2 USPATFULL

CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 1,2,3,9-tetrahydro-3-[(2-methylphenyl)methylene]-9-oxo-, methyl ester (9CI) (CA INDEX NAME)

3/3




IT 85742-74-1P 85742-75-2P 85742-76-3P
 85742-77-4P 85742-78-5P 85742-79-6P
 85742-80-9P 85742-81-0P 85742-82-1P
 85742-83-2P 85742-84-3P 85742-85-4P
 85742-86-5P 85742-87-6P 85742-88-7P
 85742-89-8P 85742-90-1P 85742-91-2P
 85742-92-3P 85742-93-4P 85742-94-5P
 85743-07-3P 85743-08-4P 85743-09-5P
 85743-10-8P 85743-11-9P 85743-12-0P
 85743-13-1P 85743-14-2P 85743-15-3P
 85743-16-4P 85743-17-5P 85743-18-6P
 85743-19-7P 85743-20-0P 85743-21-1P
 85743-22-2P 85743-23-3P 85743-24-4P
 85743-27-7P 85743-31-3P 85743-32-4P
 85743-33-5P 85743-34-6P 85743-35-7P
 85743-38-0P 85743-39-1P 85743-40-4P
 85743-41-5P 85743-42-6P 85743-46-0P
 85743-47-1P 85743-48-2P 85743-49-3P

(preparation of)


RN 85742-74-1 USPATFULL

CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 1,2,3,9-tetrahydro-3-[(3-methylphenyl)methylene]-9-oxo- (9CI) (CA INDEX NAME)




RN 85742-75-2 USPATFULL

CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 1,2,3,9-tetrahydro-3-[(4-methylphenyl)methylene]-9-oxo- (9CI) (CA INDEX NAME)




RN 85742-76-3 USPATFULL

CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 3-[(2,5-dimethylphenyl)methylene]-1,2,3,9-tetrahydro-9-oxo- (9CI) (CA INDEX NAME)




RN 85742-77-4 USPATFULL

CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 3-[(2,4-dimethylphenyl)methylene]-1,2,3,9-tetrahydro-9-oxo- (9CI) (CA INDEX NAME)




RN 85742-78-5 USPATFULL

CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 1,2,3,9-tetrahydro-3-[(3-methoxyphenyl)methylene]-9-oxo- (9CI) (CA INDEX NAME)



RN 85742-79-6 USPATFULL


CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 3-[(3-chlorophenyl)methylene]-1,2,3,9-tetrahydro-9-oxo- (9CI) (CA INDEX NAME)



RN 85742-80-9 USPATFULL


CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 3-[(2,6-dichlorophenyl)methylene]-1,2,3,9-tetrahydro-9-oxo- (9CI) (CA INDEX NAME)

NAME)




RN 85742-81-0 USPATFULL

CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 1,2,3,9-tetrahydro-3-[(2-methylphenyl)methylene]-9-oxo- (9CI) (CA INDEX NAME)




RN 85742-82-1 USPATFULL

CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 3-[(2,4-dichlorophenyl)methylene]-1,2,3,9-tetrahydro-9-oxo- (9CI) (CA INDEX NAME)




RN 85742-83-2 USPATFULL

CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 3-[(4-fluorophenyl)methylene]-1,2,3,9-tetrahydro-9-oxo- (9CI) (CA INDEX NAME)




RN 85742-84-3 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 7-chloro-2,3-dihydro-3-(phenylmethylene)- (9CI) (CA INDEX NAME)




RN 85742-85-4 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 7-chloro-2,3-dihydro-3-[(2-methylphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 85742-86-5 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 7-chloro-2,3-dihydro-3-[(3-methylphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 85742-87-6 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 7-chloro-3-[(4-fluorophenyl)methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 85742-88-7 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 7-chloro-3-[(2,6-dichlorophenyl)methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 85742-89-8 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 7-chloro-2,3-dihydro-3-[(2-methoxyphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 85742-90-1 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 7-chloro-2,3-dihydro-3-[(3-methoxyphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 85742-91-2 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 7-chloro-3-[(3,4-dimethoxyphenyl)methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 85742-92-3 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 7-chloro-2,3-dihydro-3-[(2,3,4-trimethoxyphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 85742-93-4 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 7-chloro-2,3-dihydro-3-[(2,4,5-trimethoxyphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 85742-94-5 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 7-chloro-2,3-dihydro-3-[(3,4,5-trimethoxyphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 85743-07-3 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-7-methyl-3-(phenylmethylene)- (9CI) (CA INDEX NAME)




RN 85743-08-4 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-chloro-2,3-dihydro-3-(phenylmethylene)- (9CI) (CA INDEX NAME)




RN 85743-09-5 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 5,7-dichloro-2,3-dihydro-3-(phenylmethylene)- (9CI) (CA INDEX NAME)




RN 85743-10-8 USPATFULL

CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 1,2,3,9-tetrahydro-1-methyl-9-oxo-3-(phenylmethylene)- (9CI) (CA INDEX NAME)




RN 85743-11-9 USPATFULL

CN Acetamide, N-(1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)pyrrolo[2,1-b]quinazolin-6-yl)- (9CI) (CA INDEX NAME)




RN 85743-12-0 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-2,3-dihydro-3-(phenylmethylene)- (9CI) (CA INDEX NAME)




RN 85743-13-1 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-2,3-dihydro-3-[(3,4,5-trimethoxyphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 85743-14-2 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-3-[(3,4-dichlorophenyl)methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 85743-15-3 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-2,3-dihydro-3-[(2-methylphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 85743-16-4 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-2,3-dihydro-3-[(3-methylphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 85743-17-5 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-2,3-dihydro-3-[(4-methylphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 85743-18-6 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-2,3-dihydro-3-[(2-methoxyphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 85743-19-7 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-2,3-dihydro-3-[(3-methoxyphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 85743-20-0 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-2,3-dihydro-3-[(4-methoxyphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 85743-21-1 USPTAFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-3-[(2,3-dimethoxyphenyl)methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 85743-22-2 USPTAFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-3-[(4-fluorophenyl)methylene]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 85743-23-3 USPTAFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-3-(1,3-benzodioxol-5-ylmethylene)-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 85743-24-4 USPTAFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 7-amino-2,3-dihydro-3-(phenylmethylene)- (9CI) (CA INDEX NAME)




RN 85743-27-7 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 6-amino-2,3-dihydro-1-methyl-3-(phenylmethylene)- (9CI) (CA INDEX NAME)




RN 85743-31-3 USPATFULL

CN Pyrrolo[2,1-b]quinazolin-9(1H)-one, 2,3-dihydro-7-(hydroxymethyl)-3-[(2-methylphenyl)methylene]- (9CI) (CA INDEX NAME)




RN 85743-32-4 USPATFULL

CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 1,2,3,9-tetrahydro-3-[(2-methylphenyl)methylene]-9-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 85743-33-5 USPATFULL

CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 3-[(4-fluorophenyl)methylene]-1,2,3,9-tetrahydro-9-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 85743-34-6 USPATFULL

CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 1,2,3,9-tetrahydro-1-methyl-9-oxo-3-(phenylmethylene)-, methyl ester (9CI) (CA INDEX NAME)




RN 85743-35-7 USPATFULL

CN Pyrrolo[2,1-b]quinazoline-6-carboxylic acid, 1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)-, methyl ester (9CI) (CA INDEX NAME)




RN 85743-38-0 USPATFULL

CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 1,2,3,9-tetrahydro-3-[(3-methylphenyl)methylene]-9-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 85743-39-1 USPATFULL

CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 1,2,3,9-tetrahydro-3-[(4-methylphenyl)methylene]-9-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 85743-40-4 USPATFULL

CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 1,2,3,9-tetrahydro-3-[(3-methoxyphenyl)methylene]-9-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 85743-41-5 USPATFULL

CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 3-[(2,4-dimethylphenyl)methylene]-1,2,3,9-tetrahydro-9-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 85743-42-6 USPATFULL

CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 3-[(2,5-dimethylphenyl)methylene]-1,2,3,9-tetrahydro-9-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 85743-46-0 USPATFULL

CN Pyrrolo[2,1-b]quinazoline-7-carbonitrile, 1,2,3,9-tetrahydro-3-[(2-methylphenyl)methylene]-9-oxo- (9CI) (CA INDEX NAME)




RN 85743-47-1 USPATFULL

CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 2-(diethylamino)-1,2,3,9-tetrahydro-3-[(2-methylphenyl)methylene]-9-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 85743-48-2 USPATFULL

CN Pyrrolo[2,1-b]quinazoline-6-carboxylic acid, 2-(diethylamino)-1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)-, ethyl ester (9CI) (CA INDEX NAME)



RN 85743-49-3 USPATFULL

CN Pyrrolo[2,1-b]quinazoline-7-carboxylic acid, 1,2,3,9-tetrahydro-9-oxo-3-(phenylmethylene)-, sodium salt (9CI) (CA INDEX NAME)



● Na

=> d ibib ed ab hitind 54

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, USPATFULL, BIOSIS, SYNTHLINE, EMBASE, PASCAL' - CONTINUE? (Y)/N:y

L67 ANSWER 54 OF 58 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

ACCESSION NUMBER: 2000:544022 BIOSIS

DOCUMENT NUMBER: PREV200000544022

TITLE: Effects of some pyrrolo(2,1-b)quinazoline-3-one derivatives on macrophage functions.

AUTHOR(S): Rioja, I. [Reprint author]; Terencio, M. C. [Reprint author]; Ubeda, A. [Reprint author]; Alcaraz, M. J. [Reprint author]; Tarraga, A.; Gonzalez-Tejero, A.

CORPORATE SOURCE: Department of Pharmacology, University of Valencia, Valencia, Spain

SOURCE: Methods and Findings in Experimental and Clinical Pharmacology, (July-August, 2000) Vol. 22, No. 6, pp. 512. print.
Meeting Info.: XXIII Congress of the Spanish Society of Pharmacology. Alicante, Spain. September 24-27, 2000.
CODEN: MFEPDX. ISSN: 0379-0355.

DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
Conference; (Meeting Poster)

LANGUAGE: English

ENTRY DATE: Entered STN: 13 Dec 2000

Last Updated on STN: 11 Jan 2002

ED Entered STN: 13 Dec 2000

Last Updated on STN: 11 Jan 2002

CC Immunology - General and methods 34502

General biology - Symposia, transactions and proceedings 00520

Cytology - Animal 02506

Biochemistry studies - General 10060

Pathology - Therapy 12512

Pharmacology - Connective tissue, bone and collagen-acting drugs 22012

Pharmacognosy and pharmaceutical botany 54000

IT Major Concepts

Immune System (Chemical Coordination and Homeostasis); Pharmacognosy (Pharmacology)

IT Chemicals & Biochemicals

COX-2 [cyclooxygenase-2]; PGE-2 [prostaglandin E-2]: generation; iNOS [inducible nitric oxide synthase]; isaindigotone: antiinflammatory-drug; nitric oxide: generation; pyrrolo[2,1-b]quinazoline-3-one derivatives: antiinflammatory effect; superoxide: generation

IT Miscellaneous Descriptors

Meeting Abstract; Meeting Poster

ORGN Classifier

Cruciferae 25880

Super Taxa

Dicotyledones; Angiospermae; Spermatophyta; Plantae

Organism Name

Isatis indigotica: medicinal plant

Taxa Notes

Angiosperms, Dicots, Plants, Spermatophytes, Vascular Plants

ORGN Classifier

Muridae 86375

Super Taxa

Rodentia; Mammalia; Vertebrata; Chordata; Animalia

Organism Name

RAW 264.7 cell line: murine macrophage

Taxa Notes

Animals, Chordates, Mammals, Nonhuman Vertebrates, Nonhuman Mammals,

Rodents, Vertebrates

RN 189316-00-5 (isaindigotone)
 10102-43-9 (nitric oxide)
 11062-77-4 (superoxide)
 363-24-6 (PROSTAGLANDIN E-2)

=> d ibib ed ab hitind 55

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, USPATFULL, BIOSIS, SYNTHLINE, EMBASE,
 PASCAL' - CONTINUE? (Y)/N:y

REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):ibib ed

L67 ANSWER 55 OF 58 SYNTHLINE COPYRIGHT 2006 PROUS SCIENCE on STN

ACCESSION NUMBER: 2003:196 SYNTHLINE

TITLE: Inhibition of leukocyte functions by the alkaloid
 isaindigotone from Isatis indigotica and some new
 synthetic derivatives

AUTHOR(S): Molina, P.; Tarraga, A.; Gonzalez-Tejero, A.; Rioja, I.;
 Ubeda, A.; Terencio, M.C.; Alcaraz, M.J.

SOURCE: J Nat Prod (2001), 64(10), 1297

ED Entered STN: 14 Mar 2003

Last Updated on STN: 16 May 2006

=> d ibib ed ab hitind 56-58

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, USPATFULL, BIOSIS, SYNTHLINE, EMBASE,
 PASCAL' - CONTINUE? (Y)/N:y

L67 ANSWER 56 OF 58 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights
 reserved on STN

ACCESSION NUMBER: 2003268916 EMBASE

TITLE: Ca(2+)-independent protein kinase Cs mediate heterologous
 desensitization of leukocyte chemokine receptors
 by opioid receptors.

AUTHOR: Zhang N.; Hodge D.; Rogers T.J.; Oppenheim J.J.

CORPORATE SOURCE: J.J. Oppenheim, Lab. of Molecular Immunoregulation,
 Intramural Research Support Program, Bldg. 560, Frederick,
 MD 21702-1201, United States

SOURCE: Journal of Biological Chemistry, (11 Apr 2003) Vol. 278,
 No. 15, pp. 12729-12736. .

Refs: 37

ISSN: 0021-9258 CODEN: JBCHA3

COUNTRY: United States

DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 026 Immunology, Serology and Transplantation

029 Clinical Biochemistry

LANGUAGE: English

SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 31 Jul 2003

Last Updated on STN: 31 Jul 2003

ED Entered STN: 31 Jul 2003

Last Updated on STN: 31 Jul 2003

AB Heterologous desensitization of **chemokine** receptors by opioids has been considered to contribute to their immunosuppressive effects. Previous studies show that Met-enkephalin, an endogenous opioid, down-regulates chemotaxis of selected **chemokine** receptors via phosphorylation. In the present study, we further investigated the molecular mechanism of such cross-regulation. Our data showed that preincubation with Met-enkephalin inhibited both MIP-1 α -mediated chemotaxis and Ca(2+) flux of monocytes in a dose-dependent manner. The inhibitory effects were maximal using nanomolar concentrations of activating **chemokines**, a concentration found in physiological conditions. A decrease both in **chemokine** receptor affinity and in coupling efficiency between receptors and G protein were observed, which directly contributed to the desensitization effects. However, comparing with **chemokines** such as MIP-1 α and MCP-1, opioids did not elicit a calcium flux, failed to induce MIP-1 α receptors internalization, and mediated a less potent heterologous desensitization. We hypothesized that these differences might originate from the involvement of different protein kinase C (PKC) isoforms. In our studies, opioid-mediated down-regulation of MIP-1 α receptors could be blocked by the general PKC inhibitor calphostin C, but not by the calcium-dependent classic PKC inhibitor Go6976. Western blotting analysis and immunofluorescent staining further showed that only calcium-independent PKCs were activated upon opioid stimulation. Thus, opioids achieve desensitization of **chemokine** receptors via a unique pathway, involving only calcium-independent PKC isoforms.

CT Medical Descriptors:

*immunoregulation

monocyte

desensitization

signal transduction

enzyme activity

enzyme activation

human

normal human

controlled study

human cell

article

priority journal

Drug Descriptors:

*calcium ion

*protein kinase C

*opiate receptor: EC, endogenous compound

protein kinase C inhibitor

calphostin C

chemokine**chemokine receptor: EC, endogenous compound**

monocyte chemotactic protein 1

macrophage inflammatory protein 1 α

12 (2 cyanoethyl) 6,7,12,13 tetrahydro 13 methyl 5 oxoindolo[2,3 a]pyrrolo[3,4 c]carbazole

RN (calcium ion) 14127-61-8; (protein kinase C) 141436-78-4; (calphostin C) 121263-19-2; (macrophage inflammatory protein 1 α) 155075-84-6; (12 (2 cyanoethyl) 6,7,12,13 tetrahydro 13 methyl 5 oxoindolo[2,3 a]pyrrolo[3,4 c]carbazole) 136194-77-9

L67 ANSWER 57 OF 58 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights

reserved on STN

ACCESSION NUMBER: 2002405511 EMBASE
 TITLE: Involvement of classical and novel protein kinase C isoforms in the response of human V γ 9V δ 2 T cells to phosphate antigens.
 AUTHOR: Cipriani B.; Knowles H.; Chen L.; Battistini L.; Brosnan C.F.
 CORPORATE SOURCE: Dr. C.F. Brosnan, Department of Pathology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, United States. Brosnan@aeacom.yu.edu
 SOURCE: Journal of Immunology, (15 Nov 2002) Vol. 169, No. 10, pp. 5761-5770. .
 Refs: 47
 ISSN: 0022-1767 CODEN: JOIMA3
 COUNTRY: United States
 DOCUMENT TYPE: Journal; Article
 FILE SEGMENT: 026 Immunology, Serology and Transplantation
 029 Clinical Biochemistry
 037 Drug Literature Index
 LANGUAGE: English
 SUMMARY LANGUAGE: English
 ENTRY DATE: Entered STN: 12 Dec 2002
 Last Updated on STN: 12 Dec 2002
 ED Entered STN: 12 Dec 2002
 Last Updated on STN: 12 Dec 2002
 AB Human $\gamma\delta$ T cells expressing the V γ 9V δ 2 gene segments are activated polyclonally by phosphoantigens found on a wide variety of pathogenic organisms. After ligand exposure, V γ 9V δ 2 T cells proliferate and rapidly secrete large amounts of cytokines and **chemokines** that contribute to the innate immune response to these pathogens. Neither APCs nor costimulatory molecules are required. In this study we examined whether these phosphoantigens activate protein kinase C θ (PKC θ). This novel PKC isoform is essential for Ag signaling through the $\alpha\beta$ TCR in a costimulation-dependent fashion. The results showed that isopentenyl pyrophosphate (IPP), a soluble phospholigand released by mycobacteria, led to the rapid and persistent activation of PKC θ in $\gamma\delta$ T cells, as determined by evidence of translocation and phosphorylation. In contrast, no ligand-dependent response was detected for PKC α/β or PKC δ . Using the inhibitors Go6976 and rottlerin, a role for both conventional and novel PKC isoforms in IPP-induced proliferation, CD25 expression, and cytokine and **chemokine** production was demonstrated. Gel-shift assays indicated that the transcription factors NF- κ B and AP-1 were downstream targets of PKC activation. IPP also induced the rapid and persistent phosphorylation of extracellular signal-regulated kinases 1 and 2, p38 mitogen-activated kinase, and stress-activated kinase/c-Jun N-terminal kinase, but only an inhibitor of conventional PKCs blocked these responses. We conclude that the $\gamma\delta$ T cell response to phosphoantigens is regulated by both novel and conventional PKC isoforms, with PKC θ being more responsive to ligand stimulation and PKC α/β to growth-factor availability.
 CT Medical Descriptors:
 *gene expression
 *T lymphocyte
 pathogenesis
 immune response
 cytokine production
 cytokine release
 signal transduction
 Mycobacterium

enzyme activation
 cell activation
 gene translocation
 phosphorylation
 antigen expression
 enzyme inhibition
 human
 normal human
 controlled study
 human cell
 article
 priority journal
 Drug Descriptors:
 *protein kinase C: EC, endogenous compound
 *phosphate: EC, endogenous compound
 *phosphoantigen: EC, endogenous compound
 cytokine: EC, endogenous compound
 chemokine: EC, endogenous compound
 isopentenyl diphosphate
 ligand
 protein kinase C alpha
 protein kinase C beta: EC, endogenous compound
 protein kinase C delta: EC, endogenous compound
 12 (2 cyanoethyl) 6,7,12,13 tetrahydro 13 methyl 5 oxoindolo[2,3
a]pyrrolo[3,4 c]carbazole
 rottlerin
 interleukin 2 receptor: EC, endogenous compound
 transcription factor: EC, endogenous compound
 immunoglobulin enhancer binding protein: EC, endogenous compound
 transcription factor AP 1: EC, endogenous compound
 mitogen activated protein kinase 1: EC, endogenous compound
 mitogen activated protein kinase 2: EC, endogenous compound
 synaptophysin: EC, endogenous compound
 mitogen activated protein kinase: EC, endogenous compound
 stress activated protein kinase: EC, endogenous compound
 growth factor: EC, endogenous compound
 unclassified drug

RN (protein kinase C) 141436-78-4; (phosphate) 14066-19-4, 14265-44-2;
 (isopentenyl diphosphate) 358-71-4; (12 (2 cyanoethyl) 6,7,12,13
 tetrahydro 13 methyl 5 oxoindolo[2,3 a]pyrrolo[3,4 c]
carbazole) 136194-77-9; (rottlerin) 82-08-6; (mitogen activated
 protein kinase 1) 137632-07-6; (mitogen activated protein kinase 2)
 137632-08-7; (mitogen activated protein kinase) 142243-02-5; (stress
 activated protein kinase) 155215-87-5
 CN Go 6976

L67 ANSWER 58 OF 58 PASCAL COPYRIGHT 2006 INIST-CNRS. ALL RIGHTS RESERVED.
 on STN

ACCESSION NUMBER: 2002-0240527 PASCAL

COPYRIGHT NOTICE: Copyright .COPYRG. 2002 INIST-CNRS. All rights reserved.

TITLE (IN ENGLISH): CCR5 antagonists: Bicyclic isoxazolidines as
 conformationally constrained N-1-substituted
 pyrrolidines

AUTHOR: LYNCH Christopher L.; GENTRY Amy L.; HALE Jeffrey J.;
 MILLS Sander G.; MACCOSS Malcolm; MALKOWITZ Lorraine;
 SPRINGER Martin S.; GOULD Sandra L.; DEMARTINO Julie
 A.; SICILIANO Salvatore J.; CASCIERI Margaret A.; DOSS
 George; CARELLA Anthony; CARVER Gwen; HOLMES Karen;
 SCHLEIF William A.; DANZEISEN Renee; HAZUDA Daria;

CORPORATE SOURCE: KESSLER Joseph; LINEBERGER Janet; MILLER Michael;
EMINI Emilio A.
Department of Medicinal Chemistry, Merck Research
Laboratories, PO Box 2000, Rahway, NJ 07065, United
States; Department of Immunology Research, Merck
Research Laboratories, PO Box 2000, Rahway, NJ 07065,
United States; Department of Drug Metabolism-NMR
Spectroscopy, Merck Research Laboratories, PO Box
2000, Rahway, NJ 07065, United States; Department of
Antiviral Research, Merck Research Laboratories, PO
Box 4, West Point, PA 19486, United States

SOURCE: Bioorganic & medicinal chemistry letters, (2002),
12(4), 677-679
ISSN: 0960-894X

DOCUMENT TYPE: Journal

BIBLIOGRAPHIC LEVEL: Analytic

COUNTRY: United Kingdom

LANGUAGE: English

NOTE: 1/4 p. ref. et notes

AVAILABILITY: INIST-22446, 354000102178840390

UP 20020528

AB A series of CCR5 antagonists containing bicyclic isoxazolidines was
generated through a nitrene mediated cycloaddition with olefins bearing
the preferred pharmacophores previously described. Potent antagonists (3
and 16) were generated with enhanced affinity for the CCR5 receptor while
maintaining antiviral activity against HIV.

=> d que 133

```

L19      QUE ABB=ON PLU=ON ANDERSKEWITZ, R?/AU
L20      QUE ABB=ON PLU=ON DOLLINGER, H?/AU
L21      QUE ABB=ON PLU=ON HEINE, C?/AU
L22      QUE ABB=ON PLU=ON POUZET, P?/AU
L23      QUE ABB=ON PLU=ON BOUYSSOU, T?/AU
L24      QUE ABB=ON PLU=ON BIRKE, F?/AU
L25      QUE ABB=ON PLU=ON (BOEHRINGER OR INGELHEIM)/PA,CS,SO
L26      219 SEA FILE=HCAPLUS ABB=ON PLU=ON (L19 OR L20 OR L21 OR L22 OR
        L23 OR L24)
L27      QUE ABB=ON PLU=ON ?PYRROL? (4A) ?AZOL?
L28      2 SEA FILE=HCAPLUS ABB=ON PLU=ON L26 AND L27
L29      99 SEA FILE=HCAPLUS ABB=ON PLU=ON (L19 OR L20 OR L21 OR L22 OR
        L23 OR L24) AND L25
L30      QUE ABB=ON PLU=ON ?CHEMOKIN? OR (CHEMO(W)KIN?)
L31      64 SEA FILE=HCAPLUS ABB=ON PLU=ON L25 AND L27
L32      7 SEA FILE=HCAPLUS ABB=ON PLU=ON (L29 OR L31) AND L30
L33      7 SEA FILE=HCAPLUS ABB=ON PLU=ON L28 OR L32

```

=> d que 152

```

L19      QUE ABB=ON PLU=ON ANDERSKEWITZ, R?/AU
L20      QUE ABB=ON PLU=ON DOLLINGER, H?/AU
L21      QUE ABB=ON PLU=ON HEINE, C?/AU
L22      QUE ABB=ON PLU=ON POUZET, P?/AU
L23      QUE ABB=ON PLU=ON BOUYSSOU, T?/AU
L24      QUE ABB=ON PLU=ON BIRKE, F?/AU
L49      137 SEA FILE=WPIX ABB=ON PLU=ON (L19 OR L20 OR L21 OR L22 OR L23
        OR L24)
L50      6 SEA FILE=WPIX ABB=ON PLU=ON L49 AND (?CHEMOKIN?/BIX OR
        (CHEMO/BIX(W)KIN?/BIX))
L51      6 SEA FILE=WPIX ABB=ON PLU=ON L49 AND (?PYRROL?/BIX(4A)?AZOL?/B
        IX)
L52      11 SEA FILE=WPIX ABB=ON PLU=ON L50 OR L51

```

=> d his 160

(FILE 'MEDLINE, BIOSIS, EMBASE, CABA, LIFESCI, DRUGU, DRUGB, VETU, VETB,
SCISEARCH, CONF, CONFSCI, DISSABS' ENTERED AT 11:47:28 ON 05 JUN 2006)

L60 10 S L58 OR L59

=> d que 160

```

L19      QUE ABB=ON PLU=ON ANDERSKEWITZ, R?/AU
L20      QUE ABB=ON PLU=ON DOLLINGER, H?/AU
L21      QUE ABB=ON PLU=ON HEINE, C?/AU
L22      QUE ABB=ON PLU=ON POUZET, P?/AU
L23      QUE ABB=ON PLU=ON BOUYSSOU, T?/AU
L24      QUE ABB=ON PLU=ON BIRKE, F?/AU
L27      QUE ABB=ON PLU=ON ?PYRROL? (4A) ?AZOL?
L30      QUE ABB=ON PLU=ON ?CHEMOKIN? OR (CHEMO(W)KIN?)
L57      563 SEA (L19 OR L20 OR L21 OR L22 OR L23 OR L24)
L58      9 SEA L57 AND L30
L59      1 SEA L57 AND L27
L60      10 SEA L58 OR L59

```

=> d his 165

(FILE 'PASCAL, JICST-EPLUS' ENTERED AT 11:54:17 ON 05 JUN 2006)

L65 2 S L64 AND (L27 OR L30)

=> d que l65

L19 QUE ABB=ON PLU=ON ANDERSKEWITZ, R?/AU
 L20 QUE ABB=ON PLU=ON DOLLINGER, H?/AU
 L21 QUE ABB=ON PLU=ON HEINE, C?/AU
 L22 QUE ABB=ON PLU=ON POUZET, P?/AU
 L23 QUE ABB=ON PLU=ON BOUYSSOU, T?/AU
 L24 QUE ABB=ON PLU=ON BIRKE, F?/AU
 L27 QUE ABB=ON PLU=ON ?PYRROL? (4A) ?AZOL?
 L30 QUE ABB=ON PLU=ON ?CHEMOKIN? OR (CHEMO(W)KIN?)
 L64 68 SEA (L19 OR L20 OR L21 OR L22 OR L23 OR L24)
 L65 2 SEA L64 AND (L27 OR L30)

=> dup rem l33 l52 l60 l65

DUPLICATE IS NOT AVAILABLE IN 'CONF'.

ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE

FILE 'HCAPLUS' ENTERED AT 12:07:01 ON 05 JUN 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIX' ENTERED AT 12:07:01 ON 05 JUN 2006

COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'MEDLINE' ENTERED AT 12:07:01 ON 05 JUN 2006

FILE 'BIOSIS' ENTERED AT 12:07:01 ON 05 JUN 2006

Copyright (c) 2006 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 12:07:01 ON 05 JUN 2006

Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'DRUGU' ENTERED AT 12:07:01 ON 05 JUN 2006

COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'SCISEARCH' ENTERED AT 12:07:01 ON 05 JUN 2006

Copyright (c) 2006 The Thomson Corporation

FILE 'PASCAL' ENTERED AT 12:07:01 ON 05 JUN 2006

Any reproduction or dissemination in part or in full,
 by means of any process and on any support whatsoever
 is prohibited without the prior written agreement of INIST-CNRS.
 COPYRIGHT (C) 2006 INIST-CNRS. All rights reserved.

PROCESSING COMPLETED FOR L33

PROCESSING COMPLETED FOR L52

PROCESSING COMPLETED FOR L60

PROCESSING COMPLETED FOR L65

L68 15 DUP REM L33 L52 L60 L65 (15 DUPLICATES REMOVED)

ANSWERS '1-7' FROM FILE HCAPLUS

ANSWERS '8-13' FROM FILE WPIX

ANSWERS '14-15' FROM FILE MEDLINE

=> file stnguide

FILE 'STNGUIDE' ENTERED AT 12:07:08 ON 05 JUN 2006

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE

AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jun 2, 2006 (20060602/UP).

=> d ibib ed ab 1-15

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, WPIX, MEDLINE' - CONTINUE? (Y)/N:y

L68 ANSWER 1 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 1
 ACCESSION NUMBER: 2005:472116 HCAPLUS
 DOCUMENT NUMBER: 143:26498
 TITLE: Preparation of novel piperidine-substituted indoles as CCR3 modulators
 INVENTOR(S): Martyres, Domnic; Anderskewitz, Ralf; Dollinger, Horst; Pouzet, Pascale; Birke, Franz; Bouyssou, Thierry
 PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.
 SOURCE: PCT Int. Appl., 48 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005049559	A2	20050602	WO 2004-EP12775	20041111
WO 2005049559	A3	20060413		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005153979	A1	20050714	US 2004-990059	20041116
PRIORITY APPLN. INFO.:			EP 2003-26170	A 20031117
			US 2003-528619P	P 20031211

OTHER SOURCE(S): MARPAT 143:26498

ED Entered STN: 03 Jun 2005

AB The title compds. I [R1 = (un)substituted aryl, het or a annelated species thereof (wherein het = heterocyclic ring and the annelated species = aryl-het, het-aryl or het-het-annelations); R5 = alkyl, alkoxy, acyloxy, aralkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, thioalkyl, halo, NO2, CN; R6 = alkyl, alkoxy, acyloxy, aralkyl, cycloalkyl, haloalkyl, thioalkyl, halo etc.; A = cycloalkylalkylene, alkylene, optionally substituted with halogen or OH; B = aryl or het; DE = CHCH2 or C:CH; XWV = NC:CR7 or C:CNR7; R7 = H, alkyl; Y = CF2, NR4, O, S(O)n (R4 = H, alkyl, cycloalkyl, etc.); i, j = 0-2 (wherein 0<i+j<4); n = 0-2; m = 0-4], useful as agonists or antagonists of CCR-3 (no data), were prepared E.g., a multi-step synthesis of II, starting from p-fluorothiophenol and 1,3-dibromopropane, is given. The present invention also provides pharmaceutical compns. comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compds. I or a pharmaceutically acceptable salt thereof.

L68 ANSWER 2 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 2

ACCESSION NUMBER: 2005:182651 HCAPLUS
DOCUMENT NUMBER: 142:280209
TITLE: Preparation of piperidine-substituted benzimidazoles
as CCR-3 receptor modulators
INVENTOR(S): Anderskewitz, Ralf; Martyres, Domnic;
Dollinger, Horst; Pouzet, Pascale;
Birke, Franz; Bouyssou, Thierry
PATENT ASSIGNEE(S): Boehringer Ingelheim International
GmbH, Germany; Boehringer Ingelheim
Pharma GmbH & Co. Kg
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005019203	A1	20050303	WO 2004-EP9292	20040819
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2536787	AA	20050303	CA 2004-2536787	20040819
EP 1660476	A1	20060531	EP 2004-764276	20040819
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
US 2005124659	A1	20050609	US 2004-926123	20040823
PRIORITY APPLN. INFO.:			EP 2003-18705	A 20030825
			US 2003-504823P	P 20030922
			WO 2004-EP9292	W 20040819

OTHER SOURCE(S): CASREACT 142:280209; MARPAT 142:280209

ED Entered STN: 04 Mar 2005

AB The title compds. I [R1 = aryl, heterocyclyl or a annulated species thereof, optionally substituted with R2 = alkyl, cycloalkyl, haloalkyl, etc.; R5 = haloalkyl; R6 = alkyl, alkoxy, acyloxy, etc.; A = alkylene optionally substituted with alkyl, halo, OH; B = aryl, heterocyclyl; Y = bond, CH2, CF2, etc.; i, j = 1-3; m = 0-4], useful for prevention and/or treatment of diseases wherein the activity of a CCR-3 receptor is involved, were prepared E.g., a multi-step synthesis of II.HCl, starting from 2,5-difluoronitrobenzene and 1-benzyl-4-aminopiperidine, was given. Compds. of the invention were evaluated for binding to CCR-3 receptors, e.g., II possessed a Ki of 100 nM in binding assays. The present invention also provides pharmaceutical compns. comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compds. I or a pharmaceutically acceptable salt thereof.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L68 ANSWER 3 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 3
ACCESSION NUMBER: 2005:33074 HCAPLUS

DOCUMENT NUMBER: 142:114070
 TITLE: Preparation of novel N-(heterobicycloalkane)-substituted indoles or hetero derivatives for treating or preventing CCR-3 receptor-related diseases
 INVENTOR(S): Anderskewitz, Ralf; Martyres, Domnic; Dollinger, Horst; Pouzet, Pascale; Birke, Franz; Bouyssou, Thierry
 PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma GmbH & Co.KG, Germany
 SOURCE: Eur. Pat. Appl., 23 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1496058	A1	20050112	EP 2003-15434	20030709
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CA 2531749	AA	20050120	CA 2004-2531749	20040706
WO 2005005425	A1	20050120	WO 2004-EP7356	20040706
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1648888	A1	20060426	EP 2004-740684	20040706
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
US 2005014782	A1	20050120	US 2004-886973	20040708
PRIORITY APPLN. INFO.:			EP 2003-15434	A 20030709
			US 2003-500513P	P 20030905
			WO 2004-EP7356	W 20040706

OTHER SOURCE(S): MARPAT 142:114070

ED Entered STN: 14 Jan 2005

AB The title compds. I [A = C2-C8 alkylene optionally substituted with halide or OH; B = aryl, heteroaryl ring; R1 = aryl, heteroaryl, annulated heteroaryl, etc.; R5 = C1-C6 alkyl, C1-C6 alkoxy, C1-C6 aralkyl, C3-C6 cycloalkyl, halide, NO2, etc.; X = N, CH, CR6; Y = CF2, NR4, O, S(O)n; n = 0, 1, 2; T, U, V, Z = independently (CH2)x, x = 0, 1, 2; W = C1-C3 alkylene, CH2-Z-CH2; Z = O, S, NR4; R4 = H, C1-C6 alkyl, C3-C8-cycloalkyl, (C3-C8-cycloalkyl)-C1-C6-alkyl, etc.; R6 = C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl, OR3, SR3, cyano, COR3, SO2R3, aryl, etc.; R3 = H, C1-C6 alkyl, C3-C8-cycloalkyl, (C3-C8-cycloalkyl)-C1-C6-alkyl; etc.] were prepared to be used for treating or preventing diseases related to the CCR-3 receptor. Thus, 4-FC6H4CF2(CH2)3Br was reacted with (azabicyclooctyl)benzimidazole II to give alkylated derivative III. The binding constant, Ki, for III was 10 nM.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2005:74680 HCAPLUS
DOCUMENT NUMBER: 142:212050
TITLE: Pyrrolidinohydroquinazolines--a novel class of CCR3 modulators
AUTHOR(S): Anderskewitz, Ralf; Bauer, Rolf; Bodenbach, Gisela; Gester, Dirk; Gramlich, Bernd; Morschhaeuser, Gerd; Birke, Franz W.
CORPORATE SOURCE: Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach an der Riss, D-88397, Germany
SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(3), 669-673
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 142:212050
ED Entered STN: 28 Jan 2005
AB A novel class of CCR3 modulators is described. Starting with lead compound I (Ki: 110 nM), which turned out to be an antagonist of eotaxin at the CCR3 receptor, further optimization led to compound 8b (Ki: 28 nM), which surprisingly proved to be an agonist.
REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L68 ANSWER 5 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 6
ACCESSION NUMBER: 2004:696376 HCAPLUS
DOCUMENT NUMBER: 141:225527
TITLE: Preparation of pyrroloquinazolines as modulators of chemokine activity
INVENTOR(S): Anderskewitz, Ralf; Dollinger, Horst; Heine, Claudia; Pouzet, Pascale
Arielle Jane-josee; Birke, Franz; Bouyssou, Thierry
PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim Pharma GmbH & Co. Kg
SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004072074	A1	20040826	WO 2004-EP1043	20040205
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2005027122	A1	20050203	US 2004-771756	20040204
CA 2515730	AA	20040826	CA 2004-2515730	20040205
EP 1594873	A1	20051116	EP 2004-708347	20040205
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2006515002	T2	20060518	JP 2005-518417	20040205

PRIORITY APPLN. INFO.:

EP 2003-3007 A 20030212
US 2003-499529P P 20030902
WO 2004-EP1043 W 20040205

OTHER SOURCE(S): MARPAT 141:225527

ED Entered STN: 26 Aug 2004

AB The title compds. [I; R1, R2 = H, alkyl, alkenyl, cycloalkyl, etc.; or R1 and R2 together with the interjacent carbon atom form (un)substituted 3-8 membered cycloalkyl; or R1 and R2 form together :NR4; R3 = H, alkyl, alkenyl, aryl, etc.; R4 = H, CO2R5, COR5, CN, etc.; R5 = H, alkyl, cycloalkyl, aryl, etc.; or R2 and R3 together with the interjacent group form 5-8 membered ring; or R3 and R4 together with the interjacent group form 5-8 membered ring; E1, E2 = H or taken together form a double bond; X = H, halo, alkyl, cycloalkyl, aryl, etc.; the ring A may be substituted; Ar1, Ar2 = (un)substituted 6-10 membered homoarom. ring, 5-10 membered heteroarom. ring containing up to three heteroatoms selected from N, O and S; n = 1-4] and their pharmaceutically acceptable salts, which are effective modulators of **chemokine** activity, were prepared Thus, reacting 2-aminobenzylamine with γ -butyrolactone followed by treatment of the reaction mixture with POCl3, and then reacting the resulting 1,2,3,9-tetrahydropyrrolo[2,1-b]quinazoline with 2-bromobenzaldehyde afforded 3-(2-bromobenzylidene)-1,2,3,9-tetrahydropyrrolo[2,1-b]quinazoline which showed Ki in the range 1-100 nM against CCR-3 receptor binding. The pharmaceutical composition comprising the compound I is claimed.

L68 ANSWER 6 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 7

ACCESSION NUMBER: 2004:269868 HCAPLUS

DOCUMENT NUMBER: 140:303415

TITLE: Preparation of 1-phenyl-1,2-diaminoethane derivatives as modulators of the **chemokine** receptor activity

INVENTOR(S): Dollinger, Horst; Birke, Franz; Pouzet, Pascale Arielle Jane-Josee; Cereda, Enzo; Quai, Monica

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma GmbH & Co. KG, Germany

SOURCE: U.S. Pat. Appl. Publ., 19 pp.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004063779	A1	20040401	US 2003-614363	20030707
PRIORITY APPLN. INFO.:			EP 2002-425454	A 20020710
			US 2002-412910P	P 20020923

OTHER SOURCE(S): MARPAT 140:303415

ED Entered STN: 02 Apr 2004

AB The title compds. [I; R11-R15 = H, halo, alkyl, alkoxy, etc.; R21-R25 = H, halo, alkyl, alkoxy, etc.; R1, R2 = H, alkyl, alkenyl, Ph, etc.; or NR1R2 = 5-7 membered (un)saturated heterocyclyl which optionally contain 1-2 heteroatoms selected from O, N, S; A = (CH2)2, CONH, COCH2], useful for the treatment and/or prevention of a disease, wherein the activity of a CCR3 receptor is involved, were prepared and formulated. E.g., a 4-step synthesis of I [A = (CH2)2; NR1R2 = 4-cyclohexylpiperazin-1-yl; R11, R12, R14, R15 = H; R13 = MeO; R21, R23, R25 = H; R22, R24 = Me], starting from 4-methoxybenzaldehyde and 1-cyclohexylpiperazine, was given. All the exemplified compds. I showed Ki of 0.05-1.5 μ M in the CCR3 receptor

binding protocol.

L68 ANSWER 7 OF 15 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2006:123158 HCAPLUS
 DOCUMENT NUMBER: 144:212775
 TITLE: Preparation of alkyl- and piperidine-substituted
 benzimidazoles as CCR3 modulators
 INVENTOR(S): Anderskewitz, Ralf; Martyres, Domnic;
 Birke, Franz; Bouyssou, Thierry
 PATENT ASSIGNEE(S): Boehringer Ingelheim International
 GmbH, Germany; **Boehringer Ingelheim**
 Pharma GmbH & Co. KG
 SOURCE: PCT Int. Appl., 33 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006013073	A1	20060209	WO 2005-EP8294	20050730
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM US 2006030590 A1 20060209 US 2005-191539 20050728 PRIORITY APPLN. INFO.: EP 2004-18690 A 20040806 OTHER SOURCE(S): MARPAT 144:212775 ED Entered STN: 10 Feb 2006 AB The title compds. I [R1 = (un)substituted aryl, heterocyclyl or annelated species; R5 = alkyl; R6 = alkyl, alkoxy, acyloxy, etc.; A = alkylene (optionally substituted with alkyl, halo, OH); B = aryl, heterocyclyl; Y = CF3, NR4, O, SOn; n = 0-2; m = 0-4; and their pharmaceutically acceptable salts], useful for the prevention of diseases in which CCR3 activity modulators have a therapeutic benefit, were prepared E.g., a multi-step synthesis of II.HCl, starting from 2,5-difluoronitrobenzene and 1-benzyl-4-aminopiperidine, was given. The present invention also provides pharmaceutical compns. comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compds. I or a pharmaceutically acceptable salt thereof. REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L68 ANSWER 8 OF 15 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
 ACCESSION NUMBER: 2006-154164 [16] WPIX
 DOC. NO. CPI: C2006-051806
 TITLE: New benzimidazole-derivatives, useful for treatment and
 prevention of inflammatory diseases e.g. asthma and
 allergic diseases, are **chemokine** receptor
 activity modulators.
 DERWENT CLASS: B02

INVENTOR(S) : ANDERSKEWITZ, R; BIRKE, F;
 BOUYSSOU, T; MARTYRES, D
 PATENT ASSIGNEE(S) : (BOEH) BOEHRINGER INGELHEIM INT GMBH; (BOEH) BOEHRINGER
 INGELHEIM PHARMA GMBH & CO KG
 COUNTRY COUNT: 111
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
US 2006030590	A1	20060209	(200616) *		14
WO 2006013073	A1	20060209	(200616)	EN	
RW: AT BE BG BW CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IS IT KE LS LT LU LV MC MW MZ NA NL OA PL PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW					

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 2006030590	A1	US 2005-191539	20050728
WO 2006013073	A1	WO 2005-EP8294	20050730

PRIORITY APPLN. INFO: EP 2004-18690 20040806

ED 20060308

AB US2006030590 A UPAB: 20060308

NOVELTY - Benzimidazole derivatives (I) are new.

DETAILED DESCRIPTION - Benzimidazole-derivatives of formula (I) and their salts are new.

R1 = aryl, het or their annelated species het-aryl, aryl-het or het-het (all optionally substituted by 1-3 R2);

het = heterocyclic ring;

R2 = T1;

T1 = 1-6C alkyl, 3-6C cycloalkyl, 1-6C haloalkyl, 1-6C aralkyl, halogen, CN, C(O)OR3, C(O)R3, C(O)NR3R4, NR3R4, NR3C(O)R4, NR3SO2R4, OR3, NO2, SR3, S(O)R3, SO2R3 or SO2NR3R4;

R3, R4 = H or 1-6C alkyl;

R5 = 1-6C alkyl;

R6 = T1, 1-6C alkoxy, 1-6C acyloxy, 1-6C thioalkyl, aryl or het;

A = 2-8C alkylene (optionally substituted by 1-3C alkyl, halogen or OH);

B1 = aryl or het;

Y = CF2, NR4, O or S(O)n;

n = 0-2;

m = 0-4.

ACTIVITY - Antiinflammatory; Antiasthmatic; Antiallergic; Immunosuppressive; Antirheumatic; Antiarthritic; Antiartherosclerotic; Respiratory-Gen.; Gastrointestinal-Gen.; Dermatological; Antipsoriatic; Neuroprotective; Antithyroid; Antidiabetic; Nephrotropic; Vasotropic; Antiulcer; Cytostatic; Vulnerary; Hemostatic; Antibacterial; Antiparasitic; Virucide; Anti-HIV.

MECHANISM OF ACTION - Chemokine receptor (e.g. CCR5) activity modulator.

Test details are described but no results for the specific compounds are given. In general, (I) showed IC50 value at most 10 mM.

USE - For preparation of a medicament for prevention or treatment of diseases in which CCR3 activity modulators have a therapeutic benefit (all claimed); as modulators of **chemokine** receptor activity; as agent for the treatment and prevention of inflammatory diseases e.g. asthma and allergic diseases, autoimmune pathologies (e.g. rheumatoid arthritis and atherosclerosis); for treatment of e.g. respiratory allergic diseases such as allergic rhinitis, hypersensitivity lung diseases, hypersensitivity pneumonitis, eosinophilic cellulitis (e.g. Wells's syndrome), eosinophilic pneumonias (e.g., Loeffler's syndrome, chronic eosinophilic pneumonia), eosinophilic fasciitis (e.g. Shulman's syndrome), delayed-type hypersensitivity, interstitial lung diseases (ILD, e.g. idiopathic pulmonary fibrosis or ILD associated with rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, systemic sclerosis, Sjogren's syndrome, polymyositis or dermatomyositis); systemic anaphylaxis or hypersensitivity responses, drug allergies (e.g. to penicillin or cephalosporins), eosinophilia-myalgia syndrome due to ingestion of contaminated tryptophan, insect sting allergies; autoimmune diseases such as psoriatic arthritis, multiple sclerosis, systemic lupus erythematosus, myasthenia gravis, juvenile onset diabetes; glomerulonephritis, autoimmune thyroiditis, Behcet's disease; graft rejection (e.g. in transplantation) including allograft rejection or graft versus-host disease; inflammatory bowel diseases such as Crohn's disease and ulcerative colitis; spondyloarthropathies; scleroderma; psoriasis (including T-cell mediated psoriasis) and inflammatory dermatoses such as dermatitis, eczema, atopic dermatitis, allergic contact dermatitis, urticaria; vasculitis (e.g., necrotizing, cutaneous and hypersensitivity vasculitis); eosinophilic myositis, eosinophilic fasciitis; cancers with leukocyte infiltration of the skin or organs, reperfusion injury, hematologic malignancies, cytokine-induced toxicity (e.g. septic or endotoxic shock), polymyositis, dermatomyositis and infectious diseases or conditions of human or other species e.g. HIV, AIDS, viral infections, parasitic diseases; immunoregulatory disorders or diseases.

ADVANTAGE - (I) promotes at least one function of the mammalian **chemokine** receptor (e.g. human **chemokine**) and modulates **chemokine** receptor activity.
Dwg.0/0

L68 ANSWER 9 OF 15 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
ACCESSION NUMBER: 2003-767778 [72] WPIX
DOC. NO. CPI: C2003-211050
TITLE: Use of leukotriene antagonists, preferably benzamidine derivatives, for treatment or prophylaxis of respiratory diseases in animals, e.g. chronic cough, obstructive pulmonary disease or bronchitis.
DERWENT CLASS: B05 C02 C03
INVENTOR(S): BIRKE, F; MATZEK, K
PATENT ASSIGNEE(S): (BOEH) BOEHRINGER INGELHEIM PHARMA GMBH & CO KG
COUNTRY COUNT: 105
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2003080037	A2	20031002	(200372)*	GE	18
RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS					
LU MC MW MZ NL OA PT SD SE SI SK SL SZ TR TZ UG ZM ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK					
DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR					
KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL					
PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU					
ZA ZM ZW					

DE 10213350 A1 20031016 (200376)
 US 2003225004 A1 20031204 (200380)
 AU 2003212375 A1 20031008 (200432)
 EP 1490042 A2 20041229 (200502) GE
 R: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LT LU LV
 MC MK NL PT RO SE SI SK TR
 US 6921752 B2 20050726 (200549)
 JP 2005529085 W 20050929 (200568) 30
 TW 2004007109 A 20040516 (200628)

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2003080037	A2	WO 2003-EP3021	20030324
DE 10213350	A1	DE 2002-10213350	20020326
US 2003225004	A1 Provisional	US 2002-385147P	20020603
		US 2003-395955	20030324
AU 2003212375	A1	AU 2003-212375	20030324
EP 1490042	A2	EP 2003-708263	20030324
		WO 2003-EP3021	20030324
US 6921752	B2 Provisional	US 2002-385147P	20020603
		US 2003-395955	20030324
JP 2005529085	W	JP 2003-577866	20030324
		WO 2003-EP3021	20030324
TW 2004007109	A	TW 2003-106507	20030324

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2003212375	A1 Based on	WO 2003080037
EP 1490042	A2 Based on	WO 2003080037
JP 2005529085	W Based on	WO 2003080037

PRIORITY APPLN. INFO: DE 2002-10213350 20020326

ED 20031107

AB WO2003080037 A UPAB: 20031107

NOVELTY - Use of leukotriene B4 (LTB4) antagonists (I) in the production of medicaments for the treatment or prophylaxis of respiratory diseases in pets, working or farm animals.

DETAILED DESCRIPTION - Use of leukotriene B4 (LTB4) antagonists of formula (I), including their prodrugs, in the production of medicaments for the treatment or prophylaxis of respiratory diseases in pets, working or farm animals.

A = -O-CmH2m-O-(Ph')n- or -OCH2-C6H4-CH2O-;

m = 2-6;

n = 0 or 1;

Ph' = 1,4-phenylene (optionally substituted by 1 or T);

T = 1-6C alkyl;

R1 = H, OH, CN, COR10 or CHO;

R2 = H, F, Cl, Br, CF3, CHF2, OH, OSO3H, T, OT, 5-7C cycloalkyl,

CONR8R9, Ar, OAr, CH2Ar, -CR5R6-Ar or -CMe2-R7;

R3 = H, T, OT, OH, F or Cl;

R4 = H or T;

R5 = U, CF3, CH2OH, COOH or COOU;

U = 1-4C alkyl;

R6 = H, U or CF3;

R7 = CH2OH, COOH, COOU, CONR8R9 or CH2N8R9;

R8 = H, T, Ph'', Ph''-(1-6C) alkyl, COR10, COOR10, CHO, CONH2,

CONHR10, SO2T or SO2Ph'';

Ph'' = phenyl (optionally substituted by 1 or 2 of Cl, F, CF3, U, OH and/or OU);

R9 = H or T; or

R8 + R9 = 4-6C alkylene;

R10 = T, 5-7C cycloalkyl, Ar, Het, Ar-alkyl or Het-(1-6C) alkyl;

Ar = phenyl or naphthyl (both optionally substituted by 1 or 2 of Cl, F, CF3, U, OH, OSO3H and/or OU); and

Het = pyrrolyl, pyrazolyl, imidazolyl, furyl, thienyl, pyridinyl or pyrimidinyl (all optionally substituted as for Ar).

INDEPENDENT CLAIMS are also included for:

(1) Pharmaceutical preparations containing (I) in combination with one or more of beta -mimetics and/or steroids; and

(2) Two component systems, with one component containing (I) and the other containing one or more of beta -mimetics and/or steroids.

ACTIVITY - Antiinflammatory; Antitussive; Respiratory-Gen.

A 12-year old horse, showing symptoms of coughing, respiratory problems and lethargy due to chronic bronchitis, was treated once daily for 20 days with N-ethoxycarbonyl-4-(3-(4-(2-(4-hydroxyphenyl)-prop-2-yl)-phenoxy)methyl)-benzyloxy)-benzamidine (Ia) (20 g), added to fodder (oats) in the form of a methyl cellulose suspension.

After 7 days the coughing was markedly reduced and exercise capacity, vitality and agility were greatly improved. When treatment was ceased, the symptoms recurred within 2 weeks.

MECHANISM OF ACTION - Leukotriene B4 (LTB4) antagonist.

USE - (I) are used for the treatment or prophylaxis of respiratory diseases in pets, working or farm animals, e.g. dogs, cats, horses, cows or pigs, especially for treating or preventing chronic cough, chronic obstructive pulmonary disease or chronic bronchitis in horses (all claimed).

ADVANTAGE - (I) have a rapid and lasting effect in improving the health and performance of animals suffering from respiratory diseases, are well tolerated and free of side-effects and are free of disadvantages of prior art drugs such as beta -mimetics and/or steroids, e.g. they do not affect the meat of animals for slaughter or interfere with doping tests in racing animals.

Dwg.0/0

L68 ANSWER 10 OF 15 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
 ACCESSION NUMBER: 1995-312160 [41] WPIX
 CROSS REFERENCE: 1995-312159 [41]
 DOC. NO. CPI: C1995-139007
 TITLE: New acyl-(chloro-benzyl-oxo-tetra hydro)-quinolinyl-aminoacid derivs. - useful as neurokinin antagonists for treating inflammatory disorders, etc..
 DERWENT CLASS: B02
 INVENTOR(S): BUEGER, E; DOLLINGER, H; ESSER, F; JUNG, B; SCHNORRENBURG, G; SPECK, G; BURGER, E
 PATENT ASSIGNEE(S): (BOEH) BOEHRINGER INGELHEIM INT GMBH; (BOEH) BOEHRINGER INGELHEIM KG; (BOEH) BOEHRINGER INGELHEIM PHARMA KG; (BOEH) BOEHRINGER INGELHEIM GMBH
 COUNTRY COUNT: 34
 PATENT INFORMATION:

PATENT NO	KIND DATE	WEEK	LA	PG
DE 4406885	A1 19950907	(199541)*		9
WO 9523810	A1 19950908	(199541)	GE	44
RW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE				

W: AU CA CN CZ FI HU JP KR MX NO NZ PL RU SI UA VN
 AU 9518127 A 19950918 (199551)
 FI 9603440 A 19960903 (199649)
 NO 9603655 A 19961101 (199702)
 CZ 9602542 A3 19970611 (199730)
 JP 09505317 W 19970527 (199731) 33
 NZ 281240 A 19970922 (199745)
 EP 802922 A1 19971029 (199748) GE
 R: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE
 HU 75527 T 19970528 (199805)
 US 5712397 A 19980127 (199811) 10
 KR 97701727 A 19970412 (199817)
 MX 9603272 A1 19970301 (199820)
 JP 2801087 B2 19980921 (199843) 13
 US 5922878 A 19990713 (199934)
 CN 1142228 A 19970205 (200053)
 MX 194397 B 19991203 (200110)
 EP 802922 B1 20010926 (200157) GE
 R: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE
 DE 59509647 G 20011031 (200173)

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
DE 4406885	A1	DE 1994-4406885	19940303
WO 9523810	A1	WO 1995-EP760	19950302
AU 9518127	A	AU 1995-18127	19950302
FI 9603440	A	WO 1995-EP760	19950302
		FI 1996-3440	19960903
NO 9603655	A	WO 1995-EP760	19950302
		NO 1996-3655	19960902
CZ 9602542	A3	WO 1995-EP760	19950302
		CZ 1996-2542	19950302
JP 09505317	W	JP 1995-522700	19950302
		WO 1995-EP760	19950302
NZ 281240	A	NZ 1995-281240	19950302
		WO 1995-EP760	19950302
EP 802922	A1	EP 1995-909796	19950302
		WO 1995-EP760	19950302
HU 75527	T	WO 1995-EP760	19950302
		HU 1996-2402	19950302
US 5712397	A Cont of	US 1995-398257	19950303
		US 1995-467428	19950606
KR 97701727	A	WO 1995-EP760	19950302
		KR 1996-704834	19960903
MX 9603272	A1	MX 1996-3272	19960808
JP 2801087	B2	JP 1995-522700	19950302
		WO 1995-EP760	19950302
US 5922878	A Cont of	US 1995-398257	19950303
		US 1997-863757	19970527
CN 1142228	A	CN 1995-191895	19950302
MX 194397	B	MX 1996-3272	19960808
EP 802922	B1	EP 1995-909796	19950302
		WO 1995-EP760	19950302
DE 59509647	G	DE 1995-509647	19950302
		EP 1995-909796	19950302
		WO 1995-EP760	19950302

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9518127	A Based on	WO 9523810
CZ 9602542	A3 Based on	WO 9523810
JP 09505317	W Based on	WO 9523810
NZ 281240	A Based on	WO 9523810
EP 802922	A1 Based on	WO 9523810
HU 75527	T Based on	WO 9523810
US 5712397	A	DE 4406884
KR 97701727	A Based on	WO 9523810
JP 2801087	B2 Previous Publ. Based on	JP 09505317 WO 9523810
EP 802922	B1 Based on	WO 9523810
DE 59509647	G Based on Based on	EP 802922 WO 9523810

PRIORITY APPLN. INFO: DE 1994-4406885 19940303; DE
1994-4406884 19940303

ED 19951019

AB DE 4406885 A UPAB: 20011211

Amino acid derivs. of formula R1COAR2 (I) and their salts are new. R1 = vinyl, aryl, heteroaryl, aralkyl, heteroarylalkyl, arylvinyl, heteroarylvinyl, aryloxyalkyl, aralkoxy, 3-8C cycloalkyl, (3-8C cycloalkyl)alkyl, bicycloheptyl or bicycloheptylalkyl (both opt. substd. by 1-3 Me), or adamantyl, adamantylalkyl, decahydronaphthyl, decahydronaphthylalkyl, tetrahydronaphthyl, tetrahydronaphthylalkyl, diphenylalkyl, di(arylalkyl)aminoalkyl or arylalkylaminoalkyl; aryl = phenyl (opt. substd. by 1-3 of halogen, trihalomethyl alkoxy, alkyl, OH, NO2, alkanoyl and CN) or naphthyl; heteroaryl = indolyl (opt. 1-substd. by alkyl or benzyl), pyridyl, pyrrolyl, imidazolyl or thienyl; alkyl and alkoxy have 1-3 C; A = an opt. protected D- or L-amino acid selected from Ala, Val, Leu, Ile, Ser, Thr, allothreonine, Cys, Met, Phe, Trp, N-formyl-Trp, Tyr, Pro, dihydroproline, hydroxyproline, azetidine-2-carboxylic acid, thioproline (Trp), aminoproline, pGlu, 2-aminobutyric acid, 2,3-diaminopropionic acid, 2,4-diaminobutyric acid, Glu, Asp, Gln, Asn, Lys, Arg, His, Orn, hydroxypiperidine-carboxylic acid, mercaptoproline, Tpr(O), Met(O), Tpr(O2) and Met(O2); R2 = a gp. of formula (II); R = F, Cl, Br or Et or OMe; m = 1-5.

USE - (I) are neurokinin (tachykinin) antagonists, especially substances P or neurokinin A or B antagonists, useful for treating respiratory disorders such as asthma, bronchitis, cough, expectoration or rhinitis; inflammatory eye diseases such as conjunctivitis; inflammatory skin conditions such as dermatitis and urticaria; polyarthrititis, osteoarthritis; gastrointestinal disorders such as irritable bowel or emesis; and pain such as migraine.

Dose is 1-500mg orally, parenterally, by inhalation etc. for a 67kg human.
Dwg.0/0

L68 ANSWER 11 OF 15 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN

ACCESSION NUMBER: 1995-312159 [41] WPIX

CROSS REFERENCE: 1995-312160 [41]

DOC. NO. CPI: C1995-139006

TITLE: New amino acid tetra hydro-quinolone-amide derivs. -
useful as neurokinin antagonists for treating e.g.
inflammatory disorders.

DERWENT CLASS: B02

INVENTOR(S): BUERGER, E; DOLLINGER, H; ESSER, F; JUNG, B;
SCHNORRENBURG, G; SPECK, G; BURGER, E

PATENT ASSIGNEE(S): (BOEH) BOEHRINGER INGELHEIM INT GMBH; (BOEH) BOEHRINGER
 INGELHEIM KG; (BOEH) BOEHRINGER INGELHEIM GMBH
 COUNTRY COUNT: 34
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
DE 4406884	A1	19950907	(199541)*		13
WO 9523810	A1	19950908	(199541)	GE	44
RW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE					
W: AU CA CN CZ FI HU JP KR MX NO NZ PL RU SI UA VN					
AU 9518127	A	19950918	(199551)		
ZA 9501728	A	19960228	(199614)		34
FI 9603440	A	19960903	(199649)		
CZ 9602542	A3	19970611	(199730)		
JP 09505317	W	19970527	(199731)		33
US 5712397	A	19980127	(199811)		10
KR 97701727	A	19970412	(199817)		
JP 2801087	B2	19980921	(199843)		13
US 5922878	A	19990713	(199934)		
CN 1142228	A	19970205	(200053)		
MX 194397	B	19991203	(200110)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
DE 4406884	A1	DE 1994-4406884	19940303
WO 9523810	A1	WO 1995-EP760	19950302
AU 9518127	A	AU 1995-18127	19950302
ZA 9501728	A	ZA 1995-1728	19950302
FI 9603440	A	WO 1995-EP760	19950302
		FI 1996-3440	19960903
CZ 9602542	A3	WO 1995-EP760	19950302
		CZ 1996-2542	19950302
JP 09505317	W	JP 1995-522700	19950302
		WO 1995-EP760	19950302
US 5712397	A Cont of	US 1995-398257	19950303
		US 1995-467428	19950606
KR 97701727	A	WO 1995-EP760	19950302
		KR 1996-704834	19960903
JP 2801087	B2	JP 1995-522700	19950302
		WO 1995-EP760	19950302
US 5922878	A Cont of	US 1995-398257	19950303
		US 1997-863757	19970527
CN 1142228	A	CN 1995-191895	19950302
MX 194397	B	MX 1996-3272	19960808

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9518127	A Based on	WO 9523810
CZ 9602542	A3 Based on	WO 9523810
JP 09505317	W Based on	WO 9523810
US 5712397	A	DE 4406884
KR 97701727	A Based on	WO 9523810
JP 2801087	B2 Previous Publ. Based on	JP 09505317
		WO 9523810

PRIORITY APPLN. INFO: DE 1994-4406884 19940303; DE
1994-4406885 19940303

ED 19951019

AB DE 4406884 A UPAB: 20010220

Amino acid derivs. of formula R1COAR2 (I) and their salts are new: R1 = vinyl, aryl, heteroaryl, aralkyl, heteroaralkyl, arylvinyl, heteroarylvinyl, aryloxyalkyl, aralkoxy, 3-8C cycloalkyl or (3-8C cycloalkyl)alkyl; adamantyl, adamantylalkyl, decahydronaphthyl, etc.; aryl = naphthyl, or opt. substd. phenyl; heteroaryl = opt. substd. indolyl, pyridyl, pyrrolyl, imidazolyl or thienyl; alkyl, alkoxy have 1-3 C atoms; A = an opt. protected D- or L-amino acid; R2 = a gp. of formula (II); G = F, Cl, Br or Et; m = 1-5; Y, Z = H, 1-5C alkyl, 1-5C alkoxy, opt. substd. benzyloxy, OCF₃, halogen, CF₃, CN, CH₂NH₂, CONH₂, di(1-5C alkyl)amino, 2-5C alkanoylamino, N-(1-5C alkyl)-N-(2-5C alkanoyl), NH₂ or 1-5C alkylamino; or vicinal Y+Z = OCH₂O, OCH₂CH₂O or (CH₂)₄.

USE - (I) are neurokinin (tachykinin) antagonists, especially substance P or neurokinin A or B antagonists, useful for treating respiratory disorders (e.g. asthma, bronchitis or rhinitis), inflammatory eye diseases (e.g. conjunctivitis), inflammatory skin conditions (e.g. dermatitis and urticaria), arthritis, gastrointestinal disorders (e.g. irritable bowel or emesis) and pain (e.g. migraine).

Dwg.0/0

L68 ANSWER 12 OF 15 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN

ACCESSION NUMBER: 1994-101118 [12] WPIX

CROSS REFERENCE: 1994-084612 [11]

DOC. NO. CPI: C1994-046613

TITLE: Amino acid derivs. which are neurokinin antagonists - for treating e.g. asthma, bronchitis, rhinitis, conjunctivitis, dermatitis, polyarthritis.

DERWENT CLASS: B05

INVENTOR(S): BURGER, E; DOLLINGER, H; ESSER, F; JUNG, B;
SCHNORRENBURG, G; BUERGER, E

PATENT ASSIGNEE(S): (BOEH) BOEHRINGER INGELHEIM KG; (BOEH) BOEHRINGER
INGELHEIM INT GMBH; (BOEH) BOEHRINGER INGELHEIM PHARMA KG

COUNTRY COUNT: 36

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9405693	A1	19940317	(199412)*	GE	153
RW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE					
W: AU BG BY CA CZ FI HU JP KR NO NZ PL RU SK UA					
FI 9401987	A	19940429	(199426)		
NO 9401611	A	19940502	(199428)		
AU 9349547	A	19940329	(199430)		
EP 610487	A1	19940817	(199432)	GE	
R: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE					
DE 4315437	A1	19941110	(199444)		
CZ 9401276	A3	19941116	(199504)		
JP 07501085	W	19950202	(199514)		
SK 9400650	A3	19950308	(199520)		
CN 1086222	A	19940504	(199528)		
TW 254948	A	19950821	(199543)		
US 5596000	A	19970121	(199710)		66
AU 677792	B	19970508	(199727)		
HU 70475	T	19951030	(199732)		
NZ 255380	A	19970624	(199732)		
US 5849918	A	19981215	(199906)		

CN 1206715 A 19990203 (199924)
 EP 610487 B1 19991110 (199952) GE
 R: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE
 DE 59309867 G 19991216 (200005)
 ES 2137998 T3 20000101 (200008)
 EP 979827 A1 20000216 (200014) GE
 R: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE
 US 6147212 A 20001114 (200060)
 MX 204423 B 20010928 (200246)

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9405693	A1	WO 1993-EP2329	19930828
FI 9401987	A	WO 1993-EP2329	19930828
		FI 1994-1987	19940429
NO 9401611	A	WO 1993-EP2329	19930828
		NO 1994-1611	19940502
AU 9349547	A	AU 1993-49547	19930828
EP 610487	A1	EP 1993-919208	19930828
		WO 1993-EP2329	19930828
DE 4315437	A1	DE 1993-4315437	19930508
CZ 9401276	A3	CZ 1994-1276	19930828
JP 07501085	W	WO 1993-EP2329	19930828
		JP 1994-506852	19930828
SK 9400650	A3	SK 1994-650	19940531
		WO 1993-EP2329	
CN 1086222	A	CN 1993-117349	19930903
TW 254948	A	TW 1993-107179	19930902
US 5596000	A	US 1993-116090	19930902
AU 677792	B	AU 1993-49547	19930828
HU 70475	T	WO 1993-EP2329	19930828
		HU 1994-1323	19930828
NZ 255380	A	NZ 1993-255380	19930828
		WO 1993-EP2329	19930828
US 5849918	A Div ex	US 1993-116090	19930902
		US 1995-460964	19950605
CN 1206715	A Div ex	CN 1993-117349	19930903
		CN 1997-117758	19930903
EP 610487	B1	EP 1993-919208	19930828
		WO 1993-EP2329	19930828
	Related to	EP 1999-100929	19930828
DE 59309867	G	DE 1993-509867	19930828
		EP 1993-919208	19930828
		WO 1993-EP2329	19930828
ES 2137998	T3	EP 1993-919208	19930828
EP 979827	A1 Div ex	EP 1993-919208	19930828
		EP 1999-100929	19930828
US 6147212	A CIP of	US 1993-116090	19930902
	Div ex	US 1995-460964	19950605
		US 1998-111498	19980708
MX 204423	B	MX 1993-5379	19930902

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9349547	A Based on	WO 9405693
EP 610487	A1 Based on	WO 9405693

JP 07501085	W	Based on	WO 9405693
AU 677792	B	Previous Publ.	AU 9349547
		Based on	WO 9405693
HU 70475	T	Based on	WO 9405693
NZ 255380	A	Based on	WO 9405693
EP 610487	B1	Based on	WO 9405693
DE 59309867	G	Based on	EP 610487
		Based on	WO 9405693
ES 2137998	T3	Based on	EP 610487
EP 979827	A1	Div ex	EP 610487
US 6147212	A	CIP of	US 5596000
		Div ex	US 5849918

PRIORITY APPLN. INFO: DE 1992-4229447 19920903; DE
 1992-4243496 19921222; DE
 1993-4315437 19930508

ED 19940510

AB WO 9405693 A UPAB: 20020722

Amino acid derivs. of formula (I) and their pharmaceutically acceptable salts are new. R1 = vinyl, aryl, heteroaryl, aralkyl, heteroaralkyl, arylvinyl, heteroarylvinyl, aryloxyalkyl, arylalkyloxy, 3-8C cycloalkyl, 3-8C cycloalkyl-alkyl, opt. mono-, di- or tri-Me substd. bicycloheptyl or bicycloheptyl alkyl, etc. In R1, aryl = naphthyl or Ph (this last opt. mono, di or tri-substd. by halogen, trihalo-methyl, alkoxy, alkyl, OH, NO2, alkylcarbonyl or CN); heteroaryl = indolyl (opt. substd. at position 1 with alkyl or benzyl), pyridyl, etc. A1 = Ala, Val, Leu, Ile, Ser, Thr, allo-Thr, Cys, Met, Phe, Trp (opt. N-formyl protected), Tyr, Pro, DPro (e.g. D(3,4)-Pro), Pro(OH) (e.g. Pro(3OH) or Pro(4OH)), A2t, Tpr, Pro(NH2) (e.g. Pro(nH2) or Pro(4NH2)), pGlu, Aib, 2,3-diamino-propionic acid, 2,4-diaminobutyric acid, etc. B = A2NR2R3 or R5; A2 = a lipophilic alpha-amino acid containing an opt. mono-, di- or tri-substd. Ph, or heteroaryl, cyclohexyl, cyclopentyl, naphthyl or mono- or di(1-3C) alkyl amino, etc. In A2 the substits on Ph = halogen, alkoxy, alkyl, CN or 1-pyrrolidinyl; the chain members in the 1-8 membered chain are CHR4, CO, O, S and/or NR4, etc. R4 = H, alkyl, aryl or aralkyl. In R4, aryl = naphthyl or Ph (this last opt. mono-, di- or tri-substd. with halogen, etc.); R2, R3 = alkyl, arylalkyl, heteroaryl, etc. In R2 and R3, aryl = naphthyl or Ph (this last opt. mono-, di- or tri-substd. by halogen, trihalomethyl, etc.); R5 = a gp. of formula (a) or (b); R6 = aralkyl, diarylalkyl (aryl = Ph or naphthyl and alkyl contains 1-5C), heteroaryl (1-5C)alkyl (heteroaryl = 2-, 3- or 4-pyridyl or 2- or 3-thienyl), etc.; R7 = H or 1-5C alkyl; X = O or H2; Y, Z = H, 1-5C alkyl, 1-5C alkyloxy, benzyloxy (the Ph gp. being opt mono-, di- or tri-substd. with 1-5C alkyl, especially mono-, di- or tri-substd. with 1-5C alkyl, especially Me, 1-5C

alkoxy, especially

MeO, NMe2, halogen, C3, CN or OCF3) OCF3, halogen, CF3, CN, etc. t = u = 0, t = 1 and u = 0; t = u = 1; t = 2 and u = 0; and if t = 1 and u = 0, R5 can also be a gp. of formula (c); R8 = H and R9 = OH, 1-5C alkoxy, phenyl-(1-5C) alkyloxy, naphthyl (1-5C)alkyloxy or 1-4C alkylcarbonyl; or R8 + R9 together form O or OCH2CH2O; the chirality on C is R or S.

USE - (I) are neurokinin (tachykinin) antagonists, especially with substance P antagonism but also with neurokinin A or neurokinin B antagonism. (I) can therefore be used in the prophylaxis and therapy of diseases of the respiratory system such as asthma, bronchitis, rhinitis, coughs or expectoration, inflammatory eye conditions such as conjunct

Dwg.0/0

L68 ANSWER 13 OF 15 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
 ACCESSION NUMBER: 1994-084612 [11] WPIX
 CROSS REFERENCE: 1994-101118 [12]

DOC. NO. CPI: C1994-038816
 TITLE: New di peptide neurokinin antagonists - useful in treating respiratory disorders, inflammatory eye and skin disorders, polyarthritis, osteoarthritis and pain.
 DERWENT CLASS: B05
 INVENTOR(S): BURGER, E; DOLLINGER, H; ESSER, F; JUNG, B; SCHNORRENBURG, G; BUERGER, E
 PATENT ASSIGNEE(S): (BOEH) BOEHRINGER INGELHEIM KG; (BOEH) BOEHRINGER INGELHEIM INT GMBH
 COUNTRY COUNT: 12
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
DE 4243496	A1	19940310	(199411) *		49
FI 9401987	A	19940429	(199426)		
NO 9401611	A	19940502	(199428)		
AU 9349547	A	19940329	(199430)		
ZA 9306472	A	19940831	(199435)	138	
CZ 9401276	A3	19941116	(199504)		
JP 07501085	W	19950202	(199514)		
SK 9400650	A3	19950308	(199520)		
CN 1086222	A	19940504	(199528)		
TW 254948	A	19950821	(199543)		
US 5596000	A	19970121	(199710)	66	
HU 70475	T	19951030	(199732)		
US 5849918	A	19981215	(199906)		
US 6147212	A	20001114	(200060)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
DE 4243496	A1	DE 1992-4243496	19921222
FI 9401987	A	WO 1993-EP2329	19930828
		FI 1994-1987	19940429
NO 9401611	A	WO 1993-EP2329	19930828
		NO 1994-1611	19940502
AU 9349547	A	AU 1993-49547	19930828
ZA 9306472	A	ZA 1993-6472	19930902
CZ 9401276	A3	CZ 1994-1276	19930828
JP 07501085	W	WO 1993-EP2329	19930828
		JP 1994-506852	19930828
SK 9400650	A3	SK 1994-650	19940531
		WO 1993-EP2329	
CN 1086222	A	CN 1993-117349	19930903
TW 254948	A	TW 1993-107179	19930902
US 5596000	A	US 1993-116090	19930902
HU 70475	T	WO 1993-EP2329	19930828
		HU 1994-1323	19930828
US 5849918	A Div ex	US 1993-116090	19930902
		US 1995-460964	19950605
US 6147212	A CIP of Div ex	US 1993-116090	19930902
		US 1995-460964	19950605
		US 1998-111498	19980708

FILING DETAILS:

PATENT NO	KIND	PATENT NO
-----	-----	-----

AU 9349547	A	Based on	WO 9405693
JP 07501085	W	Based on	WO 9405693
HU 70475	T	Based on	WO 9405693
US 6147212	A	CIP of	US 5596000
		Div ex	US 5849918

PRIORITY APPLN. INFO: DE 1992-4229447 19920903; DE
 1992-4243496 19921222; DE
 1993-4315437 19930508

ED 19940428

AB DE 4243496 A UPAB: 20001123

Dipeptide derivs. of formula R1-C(O)-A1-A2-N(R2)(R3) (I) and their salts are new. R1 = vinyl; Ar1; Het1; Ar1-alkyl; Het1-alkyl; Ar1-vinyl; Het1-vinyl; Ar1-oxyalkyl; Ar1-alkoxy; di(Ar1-alkyl)-aminoalkyl or Ar1-alkylaminoalkyl; R2, R3 = alkyl; Ar2-alkyl; Het2; or OH; or NR2R3 forms a gp. of formula (a) or (b): m, n = 0-3 (but m + n = 2-5); s = 2 or 3; X = -(CH2)0-2-Ar2; -CH(Ar2)2; cyclopentyl; -(CH2)0-2-cyclohexyl; pyridyl; N-methyl-N-phenylamino-carbonylmethyl; etc.; A1 = Ala, Val, Leu, Ile, Ser, Thr, alloThr, Cys, Met, Phe, Trp (opt. N-protected by CHO), Tyr, Pro, APro, Azt, Tpr, Pro(NH2), pGlu, Aib, 2,3-diaminopropionic acid, 2,4-diaminobutyric acid, Glu, Asp, Gln, Asn, Lys, Arg, His, Orn, hydroxypiperidinecarboxylic acid, Pro(SH), Tpr(O or O2) or Met(O or O2) in the D- or L-configuration or as a geometric isomer and OH and NH2 gps. are opt. protected; A2 = (i) a lipophilic amino acid containing an Ar3, heteroaryl, cyclopentyl, cyclohexyl or mono- or di-(1-3C alkyl)amino gp. separated from the amino acid backbone by a 1-8 membered chain of the formula -(CHR4)1-8-, -(CHR4)0-p-G1(CHR4)0-q- or -(CHR4)1-p-G2(CHR4)0-q-; G1 = -COO- or CONR4-; G2 = -O-; -S-; -NR4-COO-; -NR4-CO-; -NR4-CO-NR4-; or -O-CO-NR4-; R4 = alkyl; Ar1; or Ar1-alkyl; p, q = 1-6; provided that the chain is not -CH2- when R2 and R3 = alkyl or Ar2-alkyl and when NR2R3 = gp. (a); or (ii) Leu; Ile; Nle; Val; Met; or e.g. a gp. of formula (i)-(iii): x, y = 1 or 2; Ar1 = phenyl opt. mono-, di- or tri-substd. by halo, trihalomethyl, alkoxy, alkyl or CN; or naphthyl; Ar2 = phenyl opt. mono-, di- or tri-substd. by halo, trihalomethyl, alkoxy, alkyl, alkylthio, OH, NO2 or CN or on adjacent C by -O-(CH2)1 or 2-O-; or naphthyl; Ar3 = phenyl opt. mono-, di- or tri-substd. by halo, trihalomethyl, alkoxy, alkyl, CN or 1-pyrrolidinyl; or naphthyl; Het1 = indolyl opt. 1-substd. by alkyl or benzyl; pyridyl; pyrrolyl; imidazolyl; or thienyl; Het2 = indolyl; pyridyl; pyrrolyl; imidazolyl; or thienyl.

USE - Cpds. (I) are inhibitors of neurokinin (tachykinin), especially substance P. They are useful in treating respiratory disorders (e.g. asthma, bronchitis, rhinitis and cough), inflammatory eye disorders (e.g. conjunctivitis), inflammatory skin disorders (e.g. dermatitis and urticaria), polyarthrititis, osteoarthritis and pain.

Dosage is 1-55 mg for patient weighing 67 kg.
 Dwg.0/0

L68 ANSWER 14 OF 15 MEDLINE on STN DUPLICATE 4
 ACCESSION NUMBER: 2005113498 MEDLINE
 DOCUMENT NUMBER: PubMed ID: 15743194
 TITLE: Novel ligands for the chemokine receptor-3 (CCR3): a receptor-modeling study based on 5D-QSAR.
 AUTHOR: Vedani Angelo; Dobler Max; Dollinger Horst; Hasselbach Kai-Malte; Birke Franz; Lill Markus A
 CORPORATE SOURCE: Biographics Laboratory 3R, Friedensgasse 35, CH-4056 Basel, Switzerland.. admin@biograf.ch
 SOURCE: Journal of medicinal chemistry, (2005 Mar 10) Vol. 48, No. 5, pp. 1515-27.
 Journal code: 9716531. ISSN: 0022-2623.

PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200504
ENTRY DATE: Entered STN: 4 Mar 2005
Last Updated on STN: 12 Apr 2005
Entered Medline: 11 Apr 2005

ED Entered STN: 4 Mar 2005
Last Updated on STN: 12 Apr 2005
Entered Medline: 11 Apr 2005

AB We recently reported the development of a receptor-modeling concept based on 5D-QSAR (quantitative structure-activity relationships) and which explicitly allows for the simulation of induced fit. In this account, we report its utilization toward the design of novel compounds able to inhibit the chemokine receptor-3 (CCR3). The study was based on a total of 141 compounds, representing four different substance classes. Using the Quasar software, we built two receptor surrogates that yielded a cross-validated $r(2)$ value of 0.950/0.861 and a predictive $r(2)$ of 0.879/0.798, respectively. The model was then employed to predict the activity of 58 hypothetical compounds featuring two variation patterns: lipophilic substitutions and amphiphilic H-bond acceptors. Eleven of the proposed ligands show a calculated binding affinity lower than any compound within the training set; the most potent candidate molecule is expected to bind at an IC(50) of 0.3 nM.

L68 ANSWER 15 OF 15 MEDLINE on STN
ACCESSION NUMBER: 88137624 MEDLINE
DOCUMENT NUMBER: PubMed ID: 3342883
TITLE: Radioligand binding of antagonists of platelet-activating factor to intact human platelets.
AUTHOR: Ukena D; Dent G; Birke F W; Robaut C; Sybrecht G W; Barnes P J
CORPORATE SOURCE: Department of Thoracic Medicine, Brompton Hospital, London, England.
SOURCE: FEBS letters, (1988 Feb 15) Vol. 228, No. 2, pp. 285-9.
Journal code: 0155157. ISSN: 0014-5793.
PUB. COUNTRY: Netherlands
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198804
ENTRY DATE: Entered STN: 8 Mar 1990
Last Updated on STN: 3 Feb 1997
Entered Medline: 7 Apr 1988

ED Entered STN: 8 Mar 1990
Last Updated on STN: 3 Feb 1997
Entered Medline: 7 Apr 1988

AB Two new antagonists of platelet-activating factor (PAF), the pyrrolothiazole derivative 52770 RP and the triazolodiazepine WEB 2086, have been studied as radioligands in intact human platelets. [3H]52770 RP and [3H]WEB 2086 bound specifically to high-affinity sites with dissociation constants (K_d) of 14.8 and 6.1 nM, respectively. The maximal number of sites for [3H]52770 RP binding was approx. 15-fold higher than for [3H]PAF and [3H]WEB 2086. In addition, C16-PAF, lyso-PAF, WEB 2086 and 52770 RP had K_i values which were nearly identical for both [3H]PAF and [3H]WEB 2086, whereas only 52770 RP competed for [3H]52770 RP-binding sites. These results demonstrate that in human platelets the sites of [3H]WEB 2086 binding are identical to [3H]PAF-binding sites, whereas those of [3H]52770 RP are not. [3H]WEB 2086 appears, therefore, to be a suitable

antagonist radioligand for labelling PAF receptors.

=> file stnguide

FILE 'STNGUIDE' ENTERED AT 12:07:39 ON 05 JUN 2006

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE

AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Jun 2, 2006 (20060602/UP).

=> d his ful

(FILE 'HOME' ENTERED AT 10:49:58 ON 05 JUN 2006)

FILE 'ZCAPLUS' ENTERED AT 10:50:10 ON 05 JUN 2006
E US2004-771756/APPS

L1 FILE 'HCAPLUS' ENTERED AT 10:50:36 ON 05 JUN 2006
1 SEA ABB=ON PLU=ON US2004-771756/APPS
SAVE TEMP L1 WAR756HCAAPP/A

FILE 'STNGUIDE' ENTERED AT 10:50:59 ON 05 JUN 2006

FILE 'HCAPLUS' ENTERED AT 10:51:03 ON 05 JUN 2006
D IBIB ED AB IND

FILE 'STNGUIDE' ENTERED AT 10:51:04 ON 05 JUN 2006

L2 FILE 'WPIX' ENTERED AT 10:51:54 ON 05 JUN 2006
1 SEA ABB=ON PLU=ON US2004-771756/APPS
SAVE TEMP L2 WAR756WPIAPP/A

FILE 'STNGUIDE' ENTERED AT 10:52:13 ON 05 JUN 2006

FILE 'WPIX' ENTERED AT 10:52:19 ON 05 JUN 2006
D IALL CODE

FILE 'STNGUIDE' ENTERED AT 10:52:21 ON 05 JUN 2006

FILE 'REGISTRY' ENTERED AT 10:52:53 ON 05 JUN 2006

L3 FILE 'HCAPLUS' ENTERED AT 10:52:57 ON 05 JUN 2006
TRA PLU=ON L1 1- RN : 58 TERMS

L4 FILE 'REGISTRY' ENTERED AT 10:53:00 ON 05 JUN 2006
58 SEA ABB=ON PLU=ON L3
SAVE TEMP L4 WAR756REGAPP/A

FILE 'STNGUIDE' ENTERED AT 10:53:55 ON 05 JUN 2006
D SAVED

L5 FILE 'LREGISTRY' ENTERED AT 10:56:10 ON 05 JUN 2006
STR

FILE 'STNGUIDE' ENTERED AT 10:57:30 ON 05 JUN 2006

L6 FILE 'LREGISTRY' ENTERED AT 10:58:45 ON 05 JUN 2006
STR L5

FILE 'REGISTRY' ENTERED AT 11:02:11 ON 05 JUN 2006
D COST

L7 31 SEA SSS SAM L6

FILE 'STNGUIDE' ENTERED AT 11:02:58 ON 05 JUN 2006
D QUE STAT

L8 FILE 'REGISTRY' ENTERED AT 11:04:58 ON 05 JUN 2006
573 SEA SSS FUL L6
SAVE TEMP L8 WAR756PSET1/A

L9 11 SEA ABB=ON PLU=ON L4 NOT L8

D SCAN

FILE 'STNGUIDE' ENTERED AT 11:06:11 ON 05 JUN 2006

L10 FILE 'REGISTRY' ENTERED AT 11:06:48 ON 05 JUN 2006
ANALYZE PLU=ON L8 1- LC : 11 TERMS
D 1-11

FILE 'STNGUIDE' ENTERED AT 11:08:22 ON 05 JUN 2006

L11 FILE 'BEILSTEIN' ENTERED AT 11:08:37 ON 05 JUN 2006
D QUE L8
150 SEA SSS FUL L6
L12 88 SEA ABB=ON PLU=ON L11 NOT RN/FA
L13 15 SEA ABB=ON PLU=ON L12 NOT BABSAN/FA
SAVE TEMP L11 WAR756BEIS/A
SAVE TEMP L13 WAR756BEIX/A
SELECT L11 1- BABSAN

L14 FILE 'BABS' ENTERED AT 11:11:07 ON 05 JUN 2006
22 SEA ABB=ON PLU=ON (6487251/AN OR 5863646/AN OR 5577177/AN OR
6168489/AN OR 5577176/AN OR 6311218/AN OR 6170503/AN OR
5559630/AN OR 5690319/AN OR 6199365/AN OR 6254884/AN OR
6507792/AN OR 5559613/AN OR 6429378/AN OR 5563983/AN OR
6148796/AN OR 6348769/AN OR 6381124/AN OR 6392803/AN OR
6407489/AN OR 6443294/AN OR 6445593/AN)

L15 FILE 'ZCAPLUS' ENTERED AT 11:11:24 ON 05 JUN 2006
QUE ABB=ON PLU=ON AY<2004 OR PY<2004 OR PRY<2004 OR MY<2004
OR REVIEW/DT
L16 QUE ABB=ON PLU=ON AY<2004 OR PY<2004 OR PRY<2004

L17 FILE 'BABS' ENTERED AT 11:12:24 ON 05 JUN 2006
19 SEA ABB=ON PLU=ON L14 AND L15
SAVE TEMP L17 WAR756BAB1B/A
L18 3 SEA ABB=ON PLU=ON L14 NOT L17
SAVE TEMP L18 WAR756BAB1A/A

FILE 'STNGUIDE' ENTERED AT 11:13:21 ON 05 JUN 2006
D SAVED

L19 FILE 'ZCAPLUS' ENTERED AT 11:14:50 ON 05 JUN 2006
L20 QUE ABB=ON PLU=ON ANDERSKEWITZ, R?/AU
L21 QUE ABB=ON PLU=ON DOLLINGER, H?/AU
L22 QUE ABB=ON PLU=ON HEINE, C?/AU
L23 QUE ABB=ON PLU=ON POUZET, P?/AU
L24 QUE ABB=ON PLU=ON BOUYSSOU, T?/AU
L25 QUE ABB=ON PLU=ON BIRKE, F?/AU
(BOEHRINGER OR INGELHEIM)/PA,CS,SO

L26 FILE 'HCAPLUS' ENTERED AT 11:23:34 ON 05 JUN 2006
219 SEA ABB=ON PLU=ON (L19 OR L20 OR L21 OR L22 OR L23 OR L24)

L27 FILE 'ZCAPLUS' ENTERED AT 11:23:50 ON 05 JUN 2006
QUE ABB=ON PLU=ON ?PYRROL?(4A)?AZOL?

L28 FILE 'HCAPLUS' ENTERED AT 11:24:22 ON 05 JUN 2006
2 SEA ABB=ON PLU=ON L26 AND L27
L29 99 SEA ABB=ON PLU=ON (L19 OR L20 OR L21 OR L22 OR L23 OR L24)
AND L25

FILE 'STNGUIDE' ENTERED AT 11:25:12 ON 05 JUN 2006

FILE 'ZCAPLUS' ENTERED AT 11:25:25 ON 05 JUN 2006

L30 QUE ABB=ON PLU=ON ?CHEMOKIN? OR (CHEMO(W)KIN?)

FILE 'HCAPLUS' ENTERED AT 11:25:52 ON 05 JUN 2006

L31 64 SEA ABB=ON PLU=ON L25 AND L27
L32 7 SEA ABB=ON PLU=ON (L29 OR L31) AND L30
L33 7 SEA ABB=ON PLU=ON L28 OR L32
SAVE TEMP L33 WAR756HCAINV/A
L34 50 SEA ABB=ON PLU=ON L8
L35 46 SEA ABB=ON PLU=ON L34 AND L15
SAVE TEMP L35 WAR756HCA1B/A
L36 4 SEA ABB=ON PLU=ON L34 NOT L35
SAVE TEMP L36 WAR756HCA1A/A

FILE 'STNGUIDE' ENTERED AT 11:27:38 ON 05 JUN 2006

FILE 'REGISTRY' ENTERED AT 11:28:11 ON 05 JUN 2006

L37 47 SEA ABB=ON PLU=ON L8 AND L4
L38 24 SEA ABB=ON PLU=ON L37 AND BR/ELS
D SCAN

FILE 'STNGUIDE' ENTERED AT 11:28:52 ON 05 JUN 2006

FILE 'REGISTRY' ENTERED AT 11:29:27 ON 05 JUN 2006

L*** DEL 15 S L38 AND ?QUINAZOL?
L39 15 SEA ABB=ON PLU=ON L38 AND ?QUINAZOL?/CNS
D SCAN

FILE 'STNGUIDE' ENTERED AT 11:30:09 ON 05 JUN 2006

FILE 'REGISTRY' ENTERED AT 11:31:50 ON 05 JUN 2006

L40 1 SEA ABB=ON PLU=ON L39 AND C18H15BRN2/MF
SAVE TEMP L40 WAR756ES/A

FILE 'STNGUIDE' ENTERED AT 11:32:36 ON 05 JUN 2006

FILE 'HCAPLUS' ENTERED AT 11:32:38 ON 05 JUN 2006

L41 1 SEA ABB=ON PLU=ON L40
L42 1 SEA ABB=ON PLU=ON L41 AND L35
L43 46 SEA ABB=ON PLU=ON L35 OR L42
SAVE TEMP L43 WAR756HCA1B/A

FILE 'STNGUIDE' ENTERED AT 11:33:39 ON 05 JUN 2006

D SAVED

FILE 'WPIX' ENTERED AT 11:34:54 ON 05 JUN 2006

D QUE L8
L44 0 SEA SSS SAM L6
D QUE STA
L45 1 SEA SSS FUL L6
SAVE TEMP L45 WAR756WPIS/A
D SCAN
L46 1 SEA ABB=ON PLU=ON L45/DCR
SELECT L45 1- SDCN
L47 1 SEA ABB=ON PLU=ON RAF9T7/DCN
L48 1 SEA ABB=ON PLU=ON L46 OR L47
D BIB

SAVE TEMP L48 WAR756WPI1B/A
L49 137 SEA ABB=ON PLU=ON (L19 OR L20 OR L21 OR L22 OR L23 OR L24)
L50 6 SEA ABB=ON PLU=ON L49 AND (?CHEMOKIN?/BIX OR (CHEMO/BIX(W)KIN
?/BIX))
L51 6 SEA ABB=ON PLU=ON L49 AND (?PYRROL?/BIX(4A)?AZOL?/BIX)
L52 11 SEA ABB=ON PLU=ON L50 OR L51
SAVE TEMP L52 WAR756WPIINV/A

FILE 'STNGUIDE' ENTERED AT 11:40:48 ON 05 JUN 2006
D SAVED

FILE 'HCA' ENTERED AT 11:41:11 ON 05 JUN 2006

FILE 'HCAPLUS' ENTERED AT 11:41:13 ON 05 JUN 2006
L53 45 SEA ABB=ON PLU=ON L43 NOT ((L19 OR L20 OR L21 OR L22 OR L23
OR L24 OR L25))

FILE 'STNGUIDE' ENTERED AT 11:41:44 ON 05 JUN 2006

FILE 'USPATFULL, USPAT2, CASREACT, TOXCENTER, BIOSIS, PROUSDDR, CHEMCATS,
SYNTHLINE' ENTERED AT 11:42:26 ON 05 JUN 2006
L54 502 SEA ABB=ON PLU=ON L8
L55 29 SEA ABB=ON PLU=ON L54 AND L15
SAVE TEMP L55 WAR756MULS1/A
D SAVED

FILE 'STNGUIDE' ENTERED AT 11:43:52 ON 05 JUN 2006
D QUE STAT L40

FILE 'REGISTRY' ENTERED AT 11:44:17 ON 05 JUN 2006
D IDE L40

FILE 'STNGUIDE' ENTERED AT 11:44:17 ON 05 JUN 2006

FILE 'STNGUIDE' ENTERED AT 11:44:34 ON 05 JUN 2006
D QUE L43

FILE 'USPATFULL' ENTERED AT 11:45:21 ON 05 JUN 2006
L56 1 SEA ABB=ON PLU=ON L40
SAVE TEMP L56 WAR756USPES/A

FILE 'STNGUIDE' ENTERED AT 11:45:44 ON 05 JUN 2006

FILE 'MEDLINE, BIOSIS, EMBASE, CABA, LIFESCI, DRUGU, DRUGB, VETU, VETB,
SCISEARCH, CONF, CONFSCI, DISSABS' ENTERED AT 11:47:28 ON 05 JUN 2006
L57 563 SEA ABB=ON PLU=ON (L19 OR L20 OR L21 OR L22 OR L23 OR L24)
L58 9 SEA ABB=ON PLU=ON L57 AND L30
L59 1 SEA ABB=ON PLU=ON L57 AND L27
L60 10 SEA ABB=ON PLU=ON L58 OR L59
SAVE TEMP L60 WAR756MULINV WAR756MULINV/A
L61 8 SEA ABB=ON PLU=ON L27 AND L30
D COST
L62 2 SEA ABB=ON PLU=ON L61 AND L15
SAVE TEMP L62 WAR756MUL1B/A
L63 6 SEA ABB=ON PLU=ON L61 NOT L62
SAVE TEMP L63 WAR756MUL1A/A
D SAVED

FILE 'STNGUIDE' ENTERED AT 11:53:53 ON 05 JUN 2006

FILE 'PASCAL, JICST-EPLUS' ENTERED AT 11:54:17 ON 05 JUN 2006

L64 68 SEA ABB=ON PLU=ON (L19 OR L20 OR L21 OR L22 OR L23 OR L24)
L65 2 SEA ABB=ON PLU=ON L64 AND (L27 OR L30)
SAVE TEMP L65 WAR756JPINV/ WAR756JPINV/A
L66 1 SEA ABB=ON PLU=ON L27 AND L30
D BIB
SAVE TEMP L66 WAR756JP1B/A

FILE 'STNGUIDE' ENTERED AT 11:58:34 ON 05 JUN 2006

D SAVED
D QUE STAT L8
D QUE NOS L10
D L10 1-11
D QUE STAT L11
D QUE NOS L17
D QUE STAT L43
D QUE STAT L45
D QUE NOS L48
D QUE NOS L55
D QUE NOS L56
D QUE L62
D QUE L66

FILE 'HCAPLUS, BABS, WPIX, USPATFULL, USPAT2, CASREACT, TOXCENTER,
BIOSIS, SYNTHLINE, EMBASE, PASCAL' ENTERED AT 12:01:59 ON 05 JUN 2006

L67 58 DUP REM L43 L17 L48 L55 L62 L66 (40 DUPLICATES REMOVED)
ANSWERS '1-46' FROM FILE HCAPLUS
ANSWERS '47-53' FROM FILE USPATFULL
ANSWER '54' FROM FILE BIOSIS
ANSWER '55' FROM FILE SYNTHLINE
ANSWERS '56-57' FROM FILE EMBASE
ANSWER '58' FROM FILE PASCAL

FILE 'STNGUIDE' ENTERED AT 12:02:09 ON 05 JUN 2006

FILE 'HCAPLUS, USPATFULL, BIOSIS, SYNTHLINE, EMBASE, PASCAL' ENTERED AT
12:02:51 ON 05 JUN 2006

D IBIB ED AB HITSTR

FILE 'STNGUIDE' ENTERED AT 12:03:00 ON 05 JUN 2006

FILE 'HCAPLUS, USPATFULL, BIOSIS, SYNTHLINE, EMBASE, PASCAL' ENTERED AT
12:03:09 ON 05 JUN 2006

D IBIB ED AB HITSTR 2-46

FILE 'STNGUIDE' ENTERED AT 12:03:34 ON 05 JUN 2006

FILE 'HCAPLUS, USPATFULL, BIOSIS, SYNTHLINE, EMBASE, PASCAL' ENTERED AT
12:04:21 ON 05 JUN 2006

D IBIB AB HITSTR 47

FILE 'STNGUIDE' ENTERED AT 12:04:22 ON 05 JUN 2006

FILE 'HCAPLUS, USPATFULL, BIOSIS, SYNTHLINE, EMBASE, PASCAL' ENTERED AT
12:04:31 ON 05 JUN 2006

D IBIB AB HITSTR 48-53

FILE 'STNGUIDE' ENTERED AT 12:04:38 ON 05 JUN 2006

FILE 'HCAPLUS, USPATFULL, BIOSIS, SYNTHLINE, EMBASE, PASCAL' ENTERED AT

12:05:12 ON 05 JUN 2006

D IBIB ED AB HITIND 54

FILE 'STNGUIDE' ENTERED AT 12:05:12 ON 05 JUN 2006

FILE 'HCAPLUS, USPATFULL, BIOSIS, SYNTHLINE, EMBASE, PASCAL' ENTERED AT
12:05:25 ON 05 JUN 2006

D IBIB ED AB HITIND 55

FILE 'STNGUIDE' ENTERED AT 12:05:47 ON 05 JUN 2006

FILE 'HCAPLUS, USPATFULL, BIOSIS, SYNTHLINE, EMBASE, PASCAL' ENTERED AT
12:06:05 ON 05 JUN 2006

D IBIB ED AB HITIND 56-58

FILE 'STNGUIDE' ENTERED AT 12:06:06 ON 05 JUN 2006

D QUE L33

D QUE L52

D QUE L60

D QUE L65

FILE 'HCAPLUS, WPIX, MEDLINE, BIOSIS, EMBASE, DRUGU, SCISEARCH, PASCAL'
ENTERED AT 12:07:01 ON 05 JUN 2006

L68 15 DUP REM L33 L52 L60 L65 (15 DUPLICATES REMOVED)

ANSWERS '1-7' FROM FILE HCAPLUS

ANSWERS '8-13' FROM FILE WPIX

ANSWERS '14-15' FROM FILE MEDLINE

FILE 'STNGUIDE' ENTERED AT 12:07:08 ON 05 JUN 2006

FILE 'HCAPLUS, WPIX, MEDLINE' ENTERED AT 12:07:15 ON 05 JUN 2006

D IBIB ED AB 1-15

FILE 'STNGUIDE' ENTERED AT 12:07:19 ON 05 JUN 2006

FILE 'STNGUIDE' ENTERED AT 12:07:39 ON 05 JUN 2006

FILE HOME

FILE ZCAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS is strictly prohibited.

FILE COVERS 1907 - 5 Jun 2006 VOL 144 ISS 24

FILE LAST UPDATED: 4 Jun 2006 (20060604/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE HCAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 5 Jun 2006 VOL 144 ISS 24
FILE LAST UPDATED: 4 Jun 2006 (20060604/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE STNGUIDE
FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jun 2, 2006 (20060602/UP).

FILE WPIX
FILE LAST UPDATED: 2 JUN 2006 <20060602/UP>
MOST RECENT DERWENT UPDATE: 200635 <200635/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf <

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
<http://scientific.thomson.com/support/patents/coverage/latestupdates/>

>>> PLEASE BE AWARE OF THE NEW IPC REFORM IN 2006, SEE
http://www.stn-international.de/stndatabases/details/ipc_reform.html and
<http://scientific.thomson.com/media/scpdf/ipcrdwpi.pdf> <<<

FILE REGISTRY
Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 4 JUN 2006 HIGHEST RN 886746-35-6
DICTIONARY FILE UPDATES: 4 JUN 2006 HIGHEST RN 886746-35-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *

*

*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

FILE LREGISTRY

LREGISTRY IS A STATIC LEARNING FILE

NEW CAS INFORMATION USE POLICIES, ENTER HELP USAGETERMS FOR DETAILS.

FILE BEILSTEIN

FILE LAST UPDATED ON MARCH 15, 2006

FILE COVERS 1771 TO 2006.

FILE CONTAINS 9,516,393 SUBSTANCES

>>>PLEASE NOTE: Reaction Data and substance data are stored in separate documents and can not be searched together in one query. Reaction data for BEILSTEIN compounds may be displayed immediately with the display codes PRE (preparations) and REA (reactions). A substance answer set retrieved after the search for a chemical name, a compounds with available reaction information by combining with PRE/FA, REA/FA or more generally with RX/FA. The BEILSTEIN Registry Number (BRN) is the link between a BEILSTEIN compound and belonging reactions. For more detailed reaction searches BRNs can be searched as reaction partner BRNs Reactant BRN (RX.RBRN) or Product BRN (RX.PBRN).<<<

>>> FOR SEARCHING PREPARATIONS SEE HELP PRE <<<

* PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST. *

* SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE *

* ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE *

* ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS. *

* FOR PRICE INFORMATION SEE HELP COST *

NEW

* PATENT NUMBERS (PN) AND BABS ACCESSION NUMBERS (BABSAN) CAN NOW BE SEARCHED, SELECTED AND TRANSFERRED.

* NEW DISPLAY FORMATS ALLREF, ALLP AND BABSAN SHOW ALL REFERENCES, ALL PATENT REFERENCES, OR ALL BABS ACCESSION NUMBERS FOR A COMPOUND AT A GLANCE.

FILE BABS

FILE LAST UPDATED: 15 MAR 2006 <20060315/UP>

FILE COVERS 1980 TO DATE.

FILE HCA

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available

for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 1 Jun 2006 VOL 144 ISS 24
FILE LAST UPDATED: 1 Jun 2006 (20060601/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE USPATFULL

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 1 Jun 2006 (20060601/PD)
FILE LAST UPDATED: 1 Jun 2006 (20060601/ED)
HIGHEST GRANTED PATENT NUMBER: US7055175
HIGHEST APPLICATION PUBLICATION NUMBER: US2006117448
CA INDEXING IS CURRENT THROUGH 30 May 2006 (20060530/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 1 Jun 2006 (20060601/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2006
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2006

FILE USPAT2

FILE COVERS 2001 TO PUBLICATION DATE: 1 Jul 2003 (20030701/PD)
FILE LAST UPDATED: 1 Jun 2006 (20060601/ED)
HIGHEST GRANTED PATENT NUMBER: US2006069528
HIGHEST APPLICATION PUBLICATION NUMBER: US2006117441
CA INDEXING IS CURRENT THROUGH 1 Jun 2006 (20060601/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 1 Jul 2003 (20030701/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2006
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2006

FILE CASREACT

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE CONTENT:1840 - 4 Jun 2006 VOL 144 ISS 23

New CAS Information Use Policies, enter HELP USAGETERMS for details.

* CASREACT now has more than 10 million reactions *
* *

Some CASREACT records are derived from the ZIC/VINITI database (1974-1991) provided by InfoChem, INPI data prior to 1986, and Biotransformations database compiled under the direction of Professor Dr. Klaus Kieslich.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE TOXCENTER

FILE COVERS 1907 TO 30 May 2006 (20060530/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

The MEDLINE file segment has been updated with 2006 MEDLINE data and features. See HELP RLOAD for details.

TOXCENTER thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2006 vocabulary.

See <http://www.nlm.nih.gov/mesh/>

http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_med_data_changes.html

http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_2006_MeSH.html

for a description of changes.

FILE BIOSIS

FILE COVERS 1969 TO DATE.

CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNS) PRESENT
FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 31 May 2006 (20060531/ED)

FILE PROUSDDR

FILE COVERS 1980 TO 2 May 2006 (20060502/ED)

FILE CHEMCATS

FILE LAST UPDATED 3 JUNE 2006 (20060603/UP)

For details on recent updates in CHEMCATS, enter NEWS FILE at an arrow prompt. For the list of suppliers currently in the file, enter HELP SPA, HELP SPBC, HELP SPDH, HELP SPIN, HELP SPOP, and HELP SPQZ. For the list of current catalogs, enter HELP CTA, HELP CTBC, HELP CTDH, HELP CTIN, HELP CTOP, and HELP CTQZ.

This database is provided on an "as is" basis. Please consult the suppliers for current information regarding pricing, regional availability, available quantities, purities, etc. THERE ARE NO WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED. ACS is not liable for any loss of profit, goodwill or any other damages arising out of the use of this database.

CHEMCATS now contains more than 10 million records. See HELP CONTENT and NEWS FILE for details.

FILE SYNTHLINE

FILE COVERS 1984 TO 16 May 2006 (20060516/ED)

FILE MEDLINE

FILE LAST UPDATED: 3 JUN 2006 (20060603/UP). FILE COVERS 1950 TO DATE.

On December 11, 2005, the 2006 MeSH terms were loaded.

The MEDLINE reload for 2006 is now (26 Feb.) available. For details on the 2006 reload, enter HELP RLOAD at an arrow prompt (=>).
See also:

<http://www.nlm.nih.gov/mesh/>
http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html
http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_med_data_changes.html
http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_2006_MeSH.html

OLDMEDLINE is covered back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2006 vocabulary.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE EMBASE

FILE COVERS 1974 TO 5 Jun 2006 (20060605/ED)

EMBASE has been reloaded. Enter HELP RLOAD for details.

EMBASE is now updated daily. SDI frequency remains weekly (default) and biweekly.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE CABA

FILE COVERS 1973 TO 2 Jun 2006 (20060602/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

The CABA file was reloaded 7 December 2003. Enter HELP RLOAD for details.

FILE LIFESCI

FILE COVERS 1978 TO 12 May 2006 (20060512/ED)

FILE DRUGU

FILE LAST UPDATED: 3 JUN 2006 <20060603/UP>

>>> DERWENT DRUG FILE (SUBSCRIBER) <<<

>>> FILE COVERS 1983 TO DATE <<<

>>> THESAURUS AVAILABLE IN /CT <<<

FILE DRUGB

>>> FILE COVERS 1964 TO 1982 - CLOSED FILE <<<

FILE VETU

FILE LAST UPDATED: 02 JAN 2002 <20020102/UP>

FILE COVERS 1983-2001

FILE VETB

FILE LAST UPDATED: 25 SEP 94 <940925/UP>

FILE COVERS 1968-1982

FILE SCISEARCH

FILE COVERS 1974 TO 1 Jun 2006 (20060601/ED)

SCISEARCH has been reloaded, see HELP RLOAD for details.

FILE CONF

FILE LAST UPDATED: 23 DEC 2005 <20051223/UP>

FILE COVERS 1976 TO 2005.

<<< CONF IS NO LONGER BEING UPDATED AS OF JANUARY 2006 >>>

FILE CONFSCI

FILE COVERS 1973 TO 10 Apr 2006 (20060410/ED)

CSA has resumed updates, see NEWS FILE

FILE DISSABS

FILE COVERS 1861 TO 25 MAY 2006 (20060525/ED)

Only fair use as provided by the United States copyright law is permitted. PROQUEST INFORMATION AND LEARNING COMPANY MAKES NO WARRANTY REGARDING THE ACCURACY, COMPLETENESS OR TIMELINESS OF THE LICENSED MATERIALS OR ANY WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, AND SHALL NOT BE LIABLE FOR DAMAGES OF ANY KIND OR LOST PROFITS OR OTHER CLAIMS RELATED TO THE LICENSED MATERIALS OR THEIR USE.

FILE PASCAL

FILE LAST UPDATED: 29 MAY 2006 <20060529/UP>

FILE COVERS 1977 TO DATE.

>>> SIMULTANEOUS LEFT AND RIGHT TRUNCATION IS AVAILABLE
IN THE BASIC INDEX (/BI) FIELD <<<

FILE JICST-EPLUS

FILE COVERS 1985 TO 30 MAY 2006 (20060530/ED)

THE JICST-EPLUS FILE HAS BEEN RELOADED TO REFLECT THE 1999 CONTROLLED TERM (/CT) THESAURUS RELOAD.

=>

THIS PAGE BLANK (USPTO)